drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.71k
| drug2_id
int64 1
1.71k
| drug1_name
stringlengths 4
31
| drug2_name
stringlengths 4
31
| drug1_desc
stringlengths 27
1.09k
⌀ | drug2_desc
stringlengths 27
1.06k
⌀ | label
stringlengths 58
191
| label_idx
int64 0
85
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
2.58k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00604
|
DB00608
| 633 | 588 |
Cisapride
|
Chloroquine
|
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
|
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine]. Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis. **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.** Chloroquine was granted FDA Approval on 31 October 1949.
|
Cisapride may increase the QTc-prolonging activities of Chloroquine.
| 19 |
[
[
[
633,
42,
588
]
],
[
[
633,
6,
4590
],
[
4590,
160,
588
]
],
[
[
633,
180,
171
],
[
171,
26,
588
]
],
[
[
633,
42,
568
],
[
568,
187,
588
]
],
[
[
633,
42,
681
],
[
681,
196,
588
]
],
[
[
633,
42,
863
],
[
863,
42,
588
]
],
[
[
633,
55,
413
],
[
413,
42,
588
]
],
[
[
633,
209,
784
],
[
784,
42,
588
]
],
[
[
633,
104,
262
],
[
262,
196,
588
]
],
[
[
633,
69,
501
],
[
501,
42,
588
]
]
] |
[
[
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} may increase the arrhythmogenic activities of {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
]
],
[
[
"Cisapride",
"{u} may decrease the metabolism of {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
]
]
] |
Cisapride (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Chloroquine (Compound)
Cisapride can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Chloroquine
Cisapride may increase the QTc prolonging activities of Tamoxifen and Tamoxifen may reduce the serum concentration of the active metabolites of Chloroquine
Cisapride may increase the QTc prolonging activities of Clozapine and Clozapine may increase the QTc prolonging activities of Chloroquine
Cisapride may increase the QTc prolonging activities of Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Chloroquine
Cisapride may increase the severity of QTc prolonging effects when combined with Pimozide and Pimozide may increase the QTc prolonging activities of Chloroquine
Cisapride may increase the severity of QTc prolonging effects when combined with Anagrelide and Anagrelide may increase the QTc prolonging activities of Chloroquine
Cisapride may increase the arrhythmogenic activities of Amitriptyline and Amitriptyline may increase the QTc prolonging activities of Chloroquine
Cisapride may decrease the metabolism of Saquinavir and Saquinavir may increase the QTc prolonging activities of Chloroquine
|
DB09324
|
DB01082
| 807 | 897 |
Sulbactam
|
Streptomycin
|
Sulbactam is a beta (β)-lactamase inhibitor and a derivative of the basic penicillin nucleus. When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.
|
Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.
|
The serum concentration of Streptomycin can be decreased when it is combined with Sulbactam.
| 74 |
[
[
[
807,
97,
897
]
],
[
[
807,
97,
896
],
[
896,
155,
897
]
],
[
[
807,
92,
1572
],
[
1572,
246,
897
]
],
[
[
807,
97,
896
],
[
896,
1,
898
],
[
898,
155,
897
]
],
[
[
807,
182,
498
],
[
498,
28,
873
],
[
873,
97,
897
]
],
[
[
807,
92,
1572
],
[
1572,
246,
896
],
[
896,
155,
897
]
],
[
[
807,
97,
896
],
[
896,
169,
24689
],
[
24689,
15,
897
]
],
[
[
807,
182,
342
],
[
342,
21,
28521
],
[
28521,
175,
897
]
],
[
[
807,
182,
498
],
[
498,
95,
893
],
[
893,
71,
897
]
],
[
[
807,
92,
1572
],
[
1572,
246,
1331
],
[
1331,
197,
897
]
]
] |
[
[
[
"Sulbactam",
"{u} may decrease the serum concentration of {v}",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may decrease the serum concentration of {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound)",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may decrease the therapeutic efficacy of {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may decrease the serum concentration of {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound)",
"Amikacin"
],
[
"Amikacin",
"{u} (Compound) resembles {v} (Compound)",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Benzylpenicillin benzathine hydrate"
],
[
"Benzylpenicillin benzathine hydrate",
"{u} may decrease the serum concentration of {v}",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may decrease the therapeutic efficacy of {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound)",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may decrease the serum concentration of {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Aminoglycosides"
],
[
"Aminoglycosides",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the serum concentration of {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Streptomycin"
]
],
[
[
"Sulbactam",
"{u} may decrease the therapeutic efficacy of {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Capreomycin"
],
[
"Capreomycin",
"{u} may increase the neuromuscular blocking activities of {v}",
"Streptomycin"
]
]
] |
Sulbactam may decrease the serum concentration of Kanamycin and Kanamycin (Compound) resembles Streptomycin (Compound)
Sulbactam may decrease the therapeutic efficacy of Picosulfuric acid and Picosulfuric acid may decrease the therapeutic efficacy of Streptomycin
Sulbactam may decrease the serum concentration of Kanamycin and Kanamycin (Compound) resembles Amikacin (Compound) and Amikacin (Compound) resembles Streptomycin (Compound)
Sulbactam may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Benzylpenicillin benzathine hydrate and Benzylpenicillin benzathine hydrate may decrease the serum concentration of Streptomycin
Sulbactam may decrease the therapeutic efficacy of Picosulfuric acid and Picosulfuric acid may decrease the therapeutic efficacy of Kanamycin and Kanamycin (Compound) resembles Streptomycin (Compound)
Sulbactam may decrease the serum concentration of Kanamycin and Kanamycin (Compound) is included by Aminoglycosides (Pharmacologic Class) and Aminoglycosides (Pharmacologic Class) includes Streptomycin (Compound)
Sulbactam may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Streptomycin (Compound)
Sulbactam may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the serum concentration of Etacrynic acid and Etacrynic acid may increase the severity of adverse effects when combined with Streptomycin
Sulbactam may decrease the therapeutic efficacy of Picosulfuric acid and Picosulfuric acid may decrease the therapeutic efficacy of Capreomycin and Capreomycin may increase the neuromuscular blocking activities of Streptomycin
|
DB00405
|
DB00754
| 979 | 821 |
Dexbrompheniramine
|
Ethotoin
|
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
|
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.
|
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin.
| 48 |
[
[
[
979,
71,
821
]
],
[
[
979,
71,
161
],
[
161,
155,
821
]
],
[
[
979,
225,
164
],
[
164,
71,
821
]
],
[
[
979,
18,
14599
],
[
14599,
172,
821
]
],
[
[
979,
192,
1266
],
[
1266,
38,
821
]
],
[
[
979,
155,
72
],
[
72,
38,
821
]
],
[
[
979,
38,
1264
],
[
1264,
192,
821
]
],
[
[
979,
54,
1365
],
[
1365,
208,
821
]
],
[
[
979,
71,
963
],
[
963,
225,
821
]
],
[
[
979,
71,
965
],
[
965,
71,
821
]
]
] |
[
[
[
"Dexbrompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gabapentin enacarbil"
],
[
"Gabapentin enacarbil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Entacapone"
],
[
"Entacapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
]
]
] |
Dexbrompheniramine may increase the severity of adverse effects when combined with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Dexbrompheniramine may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital may increase the severity of adverse effects when combined with Ethotoin
Dexbrompheniramine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Ethotoin (Compound)
Dexbrompheniramine may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Ethotoin
Dexbrompheniramine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may increase the central nervous system depressant activities of Ethotoin
Dexbrompheniramine may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Ethotoin
Dexbrompheniramine may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Ethotoin
Dexbrompheniramine may increase the severity of adverse effects when combined with Gabapentin enacarbil and Gabapentin enacarbil may increase the severity of adverse effects when combined with Ethotoin
Dexbrompheniramine may increase the severity of adverse effects when combined with Entacapone and Entacapone may increase the severity of adverse effects when combined with Ethotoin
|
DB06206
|
DB09389
| 791 | 546 |
Sugammadex
|
Norgestrel
|
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
|
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.
|
The serum concentration of Norgestrel can be decreased when it is combined with Sugammadex.
| 74 |
[
[
[
791,
97,
546
]
],
[
[
791,
182,
342
],
[
342,
34,
546
]
],
[
[
791,
182,
342
],
[
342,
180,
171
],
[
171,
26,
546
]
],
[
[
791,
182,
794
],
[
794,
28,
219
],
[
219,
34,
546
]
],
[
[
791,
182,
665
],
[
665,
180,
156
],
[
156,
92,
546
]
],
[
[
791,
182,
760
],
[
760,
28,
764
],
[
764,
249,
546
]
],
[
[
791,
182,
665
],
[
665,
182,
342
],
[
342,
34,
546
]
],
[
[
791,
182,
744
],
[
744,
28,
613
],
[
613,
223,
546
]
],
[
[
791,
182,
169
],
[
169,
285,
384
],
[
384,
34,
546
]
],
[
[
791,
182,
744
],
[
744,
251,
147
],
[
147,
26,
546
]
]
] |
[
[
[
"Sugammadex",
"{u} may decrease the serum concentration of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may decrease the anticoagulant activities of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Protocatechualdehyde"
],
[
"Protocatechualdehyde",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may decrease the anticoagulant activities of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may decrease the therapeutic efficacy of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Pentaerythritol tetranitrate"
],
[
"Pentaerythritol tetranitrate",
"{u} may increase the anticoagulant activities of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the serum concentration of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may decrease the anticoagulant activities of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may decrease the anticoagulant activities of {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may increase the anticoagulant activities of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Norgestrel"
]
]
] |
Sugammadex may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol may decrease the anticoagulant activities of Norgestrel
Sugammadex may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Norgestrel
Sugammadex may increase the anticoagulant activities of Protocatechualdehyde and Protocatechualdehyde may increase the anticoagulant activities of Warfarin and Warfarin may decrease the anticoagulant activities of Norgestrel
Sugammadex may increase the anticoagulant activities of Bivalirudin and Bivalirudin can increase the metabolism of Carbamazepine and Carbamazepine may decrease the therapeutic efficacy of Norgestrel
Sugammadex may increase the anticoagulant activities of Pentaerythritol tetranitrate and Pentaerythritol tetranitrate may increase the anticoagulant activities of Dasatinib and Dasatinib may increase the serum concentration of Norgestrel
Sugammadex may increase the anticoagulant activities of Bivalirudin and Bivalirudin may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol may decrease the anticoagulant activities of Norgestrel
Sugammadex may increase the anticoagulant activities of Edoxaban and Edoxaban may increase the anticoagulant activities of Ticlopidine and Ticlopidine may decrease the metabolism of Norgestrel
Sugammadex may increase the anticoagulant activities of Phenindione and Phenindione (Compound) resembles Phenprocoumon (Compound) and Phenindione may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may decrease the anticoagulant activities of Norgestrel
Sugammadex may increase the anticoagulant activities of Edoxaban and Edoxaban may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Norgestrel
|
DB06216
|
DB00220
| 494 | 269 |
Asenapine
|
Nelfinavir
|
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
|
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
|
The serum concentration of Nelfinavir can be decreased when it is combined with Asenapine.
| 74 |
[
[
[
494,
97,
269
]
],
[
[
494,
97,
266
],
[
266,
69,
269
]
],
[
[
494,
249,
501
],
[
501,
1,
269
]
],
[
[
494,
92,
919
],
[
919,
246,
269
]
],
[
[
494,
6,
18777
],
[
18777,
160,
269
]
],
[
[
494,
21,
28792
],
[
28792,
175,
269
]
],
[
[
494,
180,
164
],
[
164,
26,
269
]
],
[
[
494,
180,
173
],
[
173,
33,
269
]
],
[
[
494,
225,
956
],
[
956,
42,
269
]
],
[
[
494,
42,
1187
],
[
1187,
42,
269
]
]
] |
[
[
[
"Asenapine",
"{u} may decrease the serum concentration of {v}",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} may decrease the serum concentration of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may decrease the metabolism of {v}",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} may increase the serum concentration of {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} (Compound) resembles {v} (Compound)",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} may decrease the therapeutic efficacy of {v}",
"Mitiglinide"
],
[
"Mitiglinide",
"{u} may decrease the therapeutic efficacy of {v}",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} (Compound) causes {v} (Side Effect)",
"Arthralgia"
],
[
"Arthralgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Nelfinavir"
]
],
[
[
"Asenapine",
"{u} may increase the QTc prolonging activities of {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Nelfinavir"
]
]
] |
Asenapine may decrease the serum concentration of Indinavir and Indinavir may decrease the metabolism of Nelfinavir
Asenapine may increase the serum concentration of Saquinavir and Saquinavir (Compound) resembles Nelfinavir (Compound)
Asenapine may decrease the therapeutic efficacy of Mitiglinide and Mitiglinide may decrease the therapeutic efficacy of Nelfinavir
Asenapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nelfinavir (Compound)
Asenapine (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Nelfinavir (Compound)
Asenapine can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Nelfinavir
Asenapine can increase the metabolism of Nevirapine and Nevirapine may reduce the serum concentration of the active metabolites of Nelfinavir
Asenapine may increase the severity of adverse effects when combined with Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Nelfinavir
Asenapine may increase the QTc prolonging activities of Goserelin and Goserelin may increase the QTc prolonging activities of Nelfinavir
|
DB00710
|
DB00684
| 1,320 | 906 |
Ibandronate
|
Tobramycin
|
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA approval on 16 May 2003.
|
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L
|
Ibandronate may increase the hypocalcemic activities of Tobramycin.
| 23 |
[
[
[
1320,
46,
906
]
],
[
[
1320,
46,
902
],
[
902,
155,
906
]
],
[
[
1320,
21,
28770
],
[
28770,
175,
906
]
],
[
[
1320,
155,
1342
],
[
1342,
46,
906
]
],
[
[
1320,
1,
421
],
[
421,
46,
906
]
],
[
[
1320,
225,
460
],
[
460,
248,
906
]
],
[
[
1320,
196,
588
],
[
588,
248,
906
]
],
[
[
1320,
46,
902
],
[
902,
1,
904
],
[
904,
155,
906
]
],
[
[
1320,
46,
904
],
[
904,
155,
902
],
[
902,
155,
906
]
],
[
[
1320,
21,
28770
],
[
28770,
175,
900
],
[
900,
155,
906
]
]
] |
[
[
[
"Ibandronate",
"{u} may increase the hypocalcemic activities of {v}",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} may increase the hypocalcemic activities of {v}",
"Arbekacin"
],
[
"Arbekacin",
"{u} (Compound) resembles {v} (Compound)",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Etidronic acid"
],
[
"Etidronic acid",
"{u} may increase the hypocalcemic activities of {v}",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
],
[
"Risedronic acid",
"{u} may increase the hypocalcemic activities of {v}",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etodolac"
],
[
"Etodolac",
"{u} may decrease the excretion rate {v}",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may decrease the excretion rate {v}",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} may increase the hypocalcemic activities of {v}",
"Arbekacin"
],
[
"Arbekacin",
"{u} (Compound) resembles {v} (Compound)",
"Paromomycin"
],
[
"Paromomycin",
"{u} (Compound) resembles {v} (Compound)",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} may increase the hypocalcemic activities of {v}",
"Paromomycin"
],
[
"Paromomycin",
"{u} (Compound) resembles {v} (Compound)",
"Arbekacin"
],
[
"Arbekacin",
"{u} (Compound) resembles {v} (Compound)",
"Tobramycin"
]
],
[
[
"Ibandronate",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gentamicin"
],
[
"Gentamicin",
"{u} (Compound) resembles {v} (Compound)",
"Tobramycin"
]
]
] |
Ibandronate may increase the hypocalcemic activities of Arbekacin and Arbekacin (Compound) resembles Tobramycin (Compound)
Ibandronate (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Tobramycin (Compound)
Ibandronate (Compound) resembles Etidronic acid (Compound) and Etidronic acid may increase the hypocalcemic activities of Tobramycin
Ibandronate (Compound) resembles Risedronic acid (Compound) and Risedronic acid may increase the hypocalcemic activities of Tobramycin
Ibandronate may increase the severity of adverse effects when combined with Etodolac and Etodolac may decrease the excretion rate Tobramycin
Ibandronate may increase the QTc prolonging activities of Chloroquine and Chloroquine may decrease the excretion rate Tobramycin
Ibandronate may increase the hypocalcemic activities of Arbekacin and Arbekacin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) resembles Tobramycin (Compound)
Ibandronate may increase the hypocalcemic activities of Paromomycin and Paromomycin (Compound) resembles Arbekacin (Compound) and Arbekacin (Compound) resembles Tobramycin (Compound)
Ibandronate (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Gentamicin (Compound) and Gentamicin (Compound) resembles Tobramycin (Compound)
|
DB09297
|
DB01167
| 212 | 1,084 |
Paritaprevir
|
Itraconazole
|
Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as paritaprevir. As a newer generation and directly acting HCV antiviral, paritaprevir products have better Sustained Virological Response (SVR) rates, higher barriers to resistance, fewer side effects, and a reduced pill burden compared to older agents such as,,,, and. By combining multiple antiretroviral medications into fixed dose products, the viral lifecycle
|
First synthesized in the early 1980s, itraconazole is a broad-spectrum triazole antifungal agent used to treat a variety of infections. It is a 1:1:1:1 racemic mixture of four diastereomers, made up of two enantiomeric pairs, each possessing three chiral centers. Itraconazole was first approved in the US in 1992 and is available orally. While the intravenous formulation of the drug was formerly available, it was discontinued in the US in 2007.
|
The metabolism of Itraconazole can be decreased when combined with Paritaprevir.
| 46 |
[
[
[
212,
69,
1084
]
],
[
[
212,
69,
479
],
[
479,
69,
1084
]
],
[
[
212,
69,
575
],
[
575,
42,
1084
]
],
[
[
212,
95,
564
],
[
564,
223,
1084
]
],
[
[
212,
69,
755
],
[
755,
223,
1084
]
],
[
[
212,
249,
307
],
[
307,
69,
1084
]
],
[
[
212,
69,
501
],
[
501,
95,
1084
]
],
[
[
212,
95,
1394
],
[
1394,
249,
1084
]
],
[
[
212,
249,
515
],
[
515,
95,
1084
]
],
[
[
212,
95,
1324
],
[
1324,
95,
1084
]
]
] |
[
[
[
"Paritaprevir",
"{u} may decrease the metabolism of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may decrease the metabolism of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may increase the serum concentration of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may decrease the metabolism of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may increase the serum concentration of {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may decrease the metabolism of {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may increase the serum concentration of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may increase the serum concentration of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may increase the serum concentration of {v}",
"Alprazolam"
],
[
"Alprazolam",
"{u} may increase the serum concentration of {v}",
"Itraconazole"
]
],
[
[
"Paritaprevir",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the serum concentration of {v}",
"Itraconazole"
]
]
] |
Paritaprevir may decrease the metabolism of Posaconazole and Posaconazole may decrease the metabolism of Itraconazole
Paritaprevir may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Itraconazole
Paritaprevir may increase the serum concentration of Atazanavir and Atazanavir may decrease the metabolism of Itraconazole
Paritaprevir may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Itraconazole
Paritaprevir may increase the serum concentration of Fluvastatin and Fluvastatin may decrease the metabolism of Itraconazole
Paritaprevir may decrease the metabolism of Saquinavir and Saquinavir may increase the serum concentration of Itraconazole
Paritaprevir may increase the serum concentration of Palbociclib and Palbociclib may increase the serum concentration of Itraconazole
Paritaprevir may increase the serum concentration of Alprazolam and Alprazolam may increase the serum concentration of Itraconazole
Paritaprevir may increase the serum concentration of Ceritinib and Ceritinib may increase the serum concentration of Itraconazole
|
DB09275
|
DB01410
| 78 | 116 |
Bismuth subcitrate potassium
|
Ciclesonide
|
A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).
|
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
|
The bioavailability of Ciclesonide can be decreased when combined with Bismuth subcitrate potassium.
| 2 |
[
[
[
78,
25,
116
]
],
[
[
78,
25,
96
],
[
96,
155,
116
]
],
[
[
78,
25,
82
],
[
82,
1,
116
]
],
[
[
78,
246,
86
],
[
86,
25,
116
]
],
[
[
78,
97,
1084
],
[
1084,
223,
116
]
],
[
[
78,
243,
564
],
[
564,
223,
116
]
],
[
[
78,
249,
1120
],
[
1120,
225,
116
]
],
[
[
78,
243,
862
],
[
862,
225,
116
]
],
[
[
78,
97,
588
],
[
588,
71,
116
]
],
[
[
78,
243,
764
],
[
764,
249,
116
]
]
] |
[
[
[
"Bismuth subcitrate potassium",
"{u} can decrease the bioavailability of {v}",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} can decrease the bioavailability of {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} can decrease the bioavailability of {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} may decrease the therapeutic efficacy of {v}",
"Calcium carbonate"
],
[
"Calcium carbonate",
"{u} can decrease the bioavailability of {v}",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} may decrease the serum concentration of {v}",
"Itraconazole"
],
[
"Itraconazole",
"{u} may decrease the metabolism of {v}",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} may decrease the absorption and serum concentration of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may decrease the metabolism of {v}",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} may increase the serum concentration of {v}",
"Memantine"
],
[
"Memantine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} may decrease the absorption and serum concentration of {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} may decrease the serum concentration of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ciclesonide"
]
],
[
[
"Bismuth subcitrate potassium",
"{u} may decrease the absorption and serum concentration of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the serum concentration of {v}",
"Ciclesonide"
]
]
] |
Bismuth subcitrate potassium can decrease the bioavailability of Methylprednisolone and Methylprednisolone (Compound) resembles Ciclesonide (Compound)
Bismuth subcitrate potassium can decrease the bioavailability of Prednisolone and Prednisolone (Compound) resembles Ciclesonide (Compound)
Bismuth subcitrate potassium may decrease the therapeutic efficacy of Calcium carbonate and Calcium carbonate can decrease the bioavailability of Ciclesonide
Bismuth subcitrate potassium may decrease the serum concentration of Itraconazole and Itraconazole may decrease the metabolism of Ciclesonide
Bismuth subcitrate potassium may decrease the absorption and serum concentration of Atazanavir and Atazanavir may decrease the metabolism of Ciclesonide
Bismuth subcitrate potassium may increase the serum concentration of Memantine and Memantine may increase the severity of adverse effects when combined with Ciclesonide
Bismuth subcitrate potassium may decrease the absorption and serum concentration of Trovafloxacin and Trovafloxacin may increase the severity of adverse effects when combined with Ciclesonide
Bismuth subcitrate potassium may decrease the serum concentration of Chloroquine and Chloroquine may increase the severity of adverse effects when combined with Ciclesonide
Bismuth subcitrate potassium may decrease the absorption and serum concentration of Dasatinib and Dasatinib may increase the serum concentration of Ciclesonide
|
DB01395
|
DB00784
| 1,117 | 375 |
Drospirenone
|
Mefenamic acid
|
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thrombo
|
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
|
Drospirenone may increase the hyperkalemic activities of Mefenamic acid.
| 67 |
[
[
[
1117,
90,
375
]
],
[
[
1117,
90,
4
],
[
4,
225,
375
]
],
[
[
1117,
90,
770
],
[
770,
1,
375
]
],
[
[
1117,
90,
388
],
[
388,
155,
375
]
],
[
[
1117,
6,
7784
],
[
7784,
160,
375
]
],
[
[
1117,
21,
28643
],
[
28643,
175,
375
]
],
[
[
1117,
246,
156
],
[
156,
26,
375
]
],
[
[
1117,
251,
177
],
[
177,
26,
375
]
],
[
[
1117,
188,
384
],
[
384,
28,
375
]
],
[
[
1117,
90,
687
],
[
687,
28,
375
]
]
] |
[
[
[
"Drospirenone",
"{u} may increase the hyperkalemic activities of {v}",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} may increase the hyperkalemic activities of {v}",
"Tiaprofenic acid"
],
[
"Tiaprofenic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} may increase the hyperkalemic activities of {v}",
"Floctafenine"
],
[
"Floctafenine",
"{u} (Compound) resembles {v} (Compound)",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} may increase the hyperkalemic activities of {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} may decrease the therapeutic efficacy of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} may decrease the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Mefenamic acid"
]
],
[
[
"Drospirenone",
"{u} may increase the hyperkalemic activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Mefenamic acid"
]
]
] |
Drospirenone may increase the hyperkalemic activities of Tiaprofenic acid and Tiaprofenic acid may increase the severity of adverse effects when combined with Mefenamic acid
Drospirenone may increase the hyperkalemic activities of Floctafenine and Floctafenine (Compound) resembles Mefenamic acid (Compound)
Drospirenone may increase the hyperkalemic activities of Flurbiprofen and Flurbiprofen (Compound) resembles Mefenamic acid (Compound)
Drospirenone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Mefenamic acid (Compound)
Drospirenone (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Mefenamic acid (Compound)
Drospirenone may decrease the therapeutic efficacy of Carbamazepine and Carbamazepine can increase the metabolism of Mefenamic acid
Drospirenone may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Mefenamic acid
Drospirenone may decrease the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Mefenamic acid
Drospirenone may increase the hyperkalemic activities of Nafamostat and Nafamostat may increase the anticoagulant activities of Mefenamic acid
|
DB00763
|
DB00860
| 1,107 | 82 |
Methimazole
|
Prednisolone
|
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339] On a weight basis, methimazole is 10 times more potent than the other major antithyroid thionamide used in North America, [propylthiouracil], and is the active metabolite of the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of the former British Commonwealth. Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter
|
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
|
The serum concentration of Prednisolone can be decreased when it is combined with Methimazole.
| 74 |
[
[
[
1107,
97,
82
]
],
[
[
1107,
6,
15394
],
[
15394,
160,
82
]
],
[
[
1107,
21,
28463
],
[
28463,
175,
82
]
],
[
[
1107,
188,
219
],
[
219,
28,
82
]
],
[
[
1107,
33,
1075
],
[
1075,
187,
82
]
],
[
[
1107,
225,
530
],
[
530,
223,
82
]
],
[
[
1107,
225,
369
],
[
369,
71,
82
]
],
[
[
1107,
249,
1348
],
[
1348,
234,
82
]
],
[
[
1107,
249,
1240
],
[
1240,
95,
82
]
],
[
[
1107,
6,
15394
],
[
15394,
160,
119
],
[
119,
1,
82
]
]
] |
[
[
[
"Methimazole",
"{u} may decrease the serum concentration of {v}",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} may decrease the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
],
[
"Artesunate",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may decrease the metabolism of {v}",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pergolide"
],
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} may increase the serum concentration of {v}",
"Ouabain"
],
[
"Ouabain",
"{u} may decrease the cardiotoxic activities of {v}",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} may increase the serum concentration of {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Prednisolone"
]
],
[
[
"Methimazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
]
]
] |
Methimazole (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Prednisolone (Compound)
Methimazole (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Prednisolone (Compound)
Methimazole may decrease the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Prednisolone
Methimazole may reduce the serum concentration of the active metabolites of Artesunate and Artesunate may reduce the serum concentration of the active metabolites of Prednisolone
Methimazole may increase the severity of adverse effects when combined with Dihydroergotamine and Dihydroergotamine may decrease the metabolism of Prednisolone
Methimazole may increase the severity of adverse effects when combined with Pergolide and Pergolide may increase the severity of adverse effects when combined with Prednisolone
Methimazole may increase the serum concentration of Ouabain and Ouabain may decrease the cardiotoxic activities of Prednisolone
Methimazole may increase the serum concentration of Bosutinib and Bosutinib may increase the serum concentration of Prednisolone
Methimazole (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone (Compound) resembles Prednisolone (Compound)
|
DB06802
|
DB00469
| 780 | 584 |
Nepafenac
|
Tenoxicam
|
Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.
|
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
|
The risk or severity of adverse effects can be increased when Nepafenac is combined with Tenoxicam.
| 48 |
[
[
[
780,
71,
584
]
],
[
[
780,
6,
7784
],
[
7784,
160,
584
]
],
[
[
780,
21,
28613
],
[
28613,
175,
584
]
],
[
[
780,
155,
156
],
[
156,
26,
584
]
],
[
[
780,
182,
560
],
[
560,
28,
584
]
],
[
[
780,
49,
862
],
[
862,
203,
584
]
],
[
[
780,
51,
557
],
[
557,
205,
584
]
],
[
[
780,
213,
1358
],
[
1358,
59,
584
]
],
[
[
780,
225,
239
],
[
239,
223,
584
]
],
[
[
780,
71,
582
],
[
582,
223,
584
]
]
] |
[
[
[
"Nepafenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} may increase the anticoagulant activities of {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may increase the anticoagulant activities of {v}",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} may decrease the diuretic activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} may decrease the antihypertensive activities of {v}",
"Amiloride"
],
[
"Amiloride",
"{u} may decrease the antihypertensive activities of {v}",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may decrease the metabolism of {v}",
"Tenoxicam"
]
],
[
[
"Nepafenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may decrease the metabolism of {v}",
"Tenoxicam"
]
]
] |
Nepafenac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Tenoxicam (Compound)
Nepafenac (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Tenoxicam (Compound)
Nepafenac (Compound) resembles Carbamazepine (Compound) and Carbamazepine can increase the metabolism of Tenoxicam
Nepafenac may increase the anticoagulant activities of Rivaroxaban and Rivaroxaban may increase the anticoagulant activities of Tenoxicam
Nepafenac may increase the neuroexcitatory activities of Trovafloxacin and Trovafloxacin may increase the neuroexcitatory activities of Tenoxicam
Nepafenac may decrease the diuretic activities of Torasemide and Torasemide may decrease the diuretic activities of Tenoxicam
Nepafenac may decrease the antihypertensive activities of Amiloride and Amiloride may decrease the antihypertensive activities of Tenoxicam
Nepafenac may increase the severity of adverse effects when combined with Valsartan and Valsartan may decrease the metabolism of Tenoxicam
Nepafenac may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may decrease the metabolism of Tenoxicam
|
DB00877
|
DB09048
| 404 | 476 |
Sirolimus
|
Netupitant
|
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in
|
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
|
The serum concentration of Netupitant can be increased when it is combined with Sirolimus.
| 72 |
[
[
[
404,
95,
476
]
],
[
[
404,
92,
297
],
[
297,
223,
476
]
],
[
[
404,
69,
41
],
[
41,
223,
476
]
],
[
[
404,
95,
1086
],
[
1086,
223,
476
]
],
[
[
404,
225,
1404
],
[
1404,
71,
476
]
],
[
[
404,
92,
481
],
[
481,
95,
476
]
],
[
[
404,
69,
143
],
[
143,
95,
476
]
],
[
[
404,
71,
329
],
[
329,
95,
476
]
],
[
[
404,
225,
247
],
[
247,
95,
476
]
],
[
[
404,
95,
1092
],
[
1092,
95,
476
]
]
] |
[
[
[
"Sirolimus",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may decrease the therapeutic efficacy of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may increase the serum concentration of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nicergoline"
],
[
"Nicergoline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may decrease the therapeutic efficacy of {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrendipine"
],
[
"Nitrendipine",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Sirolimus",
"{u} may increase the serum concentration of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
]
] |
Sirolimus may decrease the therapeutic efficacy of Tolbutamide and Tolbutamide may decrease the metabolism of Netupitant
Sirolimus may decrease the metabolism of Clemastine and Clemastine may decrease the metabolism of Netupitant
Sirolimus may increase the serum concentration of Clotrimazole and Clotrimazole may decrease the metabolism of Netupitant
Sirolimus may increase the severity of adverse effects when combined with Nicergoline and Nicergoline may increase the severity of adverse effects when combined with Netupitant
Sirolimus may decrease the therapeutic efficacy of Sitagliptin and Sitagliptin may increase the serum concentration of Netupitant
Sirolimus may decrease the metabolism of Erythromycin and Erythromycin may increase the serum concentration of Netupitant
Sirolimus may increase the severity of adverse effects when combined with Nitrendipine and Nitrendipine may increase the serum concentration of Netupitant
Sirolimus may increase the severity of adverse effects when combined with Bromocriptine and Bromocriptine may increase the serum concentration of Netupitant
Sirolimus may increase the serum concentration of Telaprevir and Telaprevir may increase the serum concentration of Netupitant
|
DB01337
|
DB01452
| 73 | 1,012 |
Pancuronium
|
Diamorphine
|
A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
|
Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs. As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom.
|
The risk or severity of adverse effects can be increased when Pancuronium is combined with Diamorphine.
| 48 |
[
[
[
73,
71,
1012
]
],
[
[
73,
71,
1083
],
[
1083,
38,
1012
]
],
[
[
73,
71,
579
],
[
579,
71,
1012
]
],
[
[
73,
71,
493
],
[
493,
225,
1012
]
],
[
[
73,
107,
1261
],
[
1261,
192,
1012
]
],
[
[
73,
43,
405
],
[
405,
192,
1012
]
],
[
[
73,
225,
72
],
[
72,
38,
1012
]
],
[
[
73,
249,
1049
],
[
1049,
225,
1012
]
],
[
[
73,
225,
19
],
[
19,
71,
1012
]
],
[
[
73,
225,
51
],
[
51,
225,
1012
]
]
] |
[
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Codeine"
],
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethylmorphine"
],
[
"Ethylmorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the tachycardic activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the neuromuscular blocking activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the serum concentration of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Anisotropine methylbromide"
],
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diamorphine"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diamorphine"
]
]
] |
Pancuronium may increase the severity of adverse effects when combined with Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Diamorphine
Pancuronium may increase the severity of adverse effects when combined with Codeine and Codeine may increase the severity of adverse effects when combined with Diamorphine
Pancuronium may increase the severity of adverse effects when combined with Ethylmorphine and Ethylmorphine may increase the severity of adverse effects when combined with Diamorphine
Pancuronium may increase the tachycardic activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Diamorphine
Pancuronium may increase the neuromuscular blocking activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Diamorphine
Pancuronium may increase the severity of adverse effects when combined with Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Diamorphine
Pancuronium may increase the serum concentration of Bendroflumethiazide and Bendroflumethiazide may increase the severity of adverse effects when combined with Diamorphine
Pancuronium may increase the severity of adverse effects when combined with Anisotropine methylbromide and Anisotropine methylbromide may increase the severity of adverse effects when combined with Diamorphine
Pancuronium may increase the severity of adverse effects when combined with Scopolamine and Scopolamine may increase the severity of adverse effects when combined with Diamorphine
|
DB00622
|
DB09070
| 158 | 835 |
Nicardipine
|
Tibolone
|
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
|
Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha. Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and progestogenic properties. It has been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and the treatment of post-menopausal symptoms. Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the development of osteoporosis. In June 2006, Organon Pharmaceuticals announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for tibolone had not been approved. Interestingly, the
|
Nicardipine may increase the hypotensive activities of Tibolone.
| 59 |
[
[
[
158,
82,
835
]
],
[
[
158,
223,
219
],
[
219,
28,
835
]
],
[
[
158,
186,
344
],
[
344,
32,
835
]
],
[
[
158,
223,
615
],
[
615,
32,
835
]
],
[
[
158,
223,
243
],
[
243,
37,
835
]
],
[
[
158,
69,
654
],
[
654,
50,
835
]
],
[
[
158,
59,
230
],
[
230,
213,
835
]
],
[
[
158,
236,
1051
],
[
1051,
82,
835
]
],
[
[
158,
223,
483
],
[
483,
236,
835
]
],
[
[
158,
82,
911
],
[
911,
82,
835
]
]
] |
[
[
[
"Nicardipine",
"{u} may increase the hypotensive activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may increase the antihypertensive activities of {v}",
"Udenafil"
],
[
"Udenafil",
"{u} may increase the antihypertensive activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Tipranavir"
],
[
"Tipranavir",
"{u} may increase the dermatologic adverse activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may decrease the antihypertensive activities of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
],
[
"Travoprost",
"{u} may increase the hypotensive activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Sitaxentan"
],
[
"Sitaxentan",
"{u} may increase the hypotensive activities of {v}",
"Tibolone"
]
],
[
[
"Nicardipine",
"{u} may increase the hypotensive activities of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the hypotensive activities of {v}",
"Tibolone"
]
]
] |
Nicardipine may decrease the metabolism of Warfarin and Warfarin may increase the anticoagulant activities of Tibolone
Nicardipine may increase the antihypertensive activities of Udenafil and Udenafil may increase the antihypertensive activities of Tibolone
Nicardipine may decrease the metabolism of Sildenafil and Sildenafil may increase the antihypertensive activities of Tibolone
Nicardipine may decrease the metabolism of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Tibolone
Nicardipine may decrease the metabolism of Tipranavir and Tipranavir may increase the dermatologic adverse activities of Tibolone
Nicardipine may decrease the antihypertensive activities of Yohimbine and Yohimbine may decrease the antihypertensive activities of Tibolone
Nicardipine may increase the hypotensive activities of Travoprost and Travoprost may increase the hypotensive activities of Tibolone
Nicardipine may decrease the metabolism of Sitaxentan and Sitaxentan may increase the hypotensive activities of Tibolone
Nicardipine may increase the hypotensive activities of Oxprenolol and Oxprenolol may increase the hypotensive activities of Tibolone
|
DB01239
|
DB00588
| 967 | 84 |
Chlorprothixene
|
Fluticasone propionate
|
Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
|
Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990.
|
The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluticasone propionate.
| 48 |
[
[
[
967,
71,
84
]
],
[
[
967,
7,
12023
],
[
12023,
161,
84
]
],
[
[
967,
18,
1908
],
[
1908,
161,
84
]
],
[
[
967,
18,
11160
],
[
11160,
172,
84
]
],
[
[
967,
71,
161
],
[
161,
26,
84
]
],
[
[
967,
225,
156
],
[
156,
26,
84
]
],
[
[
967,
184,
674
],
[
674,
30,
84
]
],
[
[
967,
38,
1257
],
[
1257,
192,
84
]
],
[
[
967,
192,
287
],
[
287,
38,
84
]
],
[
[
967,
54,
471
],
[
471,
208,
84
]
]
] |
[
[
[
"Chlorprothixene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} (Compound) downregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is upregulated by {v} (Compound)",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} (Compound) downregulates {v} (Gene)",
"TYMS"
],
[
"TYMS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluticasone propionate"
]
],
[
[
"Chlorprothixene",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Fluticasone propionate"
]
]
] |
Chlorprothixene (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Fluticasone propionate (Compound)
Chlorprothixene (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Fluticasone propionate (Compound)
Chlorprothixene (Compound) downregulates TYMS (Gene) and TYMS (Gene) is downregulated by Fluticasone propionate (Compound)
Chlorprothixene may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Fluticasone propionate
Chlorprothixene may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Fluticasone propionate
Chlorprothixene can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Fluticasone propionate
Chlorprothixene may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Fluticasone propionate
Chlorprothixene may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Fluticasone propionate
Chlorprothixene may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Fluticasone propionate
|
DB00367
|
DB00222
| 606 | 473 |
Levonorgestrel
|
Glimepiride
|
Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of these devices are known as Jaydess, Kyleena, and Mirena. A subdermal implant of levonorgestrel that slowly releases the hormone over a long-term period is also available. In addition to the above uses, levonorgestrel is used as a component of long-term combination contraceptives.[A181991,L7760,L7778] Globally, levonorgestrel is the most commonly used emergency contraceptive. It was initially granted FDA approval in 1982 and was the first emergency contraceptive containing only progesterone, showing high levels of efficacy and a lack of estrogen
|
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
|
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Levonorgestrel.
| 69 |
[
[
[
606,
92,
473
]
],
[
[
606,
92,
769
],
[
769,
185,
473
]
],
[
[
606,
92,
526
],
[
526,
31,
473
]
],
[
[
606,
92,
297
],
[
297,
1,
473
]
],
[
[
606,
21,
28714
],
[
28714,
175,
473
]
],
[
[
606,
180,
177
],
[
177,
26,
473
]
],
[
[
606,
246,
161
],
[
161,
26,
473
]
],
[
[
606,
251,
191
],
[
191,
26,
473
]
],
[
[
606,
188,
384
],
[
384,
28,
473
]
],
[
[
606,
249,
39
],
[
39,
185,
473
]
]
] |
[
[
[
"Levonorgestrel",
"{u} may decrease the therapeutic efficacy of {v}",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} may decrease the therapeutic efficacy of {v}",
"Gliquidone"
],
[
"Gliquidone",
"{u} may increase the hypoglycemic activities of {v}",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} may decrease the therapeutic efficacy of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may increase the hypoglycemic activities of {v}",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} may decrease the therapeutic efficacy of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} may decrease the therapeutic efficacy of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} may decrease the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} can increase the metabolism of {v}",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} may decrease the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Glimepiride"
]
],
[
[
"Levonorgestrel",
"{u} may increase the serum concentration of {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may increase the hypoglycemic activities of {v}",
"Glimepiride"
]
]
] |
Levonorgestrel may decrease the therapeutic efficacy of Gliquidone and Gliquidone may increase the hypoglycemic activities of Glimepiride
Levonorgestrel may decrease the therapeutic efficacy of Glyburide and Glyburide may increase the hypoglycemic activities of Glimepiride
Levonorgestrel may decrease the therapeutic efficacy of Tolbutamide and Tolbutamide (Compound) resembles Glimepiride (Compound)
Levonorgestrel (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Glimepiride (Compound)
Levonorgestrel can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Glimepiride
Levonorgestrel may decrease the therapeutic efficacy of Primidone and Primidone can increase the metabolism of Glimepiride
Levonorgestrel may decrease the serum concentration of Aprepitant and Aprepitant can increase the metabolism of Glimepiride
Levonorgestrel may decrease the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Glimepiride
Levonorgestrel may increase the serum concentration of Selegiline and Selegiline may increase the hypoglycemic activities of Glimepiride
|
DB00730
|
DB00281
| 1,422 | 611 |
Thiabendazole
|
Lidocaine
|
2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)
|
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
|
The metabolism of Lidocaine can be decreased when combined with Thiabendazole.
| 46 |
[
[
[
1422,
69,
611
]
],
[
[
1422,
6,
12128
],
[
12128,
160,
611
]
],
[
[
1422,
21,
28408
],
[
28408,
175,
611
]
],
[
[
1422,
69,
173
],
[
173,
26,
611
]
],
[
[
1422,
69,
1086
],
[
1086,
223,
611
]
],
[
[
1422,
251,
417
],
[
417,
69,
611
]
],
[
[
1422,
223,
497
],
[
497,
223,
611
]
],
[
[
1422,
251,
1224
],
[
1224,
97,
611
]
],
[
[
1422,
6,
12128
],
[
12128,
160,
214
],
[
214,
69,
611
]
],
[
[
1422,
21,
28408
],
[
28408,
175,
214
],
[
214,
69,
611
]
]
] |
[
[
[
"Thiabendazole",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} may decrease the serum concentration of {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} may decrease the metabolism of {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} may decrease the serum concentration of {v}",
"Cyproterone acetate"
],
[
"Cyproterone acetate",
"{u} may decrease the serum concentration of {v}",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Levobupivacaine"
],
[
"Levobupivacaine",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
]
],
[
[
"Thiabendazole",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levobupivacaine"
],
[
"Levobupivacaine",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
]
]
] |
Thiabendazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lidocaine (Compound)
Thiabendazole (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Lidocaine (Compound)
Thiabendazole may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Lidocaine
Thiabendazole may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Lidocaine
Thiabendazole may decrease the serum concentration of Primaquine and Primaquine may decrease the metabolism of Lidocaine
Thiabendazole may decrease the metabolism of Theophylline and Theophylline may decrease the metabolism of Lidocaine
Thiabendazole may decrease the serum concentration of Cyproterone acetate and Cyproterone acetate may decrease the serum concentration of Lidocaine
Thiabendazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Levobupivacaine (Compound) and Levobupivacaine may decrease the metabolism of Lidocaine
Thiabendazole (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Levobupivacaine (Compound) and Levobupivacaine may decrease the metabolism of Lidocaine
|
DB01418
|
DB00655
| 342 | 124 |
Acenocoumarol
|
Estrone
|
Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood.
|
Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
|
Acenocoumarol may decrease the anticoagulant activities of Estrone.
| 11 |
[
[
[
342,
34,
124
]
],
[
[
342,
34,
79
],
[
79,
95,
124
]
],
[
[
342,
34,
352
],
[
352,
249,
124
]
],
[
[
342,
6,
7128
],
[
7128,
160,
124
]
],
[
[
342,
21,
29618
],
[
29618,
175,
124
]
],
[
[
342,
180,
173
],
[
173,
26,
124
]
],
[
[
342,
28,
150
],
[
150,
26,
124
]
],
[
[
342,
251,
156
],
[
156,
26,
124
]
],
[
[
342,
155,
219
],
[
219,
28,
124
]
],
[
[
342,
28,
632
],
[
632,
34,
124
]
]
] |
[
[
[
"Acenocoumarol",
"{u} may decrease the anticoagulant activities of {v}",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} may decrease the anticoagulant activities of {v}",
"Estrone sulfate"
],
[
"Estrone sulfate",
"{u} may increase the serum concentration of {v}",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} may decrease the anticoagulant activities of {v}",
"Estradiol"
],
[
"Estradiol",
"{u} may increase the serum concentration of {v}",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} (Compound) causes {v} (Side Effect)",
"Metrorrhagia"
],
[
"Metrorrhagia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Estrone"
]
],
[
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may decrease the anticoagulant activities of {v}",
"Estrone"
]
]
] |
sulfate and Estrone sulfate may increase the serum concentration of Estrone
Acenocoumarol may decrease the anticoagulant activities of Estradiol and Estradiol may increase the serum concentration of Estrone
Acenocoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Estrone (Compound)
Acenocoumarol (Compound) causes Metrorrhagia (Side Effect) and Metrorrhagia (Side Effect) is caused by Estrone (Compound)
Acenocoumarol can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Estrone
Acenocoumarol may increase the anticoagulant activities of Fosphenytoin and Fosphenytoin can increase the metabolism of Estrone
Acenocoumarol may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Estrone
Acenocoumarol (Compound) resembles Warfarin (Compound) and Warfarin may increase the anticoagulant activities of Estrone
Acenocoumarol may increase the anticoagulant activities of Apixaban and Apixaban may decrease the anticoagulant activities of Estrone
|
DB01320
|
DB06697
| 150 | 539 |
Fosphenytoin
|
Artemether
|
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
|
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Fosphenytoin resulting in a loss in efficacy.
| 10 |
[
[
[
150,
141,
539
]
],
[
[
150,
6,
7128
],
[
7128,
160,
539
]
],
[
[
150,
26,
171
],
[
171,
33,
539
]
],
[
[
150,
95,
158
],
[
158,
196,
539
]
],
[
[
150,
26,
183
],
[
183,
196,
539
]
],
[
[
150,
97,
1315
],
[
1315,
196,
539
]
],
[
[
150,
38,
1262
],
[
1262,
196,
539
]
],
[
[
150,
225,
992
],
[
992,
196,
539
]
],
[
[
150,
192,
543
],
[
543,
196,
539
]
],
[
[
150,
71,
997
],
[
997,
196,
539
]
]
] |
[
[
[
"Fosphenytoin",
"{u} may reduce the serum concentration of the active metabolites of {v} and {u} may decrease the serum concentration of {v}",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Fosphenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
]
] |
and Fosphenytoin may decrease the serum concentration of Artemether
Fosphenytoin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Artemether (Compound)
Fosphenytoin can increase the metabolism of Pentobarbital and Pentobarbital may reduce the serum concentration of the active metabolites of Artemether
Fosphenytoin may increase the serum concentration of Nicardipine and Nicardipine may increase the QTc prolonging activities of Artemether
Fosphenytoin can increase the metabolism of Indapamide and Indapamide may increase the QTc prolonging activities of Artemether
Fosphenytoin may decrease the serum concentration of Bedaquiline and Bedaquiline may increase the QTc prolonging activities of Artemether
Fosphenytoin may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the QTc prolonging activities of Artemether
Fosphenytoin may increase the severity of adverse effects when combined with Olanzapine and Olanzapine may increase the QTc prolonging activities of Artemether
Fosphenytoin may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the QTc prolonging activities of Artemether
Fosphenytoin may increase the severity of adverse effects when combined with Lithium cation and Lithium cation may increase the QTc prolonging activities of Artemether
|
DB00238
|
DB00715
| 173 | 878 |
Nevirapine
|
Paroxetine
|
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
|
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
|
The metabolism of Paroxetine can be decreased when combined with Nevirapine.
| 46 |
[
[
[
173,
69,
878
]
],
[
[
173,
6,
18777
],
[
18777,
160,
878
]
],
[
[
173,
21,
28450
],
[
28450,
175,
878
]
],
[
[
173,
26,
342
],
[
342,
28,
878
]
],
[
[
173,
26,
526
],
[
526,
31,
878
]
],
[
[
173,
97,
1018
],
[
1018,
31,
878
]
],
[
[
173,
69,
297
],
[
297,
31,
878
]
],
[
[
173,
95,
1106
],
[
1106,
187,
878
]
],
[
[
173,
249,
1083
],
[
1083,
187,
878
]
],
[
[
173,
26,
645
],
[
645,
42,
878
]
]
] |
[
[
[
"Nevirapine",
"{u} may decrease the metabolism of {v}",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may increase the hypoglycemic activities of {v}",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} may decrease the serum concentration of {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may increase the hypoglycemic activities of {v}",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} may increase the serum concentration of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Paroxetine"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Paroxetine"
]
]
] |
Nevirapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Paroxetine (Compound)
Nevirapine (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Paroxetine (Compound)
Nevirapine can increase the metabolism of Acenocoumarol and Acenocoumarol may increase the anticoagulant activities of Paroxetine
Nevirapine can increase the metabolism of Glyburide and Glyburide may increase the hypoglycemic activities of Paroxetine
Nevirapine may decrease the serum concentration of Sunitinib and Sunitinib may increase the hypoglycemic activities of Paroxetine
Nevirapine may decrease the metabolism of Tolbutamide and Tolbutamide may increase the hypoglycemic activities of Paroxetine
Nevirapine may increase the serum concentration of Fosaprepitant and Fosaprepitant may reduce the serum concentration of the active metabolites of Paroxetine
Nevirapine may increase the serum concentration of Hydrocodone and Hydrocodone may reduce the serum concentration of the active metabolites of Paroxetine
Nevirapine can increase the metabolism of Azithromycin and Azithromycin may increase the QTc prolonging activities of Paroxetine
|
DB01365
|
DB00875
| 707 | 931 |
Mephentermine
|
Flupentixol
|
A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)
|
Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid. Flupentixol is an antagonist of both D1 and D2 dopamine receptors. Available as oral tablets or long-acting intramuscular injections, flupentixol is marketed under brand names such as Depixol and Fluanxol. It is approved for use in Canada and other countries around the world, but not in the US. It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity. It has been marketed to manage symptoms of depression in patients who may or may not exhibit signs
|
Mephentermine may decrease the stimulatory activities of Flupentixol.
| 60 |
[
[
[
707,
83,
931
]
],
[
[
707,
83,
1378
],
[
1378,
1,
931
]
],
[
[
707,
83,
971
],
[
971,
225,
931
]
],
[
[
707,
83,
970
],
[
970,
196,
931
]
],
[
[
707,
6,
11891
],
[
11891,
160,
931
]
],
[
[
707,
98,
1262
],
[
1262,
192,
931
]
],
[
[
707,
261,
1265
],
[
1265,
192,
931
]
],
[
[
707,
260,
543
],
[
543,
38,
931
]
],
[
[
707,
245,
491
],
[
491,
38,
931
]
],
[
[
707,
225,
716
],
[
716,
196,
931
]
]
] |
[
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Acetophenazine"
],
[
"Acetophenazine",
"{u} (Compound) resembles {v} (Compound)",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Thiothixene"
],
[
"Thiothixene",
"{u} may increase the QTc prolonging activities of {v}",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} may decrease the sedative activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} may increase the tachycardic activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} may increase the vasopressor activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} may increase the analgesic activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Flupentixol"
]
],
[
[
"Mephentermine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Terbutaline"
],
[
"Terbutaline",
"{u} may increase the QTc prolonging activities of {v}",
"Flupentixol"
]
]
] |
Mephentermine may decrease the stimulatory activities of Acetophenazine and Acetophenazine (Compound) resembles Flupentixol (Compound)
Mephentermine may decrease the stimulatory activities of Zuclopenthixol and Zuclopenthixol may increase the severity of adverse effects when combined with Flupentixol
Mephentermine may decrease the stimulatory activities of Thiothixene and Thiothixene may increase the QTc prolonging activities of Flupentixol
Mephentermine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Flupentixol (Compound)
Mephentermine may decrease the sedative activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Flupentixol
Mephentermine may increase the tachycardic activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Flupentixol
Mephentermine may increase the vasopressor activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Flupentixol
Mephentermine may increase the analgesic activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Flupentixol
Mephentermine may increase the severity of adverse effects when combined with Terbutaline and Terbutaline may increase the QTc prolonging activities of Flupentixol
|
DB01189
|
DB00373
| 914 | 647 |
Desflurane
|
Timolol
|
Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.
|
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
|
The risk or severity of adverse effects can be increased when Desflurane is combined with Timolol.
| 48 |
[
[
[
914,
71,
647
]
],
[
[
914,
21,
28506
],
[
28506,
175,
647
]
],
[
[
914,
71,
150
],
[
150,
26,
647
]
],
[
[
914,
225,
156
],
[
156,
26,
647
]
],
[
[
914,
38,
702
],
[
702,
32,
647
]
],
[
[
914,
225,
1304
],
[
1304,
47,
647
]
],
[
[
914,
71,
730
],
[
730,
47,
647
]
],
[
[
914,
196,
1007
],
[
1007,
47,
647
]
],
[
[
914,
258,
721
],
[
721,
47,
647
]
],
[
[
914,
71,
509
],
[
509,
206,
647
]
]
] |
[
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Timolol"
]
],
[
[
"Desflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Timolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Timolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Timolol"
]
],
[
[
"Desflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Timolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Apomorphine"
],
[
"Apomorphine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Timolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Timolol"
]
],
[
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the atrioventricular blocking activities of {v}",
"Timolol"
]
],
[
[
"Desflurane",
"{u} may increase the arrhythmogenic activities of {v}",
"Norepinephrine"
],
[
"Norepinephrine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Timolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tamsulosin"
],
[
"Tamsulosin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Timolol"
]
]
] |
Desflurane (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Timolol (Compound)
Desflurane may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin can increase the metabolism of Timolol
Desflurane may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Timolol
Desflurane may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Timolol
Desflurane may increase the severity of adverse effects when combined with Apomorphine and Apomorphine may increase the atrioventricular blocking activities of Timolol
Desflurane may increase the severity of adverse effects when combined with Tizanidine and Tizanidine may increase the atrioventricular blocking activities of Timolol
Desflurane may increase the QTc prolonging activities of Paliperidone and Paliperidone may increase the atrioventricular blocking activities of Timolol
Desflurane may increase the arrhythmogenic activities of Norepinephrine and Norepinephrine may increase the atrioventricular blocking activities of Timolol
Desflurane may increase the severity of adverse effects when combined with Tamsulosin and Tamsulosin may increase the orthostatic hypotensive activities of Timolol
|
DB08991
|
DB00467
| 766 | 850 |
Epirizole
|
Enoxacin
|
Epirizole is an oral nonsteroidal anti-inflammatory drug (NSAID) used for muscle and joint pain.
|
A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.
|
Epirizole may increase the neuroexcitatory activities of Enoxacin.
| 26 |
[
[
[
766,
49,
850
]
],
[
[
766,
49,
863
],
[
863,
155,
850
]
],
[
[
766,
49,
862
],
[
862,
1,
850
]
],
[
[
766,
182,
498
],
[
498,
28,
850
]
],
[
[
766,
225,
334
],
[
334,
49,
850
]
],
[
[
766,
71,
810
],
[
810,
49,
850
]
],
[
[
766,
182,
687
],
[
687,
49,
850
]
],
[
[
766,
233,
798
],
[
798,
49,
850
]
],
[
[
766,
71,
110
],
[
110,
71,
850
]
],
[
[
766,
249,
457
],
[
457,
234,
850
]
]
] |
[
[
[
"Epirizole",
"{u} may increase the neuroexcitatory activities of {v}",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the neuroexcitatory activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Loxoprofen"
],
[
"Loxoprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the neuroexcitatory activities of {v}",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the nephrotoxic activities of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the neuroexcitatory activities of {v}",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desoximetasone"
],
[
"Desoximetasone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Enoxacin"
]
],
[
[
"Epirizole",
"{u} may increase the serum concentration of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Enoxacin"
]
]
] |
Epirizole may increase the neuroexcitatory activities of Gemifloxacin and Gemifloxacin (Compound) resembles Enoxacin (Compound)
Epirizole may increase the neuroexcitatory activities of Trovafloxacin and Trovafloxacin (Compound) resembles Enoxacin (Compound)
Epirizole may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Enoxacin
Epirizole may increase the severity of adverse effects when combined with Ibuprofen and Ibuprofen may increase the neuroexcitatory activities of Enoxacin
Epirizole may increase the severity of adverse effects when combined with Loxoprofen and Loxoprofen may increase the neuroexcitatory activities of Enoxacin
Epirizole may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the neuroexcitatory activities of Enoxacin
Epirizole may increase the nephrotoxic activities of Balsalazide and Balsalazide may increase the neuroexcitatory activities of Enoxacin
Epirizole may increase the severity of adverse effects when combined with Desoximetasone and Desoximetasone may increase the severity of adverse effects when combined with Enoxacin
Epirizole may increase the serum concentration of Digoxin and Digoxin may decrease the cardiotoxic activities of Enoxacin
|
DB01592
|
DB00927
| 1,487 | 492 |
Iron
|
Famotidine
|
A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.
|
Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.
|
Iron can cause a decrease in the absorption of Famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.
| 66 |
[
[
[
1487,
89,
492
]
],
[
[
1487,
21,
28644
],
[
28644,
175,
492
]
],
[
[
1487,
97,
884
],
[
884,
42,
492
]
],
[
[
1487,
89,
494
],
[
494,
42,
492
]
],
[
[
1487,
89,
451
],
[
451,
223,
492
]
],
[
[
1487,
21,
28644
],
[
28644,
175,
156
],
[
156,
26,
492
]
],
[
[
1487,
21,
28391
],
[
28391,
175,
1210
],
[
1210,
42,
492
]
],
[
[
1487,
97,
884
],
[
884,
6,
3664
],
[
3664,
160,
492
]
],
[
[
1487,
89,
494
],
[
494,
6,
15483
],
[
15483,
160,
492
]
],
[
[
1487,
97,
884
],
[
884,
21,
28424
],
[
28424,
175,
492
]
]
] |
[
[
[
"Iron",
"{u} may decrease the absorption and serum concentration of {v}",
"Famotidine"
]
],
[
[
"Iron",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Famotidine"
]
],
[
[
"Iron",
"{u} may decrease the serum concentration of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Famotidine"
]
],
[
[
"Iron",
"{u} may decrease the absorption and serum concentration of {v}",
"Asenapine"
],
[
"Asenapine",
"{u} may increase the QTc prolonging activities of {v}",
"Famotidine"
]
],
[
[
"Iron",
"{u} may decrease the absorption and serum concentration of {v}",
"Omeprazole"
],
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Famotidine"
]
],
[
[
"Iron",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Famotidine"
]
],
[
[
"Iron",
"{u} (Compound) causes {v} (Side Effect)",
"Viral infection"
],
[
"Viral infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Famotidine"
]
],
[
[
"Iron",
"{u} may decrease the serum concentration of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A2"
],
[
"SLC22A2",
"{u} (Gene) is bound by {v} (Compound)",
"Famotidine"
]
],
[
[
"Iron",
"{u} may decrease the absorption and serum concentration of {v}",
"Asenapine"
],
[
"Asenapine",
"{u} (Compound) binds {v} (Gene)",
"HRH2"
],
[
"HRH2",
"{u} (Gene) is bound by {v} (Compound)",
"Famotidine"
]
],
[
[
"Iron",
"{u} may decrease the serum concentration of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Atrioventricular block"
],
[
"Atrioventricular block",
"{u} (Side Effect) is caused by {v} (Compound)",
"Famotidine"
]
]
] |
Iron (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Famotidine (Compound)
Iron may decrease the serum concentration of Levofloxacin and Levofloxacin may increase the QTc prolonging activities of Famotidine
Iron may decrease the absorption and serum concentration of Asenapine and Asenapine may increase the QTc prolonging activities of Famotidine
Iron may decrease the absorption and serum concentration of Omeprazole and Omeprazole may decrease the metabolism of Famotidine
Iron (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine can increase the metabolism of Famotidine
Iron (Compound) causes Viral infection (Side Effect) and Viral infection (Side Effect) is caused by Ofloxacin (Compound) and Ofloxacin may increase the QTc prolonging activities of Famotidine
Iron may decrease the serum concentration of Levofloxacin and Levofloxacin (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Famotidine (Compound)
Iron may decrease the absorption and serum concentration of Asenapine and Asenapine (Compound) binds HRH2 (Gene) and HRH2 (Gene) is bound by Famotidine (Compound)
Iron may decrease the serum concentration of Levofloxacin and Levofloxacin (Compound) causes Atrioventricular block (Side Effect) and Atrioventricular block (Side Effect) is caused by Famotidine (Compound)
|
DB00737
|
DB04844
| 1,000 | 956 |
Meclizine
|
Tetrabenazine
|
Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. Commonly marketed under the brand name Antivert in the U.S., meclizine is available as oral tablets.
|
A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
|
The risk or severity of adverse effects can be increased when Meclizine is combined with Tetrabenazine.
| 48 |
[
[
[
1000,
71,
956
]
],
[
[
1000,
21,
28398
],
[
28398,
175,
956
]
],
[
[
1000,
192,
491
],
[
491,
38,
956
]
],
[
[
1000,
38,
702
],
[
702,
192,
956
]
],
[
[
1000,
122,
1262
],
[
1262,
192,
956
]
],
[
[
1000,
225,
914
],
[
914,
196,
956
]
],
[
[
1000,
71,
499
],
[
499,
196,
956
]
],
[
[
1000,
54,
471
],
[
471,
208,
956
]
],
[
[
1000,
71,
828
],
[
828,
223,
956
]
],
[
[
1000,
225,
861
],
[
861,
223,
956
]
]
] |
[
[
[
"Meclizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
],
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the QTc prolonging activities of {v}",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may decrease the metabolism of {v}",
"Tetrabenazine"
]
],
[
[
"Meclizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Tetrabenazine"
]
]
] |
Meclizine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Tetrabenazine (Compound)
Meclizine may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Tetrabenazine
Meclizine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Tetrabenazine
Meclizine (Compound) resembles Hydroxyzine (Compound) and Meclizine may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Tetrabenazine
Meclizine may increase the severity of adverse effects when combined with Desflurane and Desflurane may increase the QTc prolonging activities of Tetrabenazine
Meclizine may increase the severity of adverse effects when combined with Clomipramine and Clomipramine may increase the QTc prolonging activities of Tetrabenazine
Meclizine may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Tetrabenazine
Meclizine may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may decrease the metabolism of Tetrabenazine
Meclizine may increase the severity of adverse effects when combined with Fluvoxamine and Fluvoxamine may decrease the metabolism of Tetrabenazine
|
DB00599
|
DB00542
| 320 | 642 |
Thiopental
|
Benazepril
|
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)
|
Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
|
Thiopental may increase the hypotensive activities of Benazepril.
| 59 |
[
[
[
320,
82,
642
]
],
[
[
320,
82,
315
],
[
315,
225,
642
]
],
[
[
320,
225,
961
],
[
961,
1,
642
]
],
[
[
320,
82,
676
],
[
676,
1,
642
]
],
[
[
320,
225,
156
],
[
156,
26,
642
]
],
[
[
320,
38,
702
],
[
702,
32,
642
]
],
[
[
320,
71,
968
],
[
968,
206,
642
]
],
[
[
320,
82,
482
],
[
482,
69,
642
]
],
[
[
320,
82,
1065
],
[
1065,
71,
642
]
],
[
[
320,
97,
1025
],
[
1025,
71,
642
]
]
] |
[
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Enalapril"
],
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Lisinopril"
],
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
]
],
[
[
"Thiopental",
"{u} may decrease the serum concentration of {v}",
"Arotinolol"
],
[
"Arotinolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
]
]
] |
Thiopental may increase the hypotensive activities of Enalapril and Enalapril may increase the severity of adverse effects when combined with Benazepril
Thiopental may increase the severity of adverse effects when combined with Fentanyl and Fentanyl (Compound) resembles Benazepril (Compound)
Thiopental may increase the hypotensive activities of Lisinopril and Lisinopril (Compound) resembles Benazepril (Compound)
Thiopental may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Benazepril
Thiopental may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Benazepril
Thiopental may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Benazepril
Thiopental may increase the hypotensive activities of Verapamil and Verapamil may decrease the metabolism of Benazepril
Thiopental may increase the hypotensive activities of Minoxidil and Minoxidil may increase the severity of adverse effects when combined with Benazepril
Thiopental may decrease the serum concentration of Arotinolol and Arotinolol may increase the severity of adverse effects when combined with Benazepril
|
DB06237
|
DB09073
| 506 | 1,394 |
Avanafil
|
Palbociclib
|
Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition. It first received FDA approval on April 27, 2012, with subsequent EMA approval in June 2013.
|
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
|
The serum concentration of Palbociclib can be increased when it is combined with Avanafil.
| 72 |
[
[
[
506,
95,
1394
]
],
[
[
506,
95,
755
],
[
755,
223,
1394
]
],
[
[
506,
95,
615
],
[
615,
95,
1394
]
],
[
[
506,
251,
402
],
[
402,
95,
1394
]
],
[
[
506,
32,
306
],
[
306,
95,
1394
]
],
[
[
506,
95,
1269
],
[
1269,
249,
1394
]
],
[
[
506,
225,
154
],
[
154,
95,
1394
]
],
[
[
506,
180,
156
],
[
156,
95,
1394
]
],
[
[
506,
82,
278
],
[
278,
95,
1394
]
],
[
[
506,
214,
534
],
[
534,
95,
1394
]
]
] |
[
[
[
"Avanafil",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} may decrease the serum concentration of {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} may increase the serum concentration of {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} may increase the hypotensive activities of {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Avanafil",
"{u} may increase the vasodilatory activities of {v}",
"Isosorbide mononitrate"
],
[
"Isosorbide mononitrate",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
]
] |
Avanafil may increase the serum concentration of Doxycycline and Doxycycline may decrease the metabolism of Palbociclib
Avanafil may increase the serum concentration of Sildenafil and Sildenafil may increase the serum concentration of Palbociclib
Avanafil may decrease the serum concentration of Brigatinib and Brigatinib may increase the serum concentration of Palbociclib
Avanafil may increase the antihypertensive activities of Aliskiren and Aliskiren may increase the serum concentration of Palbociclib
Avanafil may increase the serum concentration of Stiripentol and Stiripentol may increase the serum concentration of Palbociclib
Avanafil may increase the severity of adverse effects when combined with Vardenafil and Vardenafil may increase the serum concentration of Palbociclib
Avanafil can increase the metabolism of Carbamazepine and Carbamazepine may increase the serum concentration of Palbociclib
Avanafil may increase the hypotensive activities of Alfuzosin and Alfuzosin may increase the serum concentration of Palbociclib
Avanafil may increase the vasodilatory activities of Isosorbide mononitrate and Isosorbide mononitrate may increase the serum concentration of Palbociclib
|
DB01282
|
DB00797
| 1,353 | 1,070 |
Carbetocin
|
Tolazoline
|
Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.
|
A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.
|
The risk or severity of adverse effects can be increased when Carbetocin is combined with Tolazoline.
| 48 |
[
[
[
1353,
71,
1070
]
],
[
[
1353,
71,
702
],
[
702,
32,
1070
]
],
[
[
1353,
52,
828
],
[
828,
206,
1070
]
],
[
[
1353,
71,
605
],
[
605,
71,
1070
]
],
[
[
1353,
71,
975
],
[
975,
225,
1070
]
],
[
[
1353,
225,
146
],
[
146,
71,
1070
]
],
[
[
1353,
71,
1022
],
[
1022,
236,
1070
]
],
[
[
1353,
236,
145
],
[
145,
82,
1070
]
],
[
[
1353,
71,
1041
],
[
1041,
82,
1070
]
],
[
[
1353,
82,
453
],
[
453,
236,
1070
]
]
] |
[
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cilnidipine"
],
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
],
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Barnidipine"
],
[
"Barnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} may increase the hypotensive activities of {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the hypotensive activities of {v}",
"Thiamylal"
],
[
"Thiamylal",
"{u} may increase the hypotensive activities of {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorthalidone"
],
[
"Chlorthalidone",
"{u} may increase the hypotensive activities of {v}",
"Tolazoline"
]
],
[
[
"Carbetocin",
"{u} may increase the hypotensive activities of {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may increase the hypotensive activities of {v}",
"Tolazoline"
]
]
] |
Carbetocin may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the antihypertensive activities of Tolazoline
Carbetocin may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Tolazoline
Carbetocin may increase the severity of adverse effects when combined with Cilnidipine and Cilnidipine may increase the severity of adverse effects when combined with Tolazoline
Carbetocin may increase the severity of adverse effects when combined with Tolcapone and Tolcapone may increase the severity of adverse effects when combined with Tolazoline
Carbetocin may increase the severity of adverse effects when combined with Barnidipine and Barnidipine may increase the severity of adverse effects when combined with Tolazoline
Carbetocin may increase the severity of adverse effects when combined with Pindolol and Pindolol may increase the hypotensive activities of Tolazoline
Carbetocin may increase the hypotensive activities of Thiamylal and Thiamylal may increase the hypotensive activities of Tolazoline
Carbetocin may increase the severity of adverse effects when combined with Chlorthalidone and Chlorthalidone may increase the hypotensive activities of Tolazoline
Carbetocin may increase the hypotensive activities of Risperidone and Risperidone may increase the hypotensive activities of Tolazoline
|
DB01142
|
DB00388
| 486 | 711 |
Doxepin
|
Phenylephrine
|
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter
|
Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939.
|
Doxepin may increase the vasopressor activities of Phenylephrine.
| 83 |
[
[
[
486,
106,
711
]
],
[
[
486,
71,
705
],
[
705,
1,
711
]
],
[
[
486,
71,
726
],
[
726,
225,
711
]
],
[
[
486,
106,
728
],
[
728,
225,
711
]
],
[
[
486,
6,
12128
],
[
12128,
160,
711
]
],
[
[
486,
21,
28450
],
[
28450,
175,
711
]
],
[
[
486,
106,
713
],
[
713,
71,
711
]
],
[
[
486,
213,
149
],
[
149,
225,
711
]
],
[
[
486,
252,
1335
],
[
1335,
71,
711
]
],
[
[
486,
71,
712
],
[
712,
71,
711
]
]
] |
[
[
[
"Doxepin",
"{u} may increase the vasopressor activities of {v}",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} may increase the vasopressor activities of {v}",
"Metaraminol"
],
[
"Metaraminol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} may increase the vasopressor activities of {v}",
"Midodrine"
],
[
"Midodrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} may decrease the antihypertensive activities of {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} may decrease the sedative activities of {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylephrine"
]
],
[
[
"Doxepin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylephrine"
]
]
] |
Doxepin may increase the severity of adverse effects when combined with Salbutamol and Salbutamol (Compound) resembles Phenylephrine (Compound)
Doxepin may increase the severity of adverse effects when combined with Isoprenaline and Isoprenaline may increase the severity of adverse effects when combined with Phenylephrine
Doxepin may increase the vasopressor activities of Metaraminol and Metaraminol may increase the severity of adverse effects when combined with Phenylephrine
Doxepin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Phenylephrine (Compound)
Doxepin (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Phenylephrine (Compound)
Doxepin may increase the vasopressor activities of Midodrine and Midodrine may increase the severity of adverse effects when combined with Phenylephrine
Doxepin may decrease the antihypertensive activities of Benzphetamine and Benzphetamine may increase the severity of adverse effects when combined with Phenylephrine
Doxepin may decrease the sedative activities of Phentermine and Phentermine may increase the severity of adverse effects when combined with Phenylephrine
Doxepin may increase the severity of adverse effects when combined with Phenylpropanolamine and Phenylpropanolamine may increase the severity of adverse effects when combined with Phenylephrine
|
DB00203
|
DB01119
| 615 | 1,039 |
Sildenafil
|
Diazoxide
|
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
|
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255
|
Sildenafil may increase the antihypertensive activities of Diazoxide.
| 9 |
[
[
[
615,
32,
1039
]
],
[
[
615,
32,
1048
],
[
1048,
71,
1039
]
],
[
[
615,
18,
2570
],
[
2570,
172,
1039
]
],
[
[
615,
21,
28817
],
[
28817,
175,
1039
]
],
[
[
615,
249,
506
],
[
506,
32,
1039
]
],
[
[
615,
223,
1040
],
[
1040,
32,
1039
]
],
[
[
615,
223,
230
],
[
230,
213,
1039
]
],
[
[
615,
32,
516
],
[
516,
236,
1039
]
],
[
[
615,
249,
576
],
[
576,
236,
1039
]
],
[
[
615,
82,
278
],
[
278,
82,
1039
]
]
] |
[
[
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} (Compound) downregulates {v} (Gene)",
"CYCS"
],
[
"CYCS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} (Compound) causes {v} (Side Effect)",
"Scotoma"
],
[
"Scotoma",
"{u} (Side Effect) is caused by {v} (Compound)",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} may increase the serum concentration of {v}",
"Avanafil"
],
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Tadalafil"
],
[
"Tadalafil",
"{u} may increase the antihypertensive activities of {v}",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the hypotensive activities of {v}",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the hypotensive activities of {v}",
"Diazoxide"
]
],
[
[
"Sildenafil",
"{u} may increase the hypotensive activities of {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may increase the hypotensive activities of {v}",
"Diazoxide"
]
]
] |
Sildenafil may increase the antihypertensive activities of Chlorothiazide and Chlorothiazide may increase the severity of adverse effects when combined with Diazoxide
Sildenafil (Compound) downregulates CYCS (Gene) and CYCS (Gene) is downregulated by Diazoxide (Compound)
Sildenafil (Compound) causes Scotoma (Side Effect) and Scotoma (Side Effect) is caused by Diazoxide (Compound)
Sildenafil may increase the serum concentration of Avanafil and Avanafil may increase the antihypertensive activities of Diazoxide
Sildenafil may decrease the metabolism of Tadalafil and Tadalafil may increase the antihypertensive activities of Diazoxide
Sildenafil may decrease the metabolism of Yohimbine and Yohimbine may decrease the antihypertensive activities of Diazoxide
Sildenafil may increase the antihypertensive activities of Felodipine and Felodipine may increase the hypotensive activities of Diazoxide
Sildenafil may increase the serum concentration of Metoprolol and Metoprolol may increase the hypotensive activities of Diazoxide
Sildenafil may increase the hypotensive activities of Alfuzosin and Alfuzosin may increase the hypotensive activities of Diazoxide
|
DB00238
|
DB00320
| 173 | 530 |
Nevirapine
|
Dihydroergotamine
|
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
|
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
|
The metabolism of Dihydroergotamine can be increased when combined with Nevirapine.
| 3 |
[
[
[
173,
26,
530
]
],
[
[
173,
6,
4590
],
[
4590,
160,
530
]
],
[
[
173,
21,
28792
],
[
28792,
175,
530
]
],
[
[
173,
26,
156
],
[
156,
26,
530
]
],
[
[
173,
180,
177
],
[
177,
26,
530
]
],
[
[
173,
33,
680
],
[
680,
187,
530
]
],
[
[
173,
223,
1035
],
[
1035,
201,
530
]
],
[
[
173,
26,
519
],
[
519,
201,
530
]
],
[
[
173,
26,
262
],
[
262,
213,
530
]
],
[
[
173,
26,
453
],
[
453,
69,
530
]
]
] |
[
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} (Compound) causes {v} (Side Effect)",
"Arthralgia"
],
[
"Arthralgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} may decrease the metabolism of {v}",
"Carteolol"
],
[
"Carteolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may decrease the antihypertensive activities of {v}",
"Dihydroergotamine"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
]
]
] |
Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dihydroergotamine (Compound)
Nevirapine (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Dihydroergotamine (Compound)
Nevirapine can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Dihydroergotamine
Nevirapine can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Dihydroergotamine
Nevirapine may reduce the serum concentration of the active metabolites of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Dihydroergotamine
Nevirapine may decrease the metabolism of Carteolol and Carteolol may increase the atrioventricular blocking activities of Dihydroergotamine
Nevirapine can increase the metabolism of Celiprolol and Celiprolol may increase the atrioventricular blocking activities of Dihydroergotamine
Nevirapine can increase the metabolism of Amitriptyline and Amitriptyline may decrease the antihypertensive activities of Dihydroergotamine
Nevirapine can increase the metabolism of Risperidone and Risperidone may decrease the metabolism of Dihydroergotamine
|
DB01236
|
DB08933
| 354 | 1,114 |
Sevoflurane
|
Luliconazole
|
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.
|
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
|
The serum concentration of Luliconazole can be increased when it is combined with Sevoflurane.
| 72 |
[
[
[
354,
95,
1114
]
],
[
[
354,
6,
4590
],
[
4590,
160,
1114
]
],
[
[
354,
21,
29383
],
[
29383,
175,
1114
]
],
[
[
354,
225,
163
],
[
163,
225,
1114
]
],
[
[
354,
69,
411
],
[
411,
95,
1114
]
],
[
[
354,
225,
202
],
[
202,
95,
1114
]
],
[
[
354,
71,
281
],
[
281,
95,
1114
]
],
[
[
354,
196,
614
],
[
614,
95,
1114
]
],
[
[
354,
182,
795
],
[
795,
95,
1114
]
],
[
[
354,
180,
147
],
[
147,
95,
1114
]
]
] |
[
[
[
"Sevoflurane",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis contact"
],
[
"Dermatitis contact",
"{u} (Side Effect) is caused by {v} (Compound)",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} may decrease the metabolism of {v}",
"Sertraline"
],
[
"Sertraline",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketamine"
],
[
"Ketamine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} may increase the anticoagulant activities of {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Sevoflurane",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
]
] |
Sevoflurane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Luliconazole (Compound)
Sevoflurane (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Luliconazole (Compound)
Sevoflurane may increase the severity of adverse effects when combined with Oxycodone and Oxycodone may increase the severity of adverse effects when combined with Luliconazole
Sevoflurane may decrease the metabolism of Sertraline and Sertraline may increase the serum concentration of Luliconazole
Sevoflurane may increase the severity of adverse effects when combined with Ketamine and Ketamine may increase the serum concentration of Luliconazole
Sevoflurane may increase the severity of adverse effects when combined with Chlorpheniramine and Chlorpheniramine may increase the serum concentration of Luliconazole
Sevoflurane may increase the QTc prolonging activities of Dofetilide and Dofetilide may increase the serum concentration of Luliconazole
Sevoflurane may increase the anticoagulant activities of Ticagrelor and Ticagrelor may increase the serum concentration of Luliconazole
Sevoflurane can increase the metabolism of Rifampicin and Rifampicin may increase the serum concentration of Luliconazole
|
DB00350
|
DB00903
| 1,065 | 893 |
Minoxidil
|
Etacrynic acid
|
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
|
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
|
The risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid.
| 48 |
[
[
[
1065,
71,
893
]
],
[
[
1065,
5,
17090
],
[
17090,
159,
893
]
],
[
[
1065,
52,
968
],
[
968,
206,
893
]
],
[
[
1065,
71,
504
],
[
504,
71,
893
]
],
[
[
1065,
225,
461
],
[
461,
71,
893
]
],
[
[
1065,
186,
702
],
[
702,
71,
893
]
],
[
[
1065,
71,
426
],
[
426,
225,
893
]
],
[
[
1065,
236,
53
],
[
53,
71,
893
]
],
[
[
1065,
82,
1070
],
[
1070,
71,
893
]
],
[
[
1065,
95,
1401
],
[
1401,
71,
893
]
]
] |
[
[
[
"Minoxidil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} may increase the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} may increase the hypotensive activities of {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} may increase the hypotensive activities of {v}",
"Tolazoline"
],
[
"Tolazoline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Minoxidil",
"{u} may increase the serum concentration of {v}",
"Probenecid"
],
[
"Probenecid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
]
] |
Minoxidil (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Etacrynic acid (Compound)
Minoxidil may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Etacrynic acid
Minoxidil may increase the severity of adverse effects when combined with Propranolol and Propranolol may increase the severity of adverse effects when combined with Etacrynic acid
Minoxidil may increase the severity of adverse effects when combined with Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Etacrynic acid
Minoxidil may increase the antihypertensive activities of Brimonidine and Brimonidine may increase the severity of adverse effects when combined with Etacrynic acid
Minoxidil may increase the severity of adverse effects when combined with Dapagliflozin and Dapagliflozin may increase the severity of adverse effects when combined with Etacrynic acid
Minoxidil may increase the hypotensive activities of Phenelzine and Phenelzine may increase the severity of adverse effects when combined with Etacrynic acid
Minoxidil may increase the hypotensive activities of Tolazoline and Tolazoline may increase the severity of adverse effects when combined with Etacrynic acid
Minoxidil may increase the serum concentration of Probenecid and Probenecid may increase the severity of adverse effects when combined with Etacrynic acid
|
DB09075
|
DB00371
| 744 | 464 |
Edoxaban
|
Meprobamate
|
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and
|
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
|
The serum concentration of Meprobamate can be increased when it is combined with Edoxaban.
| 72 |
[
[
[
744,
95,
464
]
],
[
[
744,
95,
156
],
[
156,
26,
464
]
],
[
[
744,
251,
147
],
[
147,
26,
464
]
],
[
[
744,
249,
543
],
[
543,
38,
464
]
],
[
[
744,
95,
491
],
[
491,
38,
464
]
],
[
[
744,
95,
1076
],
[
1076,
223,
464
]
],
[
[
744,
28,
613
],
[
613,
223,
464
]
],
[
[
744,
97,
508
],
[
508,
223,
464
]
],
[
[
744,
95,
925
],
[
925,
71,
464
]
],
[
[
744,
95,
565
],
[
565,
225,
464
]
]
] |
[
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may decrease the metabolism of {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may decrease the serum concentration of {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may decrease the metabolism of {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Reserpine"
],
[
"Reserpine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meprobamate"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meprobamate"
]
]
] |
Edoxaban may increase the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Meprobamate
Edoxaban may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Meprobamate
Edoxaban may increase the serum concentration of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Meprobamate
Edoxaban may increase the serum concentration of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Meprobamate
Edoxaban may increase the serum concentration of Fluconazole and Fluconazole may decrease the metabolism of Meprobamate
Edoxaban may increase the anticoagulant activities of Ticlopidine and Ticlopidine may decrease the metabolism of Meprobamate
Edoxaban may decrease the serum concentration of Delavirdine and Delavirdine may decrease the metabolism of Meprobamate
Edoxaban may increase the serum concentration of Reserpine and Reserpine may increase the severity of adverse effects when combined with Meprobamate
Edoxaban may increase the serum concentration of Flurazepam and Flurazepam may increase the severity of adverse effects when combined with Meprobamate
|
DB00988
|
DB06697
| 415 | 539 |
Dopamine
|
Artemether
|
One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.
|
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
|
The metabolism of Artemether can be decreased when combined with Dopamine.
| 46 |
[
[
[
415,
69,
539
]
],
[
[
415,
6,
18777
],
[
18777,
160,
539
]
],
[
[
415,
69,
173
],
[
173,
33,
539
]
],
[
[
415,
180,
177
],
[
177,
33,
539
]
],
[
[
415,
69,
158
],
[
158,
196,
539
]
],
[
[
415,
104,
354
],
[
354,
196,
539
]
],
[
[
415,
225,
716
],
[
716,
196,
539
]
],
[
[
415,
69,
1382
],
[
1382,
55,
539
]
],
[
[
415,
69,
1093
],
[
1093,
223,
539
]
],
[
[
415,
104,
477
],
[
477,
69,
539
]
]
] |
[
[
[
"Dopamine",
"{u} may decrease the metabolism of {v}",
"Artemether"
]
],
[
[
"Dopamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Artemether"
]
],
[
[
"Dopamine",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
]
],
[
[
"Dopamine",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
]
],
[
[
"Dopamine",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Dopamine",
"{u} may increase the arrhythmogenic activities of {v}",
"Sevoflurane"
],
[
"Sevoflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Dopamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Terbutaline"
],
[
"Terbutaline",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Dopamine",
"{u} may decrease the metabolism of {v}",
"Pyrimethamine"
],
[
"Pyrimethamine",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
]
],
[
[
"Dopamine",
"{u} may decrease the metabolism of {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may decrease the metabolism of {v}",
"Artemether"
]
],
[
[
"Dopamine",
"{u} may increase the arrhythmogenic activities of {v}",
"Methoxyflurane"
],
[
"Methoxyflurane",
"{u} may decrease the metabolism of {v}",
"Artemether"
]
]
] |
Dopamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Artemether (Compound)
Dopamine may decrease the metabolism of Nevirapine and Nevirapine may reduce the serum concentration of the active metabolites of Artemether
Dopamine can increase the metabolism of Rifapentine and Rifapentine may reduce the serum concentration of the active metabolites of Artemether
Dopamine may decrease the metabolism of Nicardipine and Nicardipine may increase the QTc prolonging activities of Artemether
Dopamine may increase the arrhythmogenic activities of Sevoflurane and Sevoflurane may increase the QTc prolonging activities of Artemether
Dopamine may increase the severity of adverse effects when combined with Terbutaline and Terbutaline may increase the QTc prolonging activities of Artemether
Dopamine may decrease the metabolism of Pyrimethamine and Pyrimethamine may increase the severity of QTc prolonging effects when combined with Artemether
Dopamine may decrease the metabolism of Isoniazid and Isoniazid may decrease the metabolism of Artemether
Dopamine may increase the arrhythmogenic activities of Methoxyflurane and Methoxyflurane may decrease the metabolism of Artemether
|
DB01589
|
DB00227
| 371 | 267 |
Quazepam
|
Lovastatin
|
Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other receptors.
|
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered
|
The metabolism of Lovastatin can be decreased when combined with Quazepam.
| 46 |
[
[
[
371,
69,
267
]
],
[
[
371,
6,
4590
],
[
4590,
160,
267
]
],
[
[
371,
21,
28461
],
[
28461,
175,
267
]
],
[
[
371,
180,
147
],
[
147,
26,
267
]
],
[
[
371,
251,
225
],
[
225,
26,
267
]
],
[
[
371,
249,
173
],
[
173,
26,
267
]
],
[
[
371,
249,
680
],
[
680,
187,
267
]
],
[
[
371,
38,
1257
],
[
1257,
69,
267
]
],
[
[
371,
249,
322
],
[
322,
69,
267
]
],
[
[
371,
69,
615
],
[
615,
69,
267
]
]
] |
[
[
[
"Quazepam",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} may increase the serum concentration of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} may increase the serum concentration of {v}",
"Permethrin"
],
[
"Permethrin",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Quazepam",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
]
] |
Quazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lovastatin (Compound)
Quazepam (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Lovastatin (Compound)
Quazepam can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Lovastatin
Quazepam may decrease the serum concentration of Bosentan and Bosentan can increase the metabolism of Lovastatin
Quazepam may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Lovastatin
Quazepam may increase the serum concentration of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Lovastatin
Quazepam may increase the central nervous system depressant activities of Perampanel and Perampanel may decrease the metabolism of Lovastatin
Quazepam may increase the serum concentration of Permethrin and Permethrin may decrease the metabolism of Lovastatin
Quazepam may decrease the metabolism of Sildenafil and Sildenafil may decrease the metabolism of Lovastatin
|
DB01590
|
DB00704
| 1,392 | 1,551 |
Everolimus
|
Naltrexone
|
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
|
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
|
The serum concentration of Naltrexone can be increased when it is combined with Everolimus.
| 72 |
[
[
[
1392,
95,
1551
]
],
[
[
1392,
7,
5010
],
[
5010,
161,
1551
]
],
[
[
1392,
18,
14599
],
[
14599,
172,
1551
]
],
[
[
1392,
7,
4990
],
[
4990,
172,
1551
]
],
[
[
1392,
21,
28518
],
[
28518,
175,
1551
]
],
[
[
1392,
95,
419
],
[
419,
246,
1551
]
],
[
[
1392,
95,
1240
],
[
1240,
95,
1551
]
],
[
[
1392,
95,
491
],
[
491,
306,
1551
]
],
[
[
1392,
7,
5010
],
[
5010,
17,
2699
],
[
2699,
172,
1551
]
],
[
[
1392,
7,
1908
],
[
1908,
171,
6378
],
[
6378,
172,
1551
]
]
] |
[
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"FOXO3"
],
[
"FOXO3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"PNP"
],
[
"PNP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Alfentanil"
],
[
"Alfentanil",
"{u} may decrease the therapeutic efficacy of {v}",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} (Compound) resembles {v} (Compound) and {u} may decrease the therapeutic efficacy of {v}",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"FOXO3"
],
[
"FOXO3",
"{u} (Gene) regulates {v} (Gene)",
"FOSL1"
],
[
"FOSL1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is regulated by {v} (Gene)",
"CLTB"
],
[
"CLTB",
"{u} (Gene) is downregulated by {v} (Compound)",
"Naltrexone"
]
]
] |
Everolimus (Compound) upregulates FOXO3 (Gene) and FOXO3 (Gene) is upregulated by Naltrexone (Compound)
Everolimus (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Naltrexone (Compound)
Everolimus (Compound) upregulates PNP (Gene) and PNP (Gene) is downregulated by Naltrexone (Compound)
Everolimus (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Naltrexone (Compound)
Everolimus may increase the serum concentration of Alfentanil and Alfentanil may decrease the therapeutic efficacy of Naltrexone
Everolimus may increase the serum concentration of Bosutinib and Bosutinib may increase the serum concentration of Naltrexone
Everolimus may increase the serum concentration of Buprenorphine and Buprenorphine (Compound) resembles Naltrexone (Compound) and Buprenorphine may decrease the therapeutic efficacy of Naltrexone
Everolimus (Compound) upregulates FOXO3 (Gene) and FOXO3 (Gene) regulates FOSL1 (Gene) and FOSL1 (Gene) is downregulated by Naltrexone (Compound)
Everolimus (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is regulated by CLTB (Gene) and CLTB (Gene) is downregulated by Naltrexone (Compound)
|
DB01095
|
DB00257
| 307 | 1,086 |
Fluvastatin
|
Clotrimazole
|
Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin.
|
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
|
The metabolism of Clotrimazole can be decreased when combined with Fluvastatin.
| 46 |
[
[
[
307,
69,
1086
]
],
[
[
307,
6,
12128
],
[
12128,
160,
1086
]
],
[
[
307,
7,
12023
],
[
12023,
161,
1086
]
],
[
[
307,
21,
28613
],
[
28613,
175,
1086
]
],
[
[
307,
223,
680
],
[
680,
187,
1086
]
],
[
[
307,
223,
458
],
[
458,
189,
1086
]
],
[
[
307,
223,
286
],
[
286,
69,
1086
]
],
[
[
307,
69,
575
],
[
575,
69,
1086
]
],
[
[
307,
95,
188
],
[
188,
69,
1086
]
],
[
[
307,
70,
566
],
[
566,
69,
1086
]
]
] |
[
[
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Progesterone"
],
[
"Progesterone",
"{u} may decrease the absorption of {v}",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Lornoxicam"
],
[
"Lornoxicam",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} may increase the serum concentration of {v}",
"Clotiazepam"
],
[
"Clotiazepam",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
]
],
[
[
"Fluvastatin",
"{u} may increase the myopathic rhabdomyolysis activities of {v}",
"Gemfibrozil"
],
[
"Gemfibrozil",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
]
]
] |
Fluvastatin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Clotrimazole (Compound)
Fluvastatin (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Clotrimazole (Compound)
Fluvastatin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Clotrimazole (Compound)
Fluvastatin may decrease the metabolism of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Clotrimazole
Fluvastatin may decrease the metabolism of Progesterone and Progesterone may decrease the absorption of Clotrimazole
Fluvastatin may decrease the metabolism of Lornoxicam and Lornoxicam may decrease the metabolism of Clotrimazole
Fluvastatin may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may decrease the metabolism of Clotrimazole
Fluvastatin may increase the serum concentration of Clotiazepam and Clotiazepam may decrease the metabolism of Clotrimazole
Fluvastatin may increase the myopathic rhabdomyolysis activities of Gemfibrozil and Gemfibrozil may decrease the metabolism of Clotrimazole
|
DB00573
|
DB09211
| 745 | 1,444 |
Fenoprofen
|
Limaprost
|
An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.
|
Limaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostaglandins have a wide variety of actions, including, but not limited to muscular constriction and mediation of inflammation. Limaprost alfadex has been shown to improve peripheral circulatory failure with a vasodilator action and an antithrombotic effect. It also improves poor blood flow in the nerve tissue in cervical spondylosis and normalizes nerve function. Limaprost alfadex was discovered from collaborative research between Ono Pharmaceutical (Ono) and Dainippon Sumitomo Pharma (DSP). It was approved for the treatment of ischemic symptoms such as skin ulcer, pain and coldness
|
The therapeutic efficacy of Limaprost can be decreased when used in combination with Fenoprofen.
| 69 |
[
[
[
745,
92,
1444
]
],
[
[
745,
1,
384
],
[
384,
225,
1444
]
],
[
[
745,
182,
363
],
[
363,
225,
1444
]
],
[
[
745,
225,
689
],
[
689,
225,
1444
]
],
[
[
745,
71,
238
],
[
238,
75,
1444
]
],
[
[
745,
116,
334
],
[
334,
92,
1444
]
],
[
[
745,
71,
826
],
[
826,
92,
1444
]
],
[
[
745,
225,
785
],
[
785,
92,
1444
]
],
[
[
745,
233,
768
],
[
768,
92,
1444
]
],
[
[
745,
1,
780
],
[
780,
92,
1444
]
]
] |
[
[
[
"Fenoprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the severity of adverse effects when combined with {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} may increase the anticoagulant activities of {v}",
"Ximelagatran"
],
[
"Ximelagatran",
"{u} may increase the severity of adverse effects when combined with {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nimesulide"
],
[
"Nimesulide",
"{u} may increase the antiplatelet activities of {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxyphenbutazone"
],
[
"Oxyphenbutazone",
"{u} may decrease the therapeutic efficacy of {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Adapalene"
],
[
"Adapalene",
"{u} may decrease the therapeutic efficacy of {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} may increase the nephrotoxic activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may decrease the therapeutic efficacy of {v}",
"Limaprost"
]
],
[
[
"Fenoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Nepafenac"
],
[
"Nepafenac",
"{u} may decrease the therapeutic efficacy of {v}",
"Limaprost"
]
]
] |
Fenoprofen (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon may increase the severity of adverse effects when combined with Limaprost
Fenoprofen may increase the anticoagulant activities of Ximelagatran and Ximelagatran may increase the severity of adverse effects when combined with Limaprost
Fenoprofen may increase the severity of adverse effects when combined with Treprostinil and Treprostinil may increase the severity of adverse effects when combined with Limaprost
Fenoprofen may increase the severity of adverse effects when combined with Nimesulide and Nimesulide may increase the antiplatelet activities of Limaprost
Fenoprofen (Compound) resembles Ibuprofen (Compound) and Fenoprofen may increase the severity of adverse effects when combined with Ibuprofen and Ibuprofen may decrease the therapeutic efficacy of Limaprost
Fenoprofen may increase the severity of adverse effects when combined with Oxyphenbutazone and Oxyphenbutazone may decrease the therapeutic efficacy of Limaprost
Fenoprofen may increase the severity of adverse effects when combined with Adapalene and Adapalene may decrease the therapeutic efficacy of Limaprost
Fenoprofen may increase the nephrotoxic activities of Olsalazine and Olsalazine may decrease the therapeutic efficacy of Limaprost
Fenoprofen (Compound) resembles Nepafenac (Compound) and Nepafenac may decrease the therapeutic efficacy of Limaprost
|
DB06201
|
DB00737
| 1,439 | 1,000 |
Rufinamide
|
Meclizine
|
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
|
Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. Commonly marketed under the brand name Antivert in the U.S., meclizine is available as oral tablets.
|
The risk or severity of adverse effects can be increased when Rufinamide is combined with Meclizine.
| 48 |
[
[
[
1439,
71,
1000
]
],
[
[
1439,
71,
270
],
[
270,
71,
1000
]
],
[
[
1439,
21,
28398
],
[
28398,
175,
1000
]
],
[
[
1439,
71,
674
],
[
674,
30,
1000
]
],
[
[
1439,
71,
72
],
[
72,
38,
1000
]
],
[
[
1439,
71,
1264
],
[
1264,
192,
1000
]
],
[
[
1439,
225,
587
],
[
587,
38,
1000
]
],
[
[
1439,
71,
1268
],
[
1268,
225,
1000
]
],
[
[
1439,
249,
142
],
[
142,
71,
1000
]
],
[
[
1439,
97,
156
],
[
156,
71,
1000
]
]
] |
[
[
[
"Rufinamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vigabatrin"
],
[
"Vigabatrin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} may increase the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meclizine"
]
],
[
[
"Rufinamide",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meclizine"
]
]
] |
Rufinamide may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Meclizine
Rufinamide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Meclizine (Compound)
Rufinamide may increase the severity of adverse effects when combined with Pregabalin and Pregabalin can increase the therapeutic efficacy of Meclizine
Rufinamide may increase the severity of adverse effects when combined with Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Meclizine
Rufinamide may increase the severity of adverse effects when combined with Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Meclizine
Rufinamide may increase the severity of adverse effects when combined with Ethanol and Ethanol may increase the central nervous system depressant activities of Meclizine
Rufinamide may increase the severity of adverse effects when combined with Vigabatrin and Vigabatrin may increase the severity of adverse effects when combined with Meclizine
Rufinamide may increase the serum concentration of Phenytoin and Phenytoin may increase the severity of adverse effects when combined with Meclizine
Rufinamide may decrease the serum concentration of Carbamazepine and Carbamazepine may increase the severity of adverse effects when combined with Meclizine
|
DB00721
|
DB04844
| 985 | 956 |
Procaine
|
Tetrabenazine
|
A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients.
|
A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
|
The risk or severity of adverse effects can be increased when Procaine is combined with Tetrabenazine.
| 48 |
[
[
[
985,
71,
956
]
],
[
[
985,
21,
28562
],
[
28562,
175,
956
]
],
[
[
985,
192,
491
],
[
491,
38,
956
]
],
[
[
985,
38,
702
],
[
702,
192,
956
]
],
[
[
985,
225,
914
],
[
914,
196,
956
]
],
[
[
985,
71,
499
],
[
499,
196,
956
]
],
[
[
985,
1,
1322
],
[
1322,
55,
956
]
],
[
[
985,
71,
828
],
[
828,
223,
956
]
],
[
[
985,
225,
861
],
[
861,
223,
956
]
],
[
[
985,
225,
992
],
[
992,
225,
956
]
]
] |
[
[
[
"Procaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
],
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the QTc prolonging activities of {v}",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} (Compound) resembles {v} (Compound)",
"Procainamide"
],
[
"Procainamide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may decrease the metabolism of {v}",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Tetrabenazine"
]
],
[
[
"Procaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
]
]
] |
Procaine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Tetrabenazine (Compound)
Procaine may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Tetrabenazine
Procaine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Tetrabenazine
Procaine may increase the severity of adverse effects when combined with Desflurane and Desflurane may increase the QTc prolonging activities of Tetrabenazine
Procaine may increase the severity of adverse effects when combined with Clomipramine and Clomipramine may increase the QTc prolonging activities of Tetrabenazine
Procaine (Compound) resembles Procainamide (Compound) and Procainamide may increase the severity of QTc prolonging effects when combined with Tetrabenazine
Procaine may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may decrease the metabolism of Tetrabenazine
Procaine may increase the severity of adverse effects when combined with Fluvoxamine and Fluvoxamine may decrease the metabolism of Tetrabenazine
Procaine may increase the severity of adverse effects when combined with Olanzapine and Olanzapine may increase the severity of adverse effects when combined with Tetrabenazine
|
DB00608
|
DB09118
| 588 | 1,269 |
Chloroquine
|
Stiripentol
|
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine]. Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis. **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.** Chloroquine was granted FDA Approval on 31 October 1949.
|
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
|
The serum concentration of Stiripentol can be increased when it is combined with Chloroquine.
| 72 |
[
[
[
588,
95,
1269
]
],
[
[
588,
223,
287
],
[
287,
38,
1269
]
],
[
[
588,
42,
1262
],
[
1262,
192,
1269
]
],
[
[
588,
69,
861
],
[
861,
69,
1269
]
],
[
[
588,
223,
1415
],
[
1415,
69,
1269
]
],
[
[
588,
42,
224
],
[
224,
69,
1269
]
],
[
[
588,
248,
207
],
[
207,
69,
1269
]
],
[
[
588,
71,
349
],
[
349,
69,
1269
]
],
[
[
588,
71,
1421
],
[
1421,
223,
1269
]
],
[
[
588,
95,
476
],
[
476,
69,
1269
]
]
] |
[
[
[
"Chloroquine",
"{u} may increase the serum concentration of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may decrease the metabolism of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may decrease the metabolism of {v}",
"Piperazine"
],
[
"Piperazine",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may decrease the excretion rate {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lumiracoxib"
],
[
"Lumiracoxib",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tenofovir disoproxil"
],
[
"Tenofovir disoproxil",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Chloroquine",
"{u} may increase the serum concentration of {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
]
] |
Chloroquine may decrease the metabolism of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Stiripentol
Chloroquine may increase the QTc prolonging activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Stiripentol
Chloroquine may decrease the metabolism of Fluvoxamine and Fluvoxamine may decrease the metabolism of Stiripentol
Chloroquine may decrease the metabolism of Piperazine and Piperazine may decrease the metabolism of Stiripentol
Chloroquine may increase the QTc prolonging activities of Amoxapine and Amoxapine may decrease the metabolism of Stiripentol
Chloroquine may decrease the excretion rate Idarubicin and Idarubicin may decrease the metabolism of Stiripentol
Chloroquine may increase the severity of adverse effects when combined with Lumiracoxib and Lumiracoxib may decrease the metabolism of Stiripentol
Chloroquine may increase the severity of adverse effects when combined with Tenofovir disoproxil and Tenofovir disoproxil may decrease the metabolism of Stiripentol
Chloroquine may increase the serum concentration of Netupitant and Netupitant may decrease the metabolism of Stiripentol
|
DB01210
|
DB05676
| 1,029 | 743 |
Levobunolol
|
Apremilast
|
A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
|
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.
|
Levobunolol may decrease the antihypertensive activities of Apremilast.
| 36 |
[
[
[
1029,
59,
743
]
],
[
[
1029,
59,
687
],
[
687,
28,
743
]
],
[
[
1029,
225,
894
],
[
894,
205,
743
]
],
[
[
1029,
230,
1389
],
[
1389,
210,
743
]
],
[
[
1029,
225,
248
],
[
248,
59,
743
]
],
[
[
1029,
71,
731
],
[
731,
59,
743
]
],
[
[
1029,
270,
504
],
[
504,
59,
743
]
],
[
[
1029,
1,
1035
],
[
1035,
59,
743
]
],
[
[
1029,
155,
1022
],
[
1022,
59,
743
]
],
[
[
1029,
230,
1091
],
[
1091,
223,
743
]
]
] |
[
[
[
"Levobunolol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} may decrease the antihypertensive activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} may increase the bradycardic activities of {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may increase the immunosuppressive activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Carteolol"
],
[
"Carteolol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Levobunolol",
"{u} may increase the bradycardic activities of {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may decrease the metabolism of {v}",
"Apremilast"
]
]
] |
Levobunolol may decrease the antihypertensive activities of Nafamostat and Nafamostat may increase the anticoagulant activities of Apremilast
Levobunolol may increase the severity of adverse effects when combined with Furosemide and Furosemide may decrease the diuretic activities of Apremilast
Levobunolol may increase the bradycardic activities of Tofacitinib and Tofacitinib may increase the immunosuppressive activities of Apremilast
Levobunolol may increase the severity of adverse effects when combined with Carvedilol and Carvedilol may decrease the antihypertensive activities of Apremilast
Levobunolol may increase the severity of adverse effects when combined with Nebivolol and Nebivolol may decrease the antihypertensive activities of Apremilast
Levobunolol (Compound) resembles Propranolol (Compound) and Levobunolol may increase the severity of adverse effects when combined with Propranolol and Propranolol may decrease the antihypertensive activities of Apremilast
Levobunolol (Compound) resembles Carteolol (Compound) and Carteolol may decrease the antihypertensive activities of Apremilast
Levobunolol (Compound) resembles Pindolol (Compound) and Pindolol may decrease the antihypertensive activities of Apremilast
Levobunolol may increase the bradycardic activities of Dronedarone and Dronedarone may decrease the metabolism of Apremilast
|
DB01023
|
DB09048
| 516 | 476 |
Felodipine
|
Netupitant
|
Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.
|
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
|
The serum concentration of Netupitant can be increased when it is combined with Felodipine.
| 72 |
[
[
[
516,
95,
476
]
],
[
[
516,
95,
886
],
[
886,
223,
476
]
],
[
[
516,
249,
576
],
[
576,
223,
476
]
],
[
[
516,
52,
828
],
[
828,
223,
476
]
],
[
[
516,
223,
297
],
[
297,
223,
476
]
],
[
[
516,
69,
41
],
[
41,
223,
476
]
],
[
[
516,
225,
1086
],
[
1086,
223,
476
]
],
[
[
516,
236,
63
],
[
63,
223,
476
]
],
[
[
516,
225,
1404
],
[
1404,
71,
476
]
],
[
[
516,
223,
151
],
[
151,
95,
476
]
]
] |
[
[
[
"Felodipine",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may increase the serum concentration of {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may increase the hypotensive activities of {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nicergoline"
],
[
"Nicergoline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Netupitant"
]
],
[
[
"Felodipine",
"{u} may decrease the metabolism of {v}",
"Benzyl alcohol"
],
[
"Benzyl alcohol",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
]
] |
Felodipine may increase the serum concentration of Cimetidine and Cimetidine may decrease the metabolism of Netupitant
Felodipine may increase the serum concentration of Metoprolol and Metoprolol may decrease the metabolism of Netupitant
Felodipine may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may decrease the metabolism of Netupitant
Felodipine may decrease the metabolism of Tolbutamide and Tolbutamide may decrease the metabolism of Netupitant
Felodipine may decrease the metabolism of Clemastine and Clemastine may decrease the metabolism of Netupitant
Felodipine may increase the severity of adverse effects when combined with Clotrimazole and Clotrimazole may decrease the metabolism of Netupitant
Felodipine may increase the hypotensive activities of Tranylcypromine and Tranylcypromine may decrease the metabolism of Netupitant
Felodipine may increase the severity of adverse effects when combined with Nicergoline and Nicergoline may increase the severity of adverse effects when combined with Netupitant
Felodipine may decrease the metabolism of Benzyl alcohol and Benzyl alcohol may increase the serum concentration of Netupitant
|
DB00599
|
DB01002
| 320 | 214 |
Thiopental
|
Levobupivacaine
|
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)
|
Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In
|
The risk or severity of adverse effects can be increased when Thiopental is combined with Levobupivacaine.
| 48 |
[
[
[
320,
71,
214
]
],
[
[
320,
225,
611
],
[
611,
223,
214
]
],
[
[
320,
225,
541
],
[
541,
71,
214
]
],
[
[
320,
6,
4590
],
[
4590,
160,
214
]
],
[
[
320,
225,
161
],
[
161,
26,
214
]
],
[
[
320,
71,
150
],
[
150,
26,
214
]
],
[
[
320,
180,
147
],
[
147,
26,
214
]
],
[
[
320,
270,
171
],
[
171,
26,
214
]
],
[
[
320,
246,
674
],
[
674,
30,
214
]
],
[
[
320,
38,
1257
],
[
1257,
192,
214
]
]
] |
[
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ropivacaine"
],
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} may decrease the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Levobupivacaine"
]
],
[
[
"Thiopental",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Levobupivacaine"
]
]
] |
Thiopental may increase the severity of adverse effects when combined with Lidocaine and Lidocaine may decrease the metabolism of Levobupivacaine
Thiopental may increase the severity of adverse effects when combined with Ropivacaine and Ropivacaine may increase the severity of adverse effects when combined with Levobupivacaine
Thiopental (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levobupivacaine (Compound)
Thiopental may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Levobupivacaine
Thiopental may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin can increase the metabolism of Levobupivacaine
Thiopental can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Levobupivacaine
Thiopental (Compound) resembles Pentobarbital (Compound) and Thiopental may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Levobupivacaine
Thiopental may decrease the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Levobupivacaine
Thiopental may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Levobupivacaine
|
DB00827
|
DB01078
| 830 | 1,350 |
Cinoxacin
|
Deslanoside
|
Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
|
Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.
|
Cinoxacin may decrease the cardiotoxic activities of Deslanoside.
| 57 |
[
[
[
830,
80,
1350
]
],
[
[
830,
80,
457
],
[
457,
1,
1350
]
],
[
[
830,
203,
620
],
[
620,
80,
1350
]
],
[
[
830,
191,
243
],
[
243,
80,
1350
]
],
[
[
830,
225,
80
],
[
80,
80,
1350
]
],
[
[
830,
203,
798
],
[
798,
97,
1350
]
],
[
[
830,
89,
1505
],
[
1505,
258,
1350
]
],
[
[
830,
80,
457
],
[
457,
1,
1348
],
[
1348,
1,
1350
]
],
[
[
830,
80,
232
],
[
232,
155,
457
],
[
457,
1,
1350
]
],
[
[
830,
203,
620
],
[
620,
80,
1348
],
[
1348,
1,
1350
]
]
] |
[
[
[
"Cinoxacin",
"{u} may decrease the cardiotoxic activities of {v}",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may decrease the cardiotoxic activities of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may decrease the cardiotoxic activities of {v}",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may decrease the cardiotoxic activities of {v}",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may decrease the cardiotoxic activities of {v}",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may decrease the serum concentration of {v}",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium gluconate"
],
[
"Calcium gluconate",
"{u} may increase the arrhythmogenic activities of {v}",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may decrease the cardiotoxic activities of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Ouabain"
],
[
"Ouabain",
"{u} (Compound) resembles {v} (Compound)",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may decrease the cardiotoxic activities of {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Deslanoside"
]
],
[
[
"Cinoxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
],
[
"Ouabain",
"{u} (Compound) resembles {v} (Compound)",
"Deslanoside"
]
]
] |
Cinoxacin may decrease the cardiotoxic activities of Digoxin and Digoxin (Compound) resembles Deslanoside (Compound)
Cinoxacin may increase the neuroexcitatory activities of Mycophenolate mofetil and Mycophenolate mofetil may decrease the cardiotoxic activities of Deslanoside
Cinoxacin may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may decrease the cardiotoxic activities of Deslanoside
Cinoxacin may increase the severity of adverse effects when combined with Prednisone and Prednisone may decrease the cardiotoxic activities of Deslanoside
Cinoxacin may increase the neuroexcitatory activities of Balsalazide and Balsalazide may decrease the serum concentration of Deslanoside
Cinoxacin may decrease the absorption and serum concentration of Calcium gluconate and Calcium gluconate may increase the arrhythmogenic activities of Deslanoside
Cinoxacin may decrease the cardiotoxic activities of Digoxin and Digoxin (Compound) resembles Ouabain (Compound) and Ouabain (Compound) resembles Deslanoside (Compound)
Cinoxacin may decrease the cardiotoxic activities of Digitoxin and Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin (Compound) resembles Deslanoside (Compound)
Cinoxacin may increase the neuroexcitatory activities of Mycophenolate mofetil and Mycophenolate mofetil may decrease the cardiotoxic activities of Ouabain and Ouabain (Compound) resembles Deslanoside (Compound)
|
DB00353
|
DB01232
| 1,303 | 501 |
Methylergometrine
|
Saquinavir
|
A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
|
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351]
|
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Saquinavir.
| 48 |
[
[
[
1303,
71,
501
]
],
[
[
1303,
71,
269
],
[
269,
155,
501
]
],
[
[
1303,
6,
4590
],
[
4590,
160,
501
]
],
[
[
1303,
21,
28402
],
[
28402,
175,
501
]
],
[
[
1303,
71,
795
],
[
795,
187,
501
]
],
[
[
1303,
71,
705
],
[
705,
196,
501
]
],
[
[
1303,
71,
1208
],
[
1208,
42,
501
]
],
[
[
1303,
247,
716
],
[
716,
196,
501
]
],
[
[
1303,
195,
1304
],
[
1304,
196,
501
]
],
[
[
1303,
41,
1027
],
[
1027,
42,
501
]
]
] |
[
[
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may increase the QTc prolonging activities of {v}",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} may increase the hypertensive activities of {v}",
"Terbutaline"
],
[
"Terbutaline",
"{u} may increase the QTc prolonging activities of {v}",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} may increase the vasoconstricting activities of {v}",
"Apomorphine"
],
[
"Apomorphine",
"{u} may increase the QTc prolonging activities of {v}",
"Saquinavir"
]
],
[
[
"Methylergometrine",
"{u} may increase the vasoconstricting activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Saquinavir"
]
]
] |
Methylergometrine may increase the severity of adverse effects when combined with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saquinavir (Compound)
Methylergometrine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Saquinavir (Compound)
Methylergometrine may increase the severity of adverse effects when combined with Ticagrelor and Ticagrelor may reduce the serum concentration of the active metabolites of Saquinavir
Methylergometrine may increase the severity of adverse effects when combined with Salbutamol and Salbutamol may increase the QTc prolonging activities of Saquinavir
Methylergometrine may increase the severity of adverse effects when combined with Arsenic trioxide and Arsenic trioxide may increase the QTc prolonging activities of Saquinavir
Methylergometrine may increase the hypertensive activities of Terbutaline and Terbutaline may increase the QTc prolonging activities of Saquinavir
Methylergometrine may increase the vasoconstricting activities of Apomorphine and Apomorphine may increase the QTc prolonging activities of Saquinavir
Methylergometrine may increase the vasoconstricting activities of Sotalol and Sotalol may increase the QTc prolonging activities of Saquinavir
|
DB01440
|
DB08883
| 974 | 1,257 |
gamma-Hydroxybutyric acid
|
Perampanel
|
Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.
|
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
|
gamma-Hydroxybutyric acid may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
| 15 |
[
[
[
974,
38,
1257
]
],
[
[
974,
71,
988
],
[
988,
38,
1257
]
],
[
[
974,
192,
679
],
[
679,
38,
1257
]
],
[
[
974,
225,
579
],
[
579,
38,
1257
]
],
[
[
974,
38,
405
],
[
405,
38,
1257
]
],
[
[
974,
54,
1046
],
[
1046,
208,
1257
]
],
[
[
974,
71,
648
],
[
648,
223,
1257
]
],
[
[
974,
71,
394
],
[
394,
225,
1257
]
],
[
[
974,
71,
142
],
[
142,
97,
1257
]
],
[
[
974,
225,
156
],
[
156,
97,
1257
]
]
] |
[
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Melperone"
],
[
"Melperone",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Codeine"
],
[
"Codeine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Perampanel"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may decrease the serum concentration of {v}",
"Perampanel"
]
]
] |
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Melperone and Melperone may increase the central nervous system depressant activities of Perampanel
gamma-Hydroxybutyric acid may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Perampanel
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Codeine and Codeine may increase the central nervous system depressant activities of Perampanel
gamma-Hydroxybutyric acid may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Perampanel
gamma-Hydroxybutyric acid may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Perampanel
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Nefazodone and Nefazodone may decrease the metabolism of Perampanel
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Fluoxetine and Fluoxetine may increase the severity of adverse effects when combined with Perampanel
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Phenytoin and Phenytoin may decrease the serum concentration of Perampanel
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine may decrease the serum concentration of Perampanel
|
DB01220
|
DB01601
| 218 | 429 |
Rifaximin
|
Lopinavir
|
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.
|
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the
|
The serum concentration of Lopinavir can be increased when it is combined with Rifaximin.
| 72 |
[
[
[
218,
95,
429
]
],
[
[
218,
95,
564
],
[
564,
155,
429
]
],
[
[
218,
95,
244
],
[
244,
69,
429
]
],
[
[
218,
6,
4590
],
[
4590,
160,
429
]
],
[
[
218,
26,
161
],
[
161,
26,
429
]
],
[
[
218,
95,
430
],
[
430,
180,
429
]
],
[
[
218,
155,
177
],
[
177,
26,
429
]
],
[
[
218,
26,
194
],
[
194,
180,
429
]
],
[
[
218,
97,
59
],
[
59,
42,
429
]
],
[
[
218,
95,
987
],
[
987,
196,
429
]
]
] |
[
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Ritonavir"
],
[
"Ritonavir",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Oxiconazole"
],
[
"Oxiconazole",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} (Compound) resembles {v} (Compound)",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} can increase the metabolism of {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} may decrease the serum concentration of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
],
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Maprotiline"
],
[
"Maprotiline",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
]
] |
Rifaximin may increase the serum concentration of Atazanavir and Atazanavir (Compound) resembles Lopinavir (Compound)
Rifaximin may increase the serum concentration of Ritonavir and Ritonavir may decrease the metabolism of Lopinavir
Rifaximin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lopinavir (Compound)
Rifaximin can increase the metabolism of Primidone and Primidone can increase the metabolism of Lopinavir
Rifaximin may increase the serum concentration of Oxiconazole and Oxiconazole can increase the metabolism of Lopinavir
Rifaximin (Compound) resembles Rifapentine (Compound) and Rifapentine can increase the metabolism of Lopinavir
Rifaximin can increase the metabolism of Methylphenobarbital and Methylphenobarbital can increase the metabolism of Lopinavir
Rifaximin may decrease the serum concentration of Quinidine and Quinidine may increase the QTc prolonging activities of Lopinavir
Rifaximin may increase the serum concentration of Maprotiline and Maprotiline may increase the QTc prolonging activities of Lopinavir
|
DB00243
|
DB00196
| 379 | 1,076 |
Ranolazine
|
Fluconazole
|
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
|
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
|
The serum concentration of Fluconazole can be increased when it is combined with Ranolazine.
| 72 |
[
[
[
379,
95,
1076
]
],
[
[
379,
95,
657
],
[
657,
155,
1076
]
],
[
[
379,
6,
4590
],
[
4590,
160,
1076
]
],
[
[
379,
21,
28411
],
[
28411,
175,
1076
]
],
[
[
379,
249,
597
],
[
597,
187,
1076
]
],
[
[
379,
95,
458
],
[
458,
189,
1076
]
],
[
[
379,
196,
1007
],
[
1007,
42,
1076
]
],
[
[
379,
95,
143
],
[
143,
42,
1076
]
],
[
[
379,
249,
653
],
[
653,
42,
1076
]
],
[
[
379,
95,
262
],
[
262,
196,
1076
]
]
] |
[
[
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} (Compound) resembles {v} (Compound)",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Progesterone"
],
[
"Progesterone",
"{u} may decrease the absorption of {v}",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
]
] |
Ranolazine may increase the serum concentration of Voriconazole and Voriconazole (Compound) resembles Fluconazole (Compound)
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluconazole (Compound)
Ranolazine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Fluconazole (Compound)
Ranolazine may increase the serum concentration of Clopidogrel and Clopidogrel may reduce the serum concentration of the active metabolites of Fluconazole
Ranolazine may increase the serum concentration of Progesterone and Progesterone may decrease the absorption of Fluconazole
Ranolazine may increase the QTc prolonging activities of Paliperidone and Paliperidone may increase the QTc prolonging activities of Fluconazole
Ranolazine may increase the serum concentration of Erythromycin and Erythromycin may increase the QTc prolonging activities of Fluconazole
Ranolazine may increase the serum concentration of Thioridazine and Thioridazine may increase the QTc prolonging activities of Fluconazole
Ranolazine may increase the serum concentration of Amitriptyline and Amitriptyline may increase the QTc prolonging activities of Fluconazole
|
DB00280
|
DB00976
| 589 | 528 |
Disopyramide
|
Telithromycin
|
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
|
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
|
Disopyramide may increase the QTc-prolonging activities of Telithromycin.
| 19 |
[
[
[
589,
42,
528
]
],
[
[
589,
42,
1088
],
[
1088,
42,
528
]
],
[
[
589,
6,
4590
],
[
4590,
160,
528
]
],
[
[
589,
21,
28714
],
[
28714,
175,
528
]
],
[
[
589,
180,
173
],
[
173,
26,
528
]
],
[
[
589,
251,
147
],
[
147,
26,
528
]
],
[
[
589,
196,
150
],
[
150,
26,
528
]
],
[
[
589,
42,
1313
],
[
1313,
196,
528
]
],
[
[
589,
31,
575
],
[
575,
196,
528
]
],
[
[
589,
76,
1027
],
[
1027,
42,
528
]
]
] |
[
[
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Perflutren"
],
[
"Perflutren",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} may increase the hypoglycemic activities of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Disopyramide",
"{u} may increase the bradycardic activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
]
] |
Disopyramide may increase the QTc prolonging activities of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Telithromycin
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Disopyramide (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Telithromycin (Compound)
Disopyramide can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Telithromycin
Disopyramide may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Telithromycin
Disopyramide may increase the QTc prolonging activities of Fosphenytoin and Fosphenytoin can increase the metabolism of Telithromycin
Disopyramide may increase the QTc prolonging activities of Perflutren and Perflutren may increase the QTc prolonging activities of Telithromycin
Disopyramide may increase the hypoglycemic activities of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Telithromycin
Disopyramide may increase the bradycardic activities of Sotalol and Sotalol may increase the QTc prolonging activities of Telithromycin
|
DB01189
|
DB00656
| 914 | 175 |
Desflurane
|
Trazodone
|
Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.
|
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981.
|
The risk or severity of adverse effects can be increased when Desflurane is combined with Trazodone.
| 48 |
[
[
[
914,
71,
175
]
],
[
[
914,
196,
370
],
[
370,
1,
175
]
],
[
[
914,
225,
981
],
[
981,
1,
175
]
],
[
[
914,
225,
1014
],
[
1014,
155,
175
]
],
[
[
914,
196,
955
],
[
955,
155,
175
]
],
[
[
914,
21,
28651
],
[
28651,
175,
175
]
],
[
[
914,
225,
156
],
[
156,
26,
175
]
],
[
[
914,
192,
491
],
[
491,
38,
175
]
],
[
[
914,
38,
702
],
[
702,
192,
175
]
],
[
[
914,
196,
1322
],
[
1322,
42,
175
]
]
] |
[
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Domperidone"
],
[
"Domperidone",
"{u} (Compound) resembles {v} (Compound)",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Loxapine"
],
[
"Loxapine",
"{u} (Compound) resembles {v} (Compound)",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluphenazine"
],
[
"Fluphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Trazodone"
]
],
[
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Trazodone"
]
]
] |
Desflurane may increase the QTc prolonging activities of Domperidone and Domperidone (Compound) resembles Trazodone (Compound)
Desflurane may increase the severity of adverse effects when combined with Loxapine and Loxapine (Compound) resembles Trazodone (Compound)
Desflurane may increase the severity of adverse effects when combined with Fluphenazine and Fluphenazine (Compound) resembles Trazodone (Compound)
Desflurane may increase the QTc prolonging activities of Quetiapine and Quetiapine (Compound) resembles Trazodone (Compound)
Desflurane (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Trazodone (Compound)
Desflurane may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Trazodone
Desflurane may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Trazodone
Desflurane may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Trazodone
Desflurane may increase the QTc prolonging activities of Procainamide and Procainamide may increase the QTc prolonging activities of Trazodone
|
DB00796
|
DB00469
| 304 | 584 |
Candesartan cilexetil
|
Tenoxicam
|
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for
|
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
|
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tenoxicam.
| 48 |
[
[
[
304,
71,
584
]
],
[
[
304,
6,
7128
],
[
7128,
160,
584
]
],
[
[
304,
21,
28747
],
[
28747,
175,
584
]
],
[
[
304,
180,
161
],
[
161,
26,
584
]
],
[
[
304,
71,
687
],
[
687,
28,
584
]
],
[
[
304,
78,
894
],
[
894,
205,
584
]
],
[
[
304,
78,
1358
],
[
1358,
59,
584
]
],
[
[
304,
71,
1022
],
[
1022,
59,
584
]
],
[
[
304,
225,
1037
],
[
1037,
59,
584
]
],
[
[
304,
69,
267
],
[
267,
223,
584
]
]
] |
[
[
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the hypotensive effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the hypotensive effects when combined with {v}",
"Amiloride"
],
[
"Amiloride",
"{u} may decrease the antihypertensive activities of {v}",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} may decrease the antihypertensive activities of {v}",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the antihypertensive activities of {v}",
"Tenoxicam"
]
],
[
[
"Candesartan cilexetil",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Tenoxicam"
]
]
] |
Candesartan cilexetil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tenoxicam (Compound)
Candesartan cilexetil (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Tenoxicam (Compound)
Candesartan cilexetil can increase the metabolism of Primidone and Primidone can increase the metabolism of Tenoxicam
Candesartan cilexetil may increase the severity of adverse effects when combined with Nafamostat and Nafamostat may increase the anticoagulant activities of Tenoxicam
Candesartan cilexetil may increase the hypotensive effects when combined with Furosemide and Furosemide may decrease the diuretic activities of Tenoxicam
Candesartan cilexetil may increase the hypotensive effects when combined with Amiloride and Amiloride may decrease the antihypertensive activities of Tenoxicam
Candesartan cilexetil may increase the severity of adverse effects when combined with Pindolol and Pindolol may decrease the antihypertensive activities of Tenoxicam
Candesartan cilexetil may increase the severity of adverse effects when combined with Betaxolol and Betaxolol may decrease the antihypertensive activities of Tenoxicam
Candesartan cilexetil may decrease the metabolism of Lovastatin and Lovastatin may decrease the metabolism of Tenoxicam
|
DB00714
|
DB00381
| 1,304 | 385 |
Apomorphine
|
Amlodipine
|
Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.[A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.
|
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
|
The risk or severity of adverse effects can be increased when Apomorphine is combined with Amlodipine.
| 48 |
[
[
[
1304,
71,
385
]
],
[
[
1304,
71,
516
],
[
516,
225,
385
]
],
[
[
1304,
21,
28396
],
[
28396,
175,
385
]
],
[
[
1304,
236,
164
],
[
164,
26,
385
]
],
[
[
1304,
196,
1079
],
[
1079,
223,
385
]
],
[
[
1304,
41,
530
],
[
530,
223,
385
]
],
[
[
1304,
71,
1361
],
[
1361,
71,
385
]
],
[
[
1304,
59,
499
],
[
499,
71,
385
]
],
[
[
1304,
47,
1025
],
[
1025,
71,
385
]
],
[
[
1304,
92,
392
],
[
392,
71,
385
]
]
] |
[
[
[
"Apomorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may decrease the metabolism of {v}",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} may increase the vasoconstricting activities of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may decrease the metabolism of {v}",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levosimendan"
],
[
"Levosimendan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} may decrease the antihypertensive activities of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Arotinolol"
],
[
"Arotinolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
]
],
[
[
"Apomorphine",
"{u} may decrease the therapeutic efficacy of {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
]
]
] |
Apomorphine may increase the severity of adverse effects when combined with Felodipine and Felodipine may increase the severity of adverse effects when combined with Amlodipine
Apomorphine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Amlodipine (Compound)
Apomorphine may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Amlodipine
Apomorphine may increase the QTc prolonging activities of Crizotinib and Crizotinib may decrease the metabolism of Amlodipine
Apomorphine may increase the vasoconstricting activities of Dihydroergotamine and Dihydroergotamine may decrease the metabolism of Amlodipine
Apomorphine may increase the severity of adverse effects when combined with Levosimendan and Levosimendan may increase the severity of adverse effects when combined with Amlodipine
Apomorphine may decrease the antihypertensive activities of Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Amlodipine
Apomorphine may increase the atrioventricular blocking activities of Arotinolol and Arotinolol may increase the severity of adverse effects when combined with Amlodipine
Apomorphine may decrease the therapeutic efficacy of Chlorpromazine and Chlorpromazine may increase the severity of adverse effects when combined with Amlodipine
|
DB00471
|
DB08873
| 373 | 1,113 |
Montelukast
|
Boceprevir
|
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy. Regardless, in 2008-2009, there were FDA-led investigations into the possibility of montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and others in individuals who used the medication. And although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L632
|
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier
|
The metabolism of Boceprevir can be decreased when combined with Montelukast.
| 46 |
[
[
[
373,
69,
1113
]
],
[
[
373,
6,
4590
],
[
4590,
160,
1113
]
],
[
[
373,
21,
28461
],
[
28461,
175,
1113
]
],
[
[
373,
69,
795
],
[
795,
187,
1113
]
],
[
[
373,
69,
235
],
[
235,
69,
1113
]
],
[
[
373,
69,
1086
],
[
1086,
223,
1113
]
],
[
[
373,
69,
1091
],
[
1091,
95,
1113
]
],
[
[
373,
95,
1114
],
[
1114,
249,
1113
]
],
[
[
373,
249,
531
],
[
531,
95,
1113
]
],
[
[
373,
69,
1095
],
[
1095,
249,
1113
]
]
] |
[
[
[
"Montelukast",
"{u} may decrease the metabolism of {v}",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} may decrease the metabolism of {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may decrease the metabolism of {v}",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} may decrease the metabolism of {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may increase the serum concentration of {v}",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
],
[
"Luliconazole",
"{u} may increase the serum concentration of {v}",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} may increase the serum concentration of {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Boceprevir"
]
],
[
[
"Montelukast",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may increase the serum concentration of {v}",
"Boceprevir"
]
]
] |
Montelukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound)
Montelukast (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Boceprevir (Compound)
Montelukast may decrease the metabolism of Ticagrelor and Ticagrelor may reduce the serum concentration of the active metabolites of Boceprevir
Montelukast may decrease the metabolism of Zafirlukast and Zafirlukast may decrease the metabolism of Boceprevir
Montelukast may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Boceprevir
Montelukast may decrease the metabolism of Dronedarone and Dronedarone may increase the serum concentration of Boceprevir
Montelukast may increase the serum concentration of Luliconazole and Luliconazole may increase the serum concentration of Boceprevir
Montelukast may increase the serum concentration of Conivaptan and Conivaptan may increase the serum concentration of Boceprevir
Montelukast may decrease the metabolism of Cobicistat and Cobicistat may increase the serum concentration of Boceprevir
|
DB01236
|
DB00555
| 354 | 673 |
Sevoflurane
|
Lamotrigine
|
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.
|
Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850]
|
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lamotrigine.
| 48 |
[
[
[
354,
71,
673
]
],
[
[
354,
71,
1359
],
[
1359,
1,
673
]
],
[
[
354,
21,
28450
],
[
28450,
175,
673
]
],
[
[
354,
180,
147
],
[
147,
26,
673
]
],
[
[
354,
192,
679
],
[
679,
38,
673
]
],
[
[
354,
38,
1261
],
[
1261,
192,
673
]
],
[
[
354,
54,
471
],
[
471,
208,
673
]
],
[
[
354,
69,
1088
],
[
1088,
223,
673
]
],
[
[
354,
196,
143
],
[
143,
223,
673
]
],
[
[
354,
71,
915
],
[
915,
71,
673
]
]
] |
[
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triamterene"
],
[
"Triamterene",
"{u} (Compound) resembles {v} (Compound)",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} may decrease the metabolism of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may decrease the metabolism of {v}",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Lamotrigine"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fencamfamin"
],
[
"Fencamfamin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lamotrigine"
]
]
] |
Sevoflurane may increase the severity of adverse effects when combined with Triamterene and Triamterene (Compound) resembles Lamotrigine (Compound)
Sevoflurane (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Lamotrigine (Compound)
Sevoflurane can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Lamotrigine
Sevoflurane may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Lamotrigine
Sevoflurane may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Lamotrigine
Sevoflurane may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Lamotrigine
Sevoflurane may decrease the metabolism of Clarithromycin and Clarithromycin may decrease the metabolism of Lamotrigine
Sevoflurane may increase the QTc prolonging activities of Erythromycin and Erythromycin may decrease the metabolism of Lamotrigine
Sevoflurane may increase the severity of adverse effects when combined with Fencamfamin and Fencamfamin may increase the severity of adverse effects when combined with Lamotrigine
|
DB00373
|
DB00727
| 647 | 1,354 |
Timolol
|
Nitroglycerin
|
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
|
Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure experienced relief from chest pain.[A180166,A180172] Its use as a treatment for angina dates back to 1879 and is still used to treat and prevent angina. Nitroglycerin causes vasodilation in both arteries and veins. Nitroglycerin is used in a variety of different conditions, including angina pectoris due to coronary artery disease,[L7102,L7141,L38369,L42320] peri-operative hypertension, congestive heart failure, and chronic anal fissure. It is also used to induce intraoperative hypotension.
|
The risk or severity of adverse effects can be increased when Timolol is combined with Nitroglycerin.
| 48 |
[
[
[
647,
71,
1354
]
],
[
[
647,
5,
17096
],
[
17096,
164,
1354
]
],
[
[
647,
21,
29099
],
[
29099,
175,
1354
]
],
[
[
647,
52,
828
],
[
828,
206,
1354
]
],
[
[
647,
186,
506
],
[
506,
214,
1354
]
],
[
[
647,
71,
1367
],
[
1367,
71,
1354
]
],
[
[
647,
71,
1357
],
[
1357,
225,
1354
]
],
[
[
647,
225,
914
],
[
914,
71,
1354
]
],
[
[
647,
69,
681
],
[
681,
71,
1354
]
],
[
[
647,
116,
1029
],
[
1029,
225,
1354
]
]
] |
[
[
[
"Timolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is palliated by {v} (Compound)",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} may increase the antihypertensive activities of {v}",
"Avanafil"
],
[
"Avanafil",
"{u} may increase the vasodilatory activities of {v}",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
],
[
"Methazolamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
],
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} may decrease the metabolism of {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroglycerin"
]
],
[
[
"Timolol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Levobunolol"
],
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroglycerin"
]
]
] |
Timolol (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is palliated by Nitroglycerin (Compound)
Timolol (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Nitroglycerin (Compound)
Timolol may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Nitroglycerin
Timolol may increase the antihypertensive activities of Avanafil and Avanafil may increase the vasodilatory activities of Nitroglycerin
Timolol may increase the severity of adverse effects when combined with Methazolamide and Methazolamide may increase the severity of adverse effects when combined with Nitroglycerin
Timolol may increase the severity of adverse effects when combined with Diclofenamide and Diclofenamide may increase the severity of adverse effects when combined with Nitroglycerin
Timolol may increase the severity of adverse effects when combined with Desflurane and Desflurane may increase the severity of adverse effects when combined with Nitroglycerin
Timolol may decrease the metabolism of Clozapine and Clozapine may increase the severity of adverse effects when combined with Nitroglycerin
Timolol (Compound) resembles Levobunolol (Compound) and Timolol may increase the severity of adverse effects when combined with Levobunolol and Levobunolol may increase the severity of adverse effects when combined with Nitroglycerin
|
DB06288
|
DB04908
| 980 | 929 |
Amisulpride
|
Flibanserin
|
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea
|
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
|
The risk or severity of adverse effects can be increased when Amisulpride is combined with Flibanserin.
| 48 |
[
[
[
980,
71,
929
]
],
[
[
980,
192,
1083
],
[
1083,
38,
929
]
],
[
[
980,
38,
1264
],
[
1264,
192,
929
]
],
[
[
980,
54,
1046
],
[
1046,
208,
929
]
],
[
[
980,
58,
990
],
[
990,
71,
929
]
],
[
[
980,
225,
194
],
[
194,
71,
929
]
],
[
[
980,
225,
193
],
[
193,
225,
929
]
],
[
[
980,
71,
941
],
[
941,
71,
929
]
],
[
[
980,
211,
997
],
[
997,
71,
929
]
],
[
[
980,
58,
196
],
[
196,
225,
929
]
]
] |
[
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Mesoridazine"
],
[
"Mesoridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
]
] |
Amisulpride may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Flibanserin
Amisulpride may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Flibanserin
Amisulpride may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Flibanserin
Amisulpride may increase the antipsychotic activities of Mesoridazine and Mesoridazine may increase the severity of adverse effects when combined with Flibanserin
Amisulpride may increase the severity of adverse effects when combined with Methylphenobarbital and Methylphenobarbital may increase the severity of adverse effects when combined with Flibanserin
Amisulpride may increase the severity of adverse effects when combined with Levomilnacipran and Levomilnacipran may increase the severity of adverse effects when combined with Flibanserin
Amisulpride may increase the severity of adverse effects when combined with Clidinium and Clidinium may increase the severity of adverse effects when combined with Flibanserin
Amisulpride may increase the neurotoxic activities of Lithium cation and Lithium cation may increase the severity of adverse effects when combined with Flibanserin
Amisulpride may increase the antipsychotic activities of Iloperidone and Iloperidone may increase the severity of adverse effects when combined with Flibanserin
|
DB00599
|
DB00584
| 320 | 315 |
Thiopental
|
Enalapril
|
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)
|
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v
|
Thiopental may increase the hypotensive activities of Enalapril.
| 59 |
[
[
[
320,
82,
315
]
],
[
[
320,
82,
656
],
[
656,
71,
315
]
],
[
[
320,
82,
676
],
[
676,
225,
315
]
],
[
[
320,
6,
4590
],
[
4590,
160,
315
]
],
[
[
320,
270,
171
],
[
171,
26,
315
]
],
[
[
320,
225,
161
],
[
161,
26,
315
]
],
[
[
320,
71,
150
],
[
150,
26,
315
]
],
[
[
320,
180,
147
],
[
147,
26,
315
]
],
[
[
320,
38,
702
],
[
702,
32,
315
]
],
[
[
320,
71,
828
],
[
828,
206,
315
]
]
] |
[
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Fosinopril"
],
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Lisinopril"
],
[
"Lisinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Enalapril"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Enalapril"
]
]
] |
Thiopental may increase the hypotensive activities of Fosinopril and Fosinopril may increase the severity of adverse effects when combined with Enalapril
Thiopental may increase the hypotensive activities of Lisinopril and Lisinopril may increase the severity of adverse effects when combined with Enalapril
Thiopental (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enalapril (Compound)
Thiopental (Compound) resembles Pentobarbital (Compound) and Thiopental may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Enalapril
Thiopental may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Enalapril
Thiopental may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin can increase the metabolism of Enalapril
Thiopental can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Enalapril
Thiopental may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Enalapril
Thiopental may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Enalapril
|
DB09075
|
DB01253
| 744 | 376 |
Edoxaban
|
Ergometrine
|
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and
|
An ergot alkaloid with uterine and vascular smooth muscle contractile properties.
|
The serum concentration of Ergometrine can be increased when it is combined with Edoxaban.
| 72 |
[
[
[
744,
95,
376
]
],
[
[
744,
249,
1303
],
[
1303,
155,
376
]
],
[
[
744,
95,
563
],
[
563,
155,
376
]
],
[
[
744,
95,
247
],
[
247,
71,
376
]
],
[
[
744,
251,
147
],
[
147,
26,
376
]
],
[
[
744,
95,
156
],
[
156,
26,
376
]
],
[
[
744,
95,
504
],
[
504,
195,
376
]
],
[
[
744,
97,
508
],
[
508,
223,
376
]
],
[
[
744,
95,
429
],
[
429,
223,
376
]
],
[
[
744,
249,
648
],
[
648,
223,
376
]
]
] |
[
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} (Compound) resembles {v} (Compound)",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may increase the vasoconstricting activities of {v}",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may decrease the serum concentration of {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may decrease the metabolism of {v}",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may decrease the metabolism of {v}",
"Ergometrine"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Ergometrine"
]
]
] |
Edoxaban may increase the serum concentration of Methylergometrine and Methylergometrine (Compound) resembles Ergometrine (Compound)
Edoxaban may increase the serum concentration of Ergotamine and Ergotamine (Compound) resembles Ergometrine (Compound)
Edoxaban may increase the serum concentration of Bromocriptine and Bromocriptine may increase the severity of adverse effects when combined with Ergometrine
Edoxaban may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Ergometrine
Edoxaban may increase the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Ergometrine
Edoxaban may increase the serum concentration of Propranolol and Propranolol may increase the vasoconstricting activities of Ergometrine
Edoxaban may decrease the serum concentration of Delavirdine and Delavirdine may decrease the metabolism of Ergometrine
Edoxaban may increase the serum concentration of Lopinavir and Lopinavir may decrease the metabolism of Ergometrine
Edoxaban may increase the serum concentration of Nefazodone and Nefazodone may decrease the metabolism of Ergometrine
|
DB00974
|
DB00735
| 749 | 827 |
Edetic acid
|
Naftifine
|
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
|
Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
|
Edetic acid may increase the anticoagulant activities of Naftifine.
| 5 |
[
[
[
749,
28,
827
]
],
[
[
749,
21,
28463
],
[
28463,
175,
827
]
],
[
[
749,
28,
665
],
[
665,
28,
827
]
],
[
[
749,
182,
773
],
[
773,
28,
827
]
],
[
[
749,
28,
833
],
[
833,
71,
827
]
],
[
[
749,
28,
800
],
[
800,
225,
827
]
],
[
[
749,
34,
124
],
[
124,
225,
827
]
],
[
[
749,
28,
798
],
[
798,
79,
827
]
],
[
[
749,
225,
1444
],
[
1444,
246,
827
]
],
[
[
749,
21,
28463
],
[
28463,
175,
883
],
[
883,
1,
827
]
]
] |
[
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may increase the anticoagulant activities of {v}",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Citric acid"
],
[
"Citric acid",
"{u} may increase the anticoagulant activities of {v}",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Tolmetin"
],
[
"Tolmetin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Icatibant"
],
[
"Icatibant",
"{u} may increase the severity of adverse effects when combined with {v}",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} may decrease the anticoagulant activities of {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the nephrotoxic activities of {v}",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Limaprost"
],
[
"Limaprost",
"{u} may decrease the therapeutic efficacy of {v}",
"Naftifine"
]
],
[
[
"Edetic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Toremifene"
],
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Naftifine"
]
]
] |
Edetic acid (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Naftifine (Compound)
Edetic acid may increase the anticoagulant activities of Bivalirudin and Bivalirudin may increase the anticoagulant activities of Naftifine
Edetic acid may increase the anticoagulant activities of Citric acid and Citric acid may increase the anticoagulant activities of Naftifine
Edetic acid may increase the anticoagulant activities of Tolmetin and Tolmetin may increase the severity of adverse effects when combined with Naftifine
Edetic acid may increase the anticoagulant activities of Icatibant and Icatibant may increase the severity of adverse effects when combined with Naftifine
Edetic acid may decrease the anticoagulant activities of Estrone and Estrone may increase the severity of adverse effects when combined with Naftifine
Edetic acid may increase the anticoagulant activities of Balsalazide and Balsalazide may increase the nephrotoxic activities of Naftifine
Edetic acid may increase the severity of adverse effects when combined with Limaprost and Limaprost may decrease the therapeutic efficacy of Naftifine
Edetic acid (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Toremifene (Compound) and Toremifene (Compound) resembles Naftifine (Compound)
|
DB00321
|
DB08881
| 262 | 495 |
Amitriptyline
|
Vemurafenib
|
Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
|
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
|
The serum concentration of Vemurafenib can be increased when it is combined with Amitriptyline.
| 72 |
[
[
[
262,
95,
495
]
],
[
[
262,
6,
6988
],
[
6988,
160,
495
]
],
[
[
262,
18,
6378
],
[
6378,
172,
495
]
],
[
[
262,
7,
16154
],
[
16154,
172,
495
]
],
[
[
262,
21,
29318
],
[
29318,
175,
495
]
],
[
[
262,
180,
171
],
[
171,
26,
495
]
],
[
[
262,
196,
1313
],
[
1313,
196,
495
]
],
[
[
262,
225,
914
],
[
914,
196,
495
]
],
[
[
262,
38,
1262
],
[
1262,
196,
495
]
],
[
[
262,
69,
610
],
[
610,
196,
495
]
]
] |
[
[
[
"Amitriptyline",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"ORM1"
],
[
"ORM1",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} (Compound) downregulates {v} (Gene)",
"CLTB"
],
[
"CLTB",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} (Compound) upregulates {v} (Gene)",
"HMGCS1"
],
[
"HMGCS1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Arthritis"
],
[
"Arthritis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} may increase the QTc prolonging activities of {v}",
"Perflutren"
],
[
"Perflutren",
"{u} may increase the QTc prolonging activities of {v}",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
],
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the QTc prolonging activities of {v}",
"Vemurafenib"
]
],
[
[
"Amitriptyline",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Vemurafenib"
]
]
] |
Amitriptyline (Compound) binds ORM1 (Gene) and ORM1 (Gene) is bound by Vemurafenib (Compound)
Amitriptyline (Compound) downregulates CLTB (Gene) and CLTB (Gene) is downregulated by Vemurafenib (Compound)
Amitriptyline (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is downregulated by Vemurafenib (Compound)
Amitriptyline (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Vemurafenib (Compound)
Amitriptyline can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Vemurafenib
Amitriptyline may increase the QTc prolonging activities of Perflutren and Perflutren may increase the QTc prolonging activities of Vemurafenib
Amitriptyline may increase the severity of adverse effects when combined with Desflurane and Desflurane may increase the QTc prolonging activities of Vemurafenib
Amitriptyline may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the QTc prolonging activities of Vemurafenib
Amitriptyline may decrease the metabolism of Atomoxetine and Atomoxetine may increase the QTc prolonging activities of Vemurafenib
|
DB09216
|
DB01377
| 449 | 94 |
Tolfenamic acid
|
Magnesium oxide
|
Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.
|
Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.
|
The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Magnesium oxide.
| 48 |
[
[
[
449,
71,
94
]
],
[
[
449,
71,
80
],
[
80,
179,
94
]
],
[
[
449,
71,
405
],
[
405,
71,
94
]
],
[
[
449,
225,
238
],
[
238,
71,
94
]
],
[
[
449,
49,
877
],
[
877,
89,
94
]
],
[
[
449,
225,
1084
],
[
1084,
251,
94
]
],
[
[
449,
71,
1320
],
[
1320,
251,
94
]
],
[
[
449,
213,
1027
],
[
1027,
251,
94
]
],
[
[
449,
71,
80
],
[
80,
1,
128
],
[
128,
179,
94
]
],
[
[
449,
71,
115
],
[
115,
95,
124
],
[
124,
179,
94
]
]
] |
[
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} can decrease the bioavailability of {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nimesulide"
],
[
"Nimesulide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the neuroexcitatory activities of {v}",
"Fleroxacin"
],
[
"Fleroxacin",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Itraconazole"
],
[
"Itraconazole",
"{u} may decrease the serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibandronate"
],
[
"Ibandronate",
"{u} may decrease the serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may decrease the antihypertensive activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may decrease the serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Cortisone acetate"
],
[
"Cortisone acetate",
"{u} can decrease the bioavailability of {v}",
"Magnesium oxide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Equilin"
],
[
"Equilin",
"{u} may increase the serum concentration of {v}",
"Estrone"
],
[
"Estrone",
"{u} can decrease the bioavailability of {v}",
"Magnesium oxide"
]
]
] |
Tolfenamic acid may increase the severity of adverse effects when combined with Prednisone and Prednisone can decrease the bioavailability of Magnesium oxide
Tolfenamic acid may increase the severity of adverse effects when combined with Magnesium sulfate and Magnesium sulfate may increase the severity of adverse effects when combined with Magnesium oxide
Tolfenamic acid may increase the severity of adverse effects when combined with Nimesulide and Nimesulide may increase the severity of adverse effects when combined with Magnesium oxide
Tolfenamic acid may increase the neuroexcitatory activities of Fleroxacin and Fleroxacin may decrease the absorption and serum concentration of Magnesium oxide
Tolfenamic acid may increase the severity of adverse effects when combined with Itraconazole and Itraconazole may decrease the serum concentration of Magnesium oxide
Tolfenamic acid may increase the severity of adverse effects when combined with Ibandronate and Ibandronate may decrease the serum concentration of Magnesium oxide
Tolfenamic acid may decrease the antihypertensive activities of Sotalol and Sotalol may decrease the serum concentration of Magnesium oxide
Tolfenamic acid may increase the severity of adverse effects when combined with Prednisone and Prednisone (Compound) resembles Cortisone acetate (Compound) and Cortisone acetate can decrease the bioavailability of Magnesium oxide
Tolfenamic acid may increase the severity of adverse effects when combined with Equilin and Equilin may increase the serum concentration of Estrone and Estrone can decrease the bioavailability of Magnesium oxide
|
DB11560
|
DB00549
| 427 | 235 |
Lesinurad
|
Zafirlukast
|
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia. Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In August 2017, a combination oral therapy consisting of lesinurad and was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with uncontrolled gout.
|
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
|
The metabolism of Zafirlukast can be decreased when combined with Lesinurad.
| 46 |
[
[
[
427,
69,
235
]
],
[
[
427,
180,
156
],
[
156,
26,
235
]
],
[
[
427,
69,
1417
],
[
1417,
223,
235
]
],
[
[
427,
69,
307
],
[
307,
69,
235
]
],
[
[
427,
180,
191
],
[
191,
249,
235
]
],
[
[
427,
95,
1019
],
[
1019,
249,
235
]
],
[
[
427,
251,
684
],
[
684,
97,
235
]
],
[
[
427,
180,
156
],
[
156,
26,
526
],
[
526,
155,
235
]
],
[
[
427,
180,
147
],
[
147,
97,
1437
],
[
1437,
95,
235
]
],
[
[
427,
69,
1417
],
[
1417,
223,
526
],
[
526,
155,
235
]
]
] |
[
[
[
"Lesinurad",
"{u} may decrease the metabolism of {v}",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
],
[
"Topiroxostat",
"{u} may decrease the metabolism of {v}",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} may decrease the metabolism of {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} can increase the metabolism of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may increase the serum concentration of {v}",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} may decrease the serum concentration of {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} (Compound) resembles {v} (Compound)",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Tolvaptan"
],
[
"Tolvaptan",
"{u} may increase the serum concentration of {v}",
"Zafirlukast"
]
],
[
[
"Lesinurad",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
],
[
"Topiroxostat",
"{u} may decrease the metabolism of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} (Compound) resembles {v} (Compound)",
"Zafirlukast"
]
]
] |
Lesinurad can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Zafirlukast
Lesinurad may decrease the metabolism of Topiroxostat and Topiroxostat may decrease the metabolism of Zafirlukast
Lesinurad may decrease the metabolism of Fluvastatin and Fluvastatin may decrease the metabolism of Zafirlukast
Lesinurad can increase the metabolism of Aprepitant and Aprepitant may increase the serum concentration of Zafirlukast
Lesinurad may increase the serum concentration of Mifepristone and Mifepristone may increase the serum concentration of Zafirlukast
Lesinurad may decrease the serum concentration of Dabrafenib and Dabrafenib may decrease the serum concentration of Zafirlukast
Lesinurad can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Glyburide and Glyburide (Compound) resembles Zafirlukast (Compound)
Lesinurad can increase the metabolism of Rifampicin and Rifampicin may decrease the serum concentration of Tolvaptan and Tolvaptan may increase the serum concentration of Zafirlukast
Lesinurad may decrease the metabolism of Topiroxostat and Topiroxostat may decrease the metabolism of Glyburide and Glyburide (Compound) resembles Zafirlukast (Compound)
|
DB09080
|
DB09063
| 638 | 1,324 |
Olodaterol
|
Ceritinib
|
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated
|
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the
|
The serum concentration of Ceritinib can be increased when it is combined with Olodaterol.
| 72 |
[
[
[
638,
95,
1324
]
],
[
[
638,
196,
956
],
[
956,
42,
1324
]
],
[
[
638,
225,
224
],
[
224,
196,
1324
]
],
[
[
638,
69,
1076
],
[
1076,
196,
1324
]
],
[
[
638,
196,
863
],
[
863,
196,
1324
]
],
[
[
638,
261,
610
],
[
610,
196,
1324
]
],
[
[
638,
93,
1303
],
[
1303,
71,
1324
]
],
[
[
638,
190,
1037
],
[
1037,
76,
1324
]
],
[
[
638,
196,
1027
],
[
1027,
76,
1324
]
],
[
[
638,
105,
1049
],
[
1049,
76,
1324
]
]
] |
[
[
[
"Olodaterol",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may increase the QTc prolonging activities of {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may increase the QTc prolonging activities of {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may decrease the metabolism of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may increase the QTc prolonging activities of {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may increase the tachycardic activities of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may increase the hypertensive activities of {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may decrease the bronchodilatory activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the bradycardic activities of {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may increase the QTc prolonging activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the bradycardic activities of {v}",
"Ceritinib"
]
],
[
[
"Olodaterol",
"{u} may increase the hypokalemic activities of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the bradycardic activities of {v}",
"Ceritinib"
]
]
] |
Olodaterol may increase the QTc prolonging activities of Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Ceritinib
Olodaterol may increase the severity of adverse effects when combined with Amoxapine and Amoxapine may increase the QTc prolonging activities of Ceritinib
Olodaterol may decrease the metabolism of Fluconazole and Fluconazole may increase the QTc prolonging activities of Ceritinib
Olodaterol may increase the QTc prolonging activities of Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Ceritinib
Olodaterol may increase the tachycardic activities of Atomoxetine and Atomoxetine may increase the QTc prolonging activities of Ceritinib
Olodaterol may increase the hypertensive activities of Methylergometrine and Methylergometrine may increase the severity of adverse effects when combined with Ceritinib
Olodaterol may decrease the bronchodilatory activities of Betaxolol and Betaxolol may increase the bradycardic activities of Ceritinib
Olodaterol may increase the QTc prolonging activities of Sotalol and Sotalol may increase the bradycardic activities of Ceritinib
Olodaterol may increase the hypokalemic activities of Bendroflumethiazide and Bendroflumethiazide may increase the bradycardic activities of Ceritinib
|
DB09279
|
DB01026
| 1,363 | 496 |
Fimasartan
|
Ketoconazole
|
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name _Kanarb_ by Boryung Pharmaceuticals.
|
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
|
The serum concentration of Ketoconazole can be increased when it is combined with Fimasartan.
| 72 |
[
[
[
1363,
95,
496
]
],
[
[
1363,
236,
164
],
[
164,
26,
496
]
],
[
[
1363,
225,
392
],
[
392,
69,
496
]
],
[
[
1363,
71,
334
],
[
334,
69,
496
]
],
[
[
1363,
236,
145
],
[
145,
69,
496
]
],
[
[
1363,
52,
968
],
[
968,
69,
496
]
],
[
[
1363,
95,
198
],
[
198,
69,
496
]
],
[
[
1363,
82,
453
],
[
453,
69,
496
]
],
[
[
1363,
225,
605
],
[
605,
225,
496
]
],
[
[
1363,
71,
238
],
[
238,
225,
496
]
]
] |
[
[
[
"Fimasartan",
"{u} may increase the serum concentration of {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the hypotensive activities of {v}",
"Thiamylal"
],
[
"Thiamylal",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the hypotensive activities of {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cilnidipine"
],
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketoconazole"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nimesulide"
],
[
"Nimesulide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketoconazole"
]
]
] |
Fimasartan may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Ketoconazole
Fimasartan may increase the severity of adverse effects when combined with Chlorpromazine and Chlorpromazine may decrease the metabolism of Ketoconazole
Fimasartan may increase the severity of adverse effects when combined with Ibuprofen and Ibuprofen may decrease the metabolism of Ketoconazole
Fimasartan may increase the hypotensive activities of Thiamylal and Thiamylal may decrease the metabolism of Ketoconazole
Fimasartan may increase the orthostatic hypotensive activities of Levodopa and Levodopa may decrease the metabolism of Ketoconazole
Fimasartan may increase the serum concentration of Cyclosporine and Cyclosporine may decrease the metabolism of Ketoconazole
Fimasartan may increase the hypotensive activities of Risperidone and Risperidone may decrease the metabolism of Ketoconazole
Fimasartan may increase the severity of adverse effects when combined with Cilnidipine and Cilnidipine may increase the severity of adverse effects when combined with Ketoconazole
Fimasartan may increase the severity of adverse effects when combined with Nimesulide and Nimesulide may increase the severity of adverse effects when combined with Ketoconazole
|
DB00264
|
DB09120
| 576 | 1,119 |
Metoprolol
|
Zucapsaicin
|
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.
|
Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain. It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular functions. Zucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain. These conditions include herpes simplex (HSV) infections, cluster headaches, migraine, and osteoarthritis of the knee. Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.
|
The serum concentration of Zucapsaicin can be increased when it is combined with Metoprolol.
| 72 |
[
[
[
576,
95,
1119
]
],
[
[
576,
223,
434
],
[
434,
69,
1119
]
],
[
[
576,
95,
318
],
[
318,
69,
1119
]
],
[
[
576,
71,
426
],
[
426,
69,
1119
]
],
[
[
576,
52,
248
],
[
248,
69,
1119
]
],
[
[
576,
180,
142
],
[
142,
69,
1119
]
],
[
[
576,
225,
214
],
[
214,
69,
1119
]
],
[
[
576,
201,
563
],
[
563,
69,
1119
]
],
[
[
576,
69,
657
],
[
657,
69,
1119
]
],
[
[
576,
185,
569
],
[
569,
69,
1119
]
]
] |
[
[
[
"Metoprolol",
"{u} may increase the serum concentration of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} may decrease the metabolism of {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} may increase the serum concentration of {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
],
[
"Levobupivacaine",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} may decrease the metabolism of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
],
[
[
"Metoprolol",
"{u} may increase the hypoglycemic activities of {v}",
"Chlorpropamide"
],
[
"Chlorpropamide",
"{u} may decrease the metabolism of {v}",
"Zucapsaicin"
]
]
] |
Metoprolol may decrease the metabolism of Flunarizine and Flunarizine may decrease the metabolism of Zucapsaicin
Metoprolol may increase the serum concentration of Rabeprazole and Rabeprazole may decrease the metabolism of Zucapsaicin
Metoprolol may increase the severity of adverse effects when combined with Dapagliflozin and Dapagliflozin may decrease the metabolism of Zucapsaicin
Metoprolol may increase the orthostatic hypotensive activities of Carvedilol and Carvedilol may decrease the metabolism of Zucapsaicin
Metoprolol can increase the metabolism of Phenytoin and Phenytoin may decrease the metabolism of Zucapsaicin
Metoprolol may increase the severity of adverse effects when combined with Levobupivacaine and Levobupivacaine may decrease the metabolism of Zucapsaicin
Metoprolol may increase the atrioventricular blocking activities of Ergotamine and Ergotamine may decrease the metabolism of Zucapsaicin
Metoprolol may decrease the metabolism of Voriconazole and Voriconazole may decrease the metabolism of Zucapsaicin
Metoprolol may increase the hypoglycemic activities of Chlorpropamide and Chlorpropamide may decrease the metabolism of Zucapsaicin
|
DB00599
|
DB00325
| 320 | 1,050 |
Thiopental
|
Nitroprusside
|
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)
|
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
|
Thiopental may increase the hypotensive activities of Nitroprusside.
| 59 |
[
[
[
320,
82,
1050
]
],
[
[
320,
38,
702
],
[
702,
32,
1050
]
],
[
[
320,
71,
968
],
[
968,
206,
1050
]
],
[
[
320,
82,
1304
],
[
1304,
71,
1050
]
],
[
[
320,
82,
1357
],
[
1357,
225,
1050
]
],
[
[
320,
52,
1326
],
[
1326,
71,
1050
]
],
[
[
320,
54,
1365
],
[
1365,
71,
1050
]
],
[
[
320,
38,
1265
],
[
1265,
71,
1050
]
],
[
[
320,
52,
183
],
[
183,
225,
1050
]
],
[
[
320,
225,
347
],
[
347,
71,
1050
]
]
] |
[
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Apomorphine"
],
[
"Apomorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Methyclothiazide"
],
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoflurane"
],
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
]
] |
Thiopental may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Nitroprusside
Thiopental may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Nitroprusside
Thiopental may increase the hypotensive activities of Apomorphine and Apomorphine may increase the severity of adverse effects when combined with Nitroprusside
Thiopental may increase the hypotensive activities of Diclofenamide and Diclofenamide may increase the severity of adverse effects when combined with Nitroprusside
Thiopental may increase the orthostatic hypotensive activities of Methyclothiazide and Methyclothiazide may increase the severity of adverse effects when combined with Nitroprusside
Thiopental may increase the sedative activities of Pramipexole and Pramipexole may increase the severity of adverse effects when combined with Nitroprusside
Thiopental may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the severity of adverse effects when combined with Nitroprusside
Thiopental may increase the orthostatic hypotensive activities of Indapamide and Indapamide may increase the severity of adverse effects when combined with Nitroprusside
Thiopental may increase the severity of adverse effects when combined with Isoflurane and Isoflurane may increase the severity of adverse effects when combined with Nitroprusside
|
DB01421
|
DB00390
| 904 | 457 |
Paromomycin
|
Digoxin
|
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
|
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
|
The serum concentration of Digoxin can be decreased when it is combined with Paromomycin.
| 74 |
[
[
[
904,
97,
457
]
],
[
[
904,
97,
1350
],
[
1350,
155,
457
]
],
[
[
904,
97,
1347
],
[
1347,
1,
457
]
],
[
[
904,
7,
4893
],
[
4893,
172,
457
]
],
[
[
904,
18,
5353
],
[
5353,
172,
457
]
],
[
[
904,
21,
28549
],
[
28549,
175,
457
]
],
[
[
904,
79,
1151
],
[
1151,
71,
457
]
],
[
[
904,
225,
894
],
[
894,
71,
457
]
],
[
[
904,
94,
11
],
[
11,
249,
457
]
],
[
[
904,
233,
198
],
[
198,
249,
457
]
]
] |
[
[
[
"Paromomycin",
"{u} may decrease the serum concentration of {v}",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} may decrease the serum concentration of {v}",
"Deslanoside"
],
[
"Deslanoside",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} may decrease the serum concentration of {v}",
"Acetyldigitoxin"
],
[
"Acetyldigitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} (Compound) upregulates {v} (Gene)",
"PIP4K2B"
],
[
"PIP4K2B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} may increase the nephrotoxic activities of {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} may decrease the excretion rate {v}",
"Carprofen"
],
[
"Carprofen",
"{u} may increase the serum concentration of {v}",
"Digoxin"
]
],
[
[
"Paromomycin",
"{u} may increase the nephrotoxic activities of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the serum concentration of {v}",
"Digoxin"
]
]
] |
Paromomycin may decrease the serum concentration of Deslanoside and Deslanoside (Compound) resembles Digoxin (Compound)
Paromomycin may decrease the serum concentration of Acetyldigitoxin and Acetyldigitoxin (Compound) resembles Digoxin (Compound)
Paromomycin (Compound) upregulates PIP4K2B (Gene) and PIP4K2B (Gene) is downregulated by Digoxin (Compound)
Paromomycin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Digoxin (Compound)
Paromomycin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Digoxin (Compound)
Paromomycin may increase the nephrotoxic activities of Amphotericin B and Amphotericin B may increase the severity of adverse effects when combined with Digoxin
Paromomycin may increase the severity of adverse effects when combined with Furosemide and Furosemide may increase the severity of adverse effects when combined with Digoxin
Paromomycin may decrease the excretion rate Carprofen and Carprofen may increase the serum concentration of Digoxin
Paromomycin may increase the nephrotoxic activities of Cyclosporine and Cyclosporine may increase the serum concentration of Digoxin
|
DB00588
|
DB00653
| 84 | 405 |
Fluticasone propionate
|
Magnesium sulfate
|
Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990.
|
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
|
Fluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate.
| 15 |
[
[
[
84,
38,
405
]
],
[
[
84,
225,
977
],
[
977,
38,
405
]
],
[
[
84,
71,
1097
],
[
1097,
38,
405
]
],
[
[
84,
69,
41
],
[
41,
38,
405
]
],
[
[
84,
38,
1262
],
[
1262,
192,
405
]
],
[
[
84,
184,
674
],
[
674,
38,
405
]
],
[
[
84,
38,
1265
],
[
1265,
38,
405
]
],
[
[
84,
192,
1266
],
[
1266,
38,
405
]
],
[
[
84,
71,
54
],
[
54,
43,
405
]
],
[
[
84,
44,
25
],
[
25,
43,
405
]
]
] |
[
[
[
"Fluticasone propionate",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tubocurarine"
],
[
"Tubocurarine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fluticasone propionate",
"{u} may increase the adverse neuromuscular activities of {v}",
"Atracurium besylate"
],
[
"Atracurium besylate",
"{u} may increase the neuromuscular blocking activities of {v}",
"Magnesium sulfate"
]
]
] |
Fluticasone propionate may increase the severity of adverse effects when combined with Butalbital and Butalbital may increase the central nervous system depressant activities of Magnesium sulfate
Fluticasone propionate may increase the severity of adverse effects when combined with Ezogabine and Ezogabine may increase the central nervous system depressant activities of Magnesium sulfate
Fluticasone propionate may decrease the metabolism of Clemastine and Clemastine may increase the central nervous system depressant activities of Magnesium sulfate
Fluticasone propionate may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Magnesium sulfate
Fluticasone propionate can increase the therapeutic efficacy of Pregabalin and Pregabalin may increase the central nervous system depressant activities of Magnesium sulfate
Fluticasone propionate may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Magnesium sulfate
Fluticasone propionate may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Magnesium sulfate
Fluticasone propionate may increase the severity of adverse effects when combined with Tubocurarine and Tubocurarine may increase the neuromuscular blocking activities of Magnesium sulfate
Fluticasone propionate may increase the adverse neuromuscular activities of Atracurium besylate and Atracurium besylate may increase the neuromuscular blocking activities of Magnesium sulfate
|
DB00298
|
DB09009
| 933 | 923 |
Dapiprazole
|
Articaine
|
Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is found in ophthalmic solutions used to reverse mydriasis after an eye examination.
|
Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
|
The risk or severity of adverse effects can be increased when Dapiprazole is combined with Articaine.
| 48 |
[
[
[
933,
71,
923
]
],
[
[
933,
38,
1262
],
[
1262,
192,
923
]
],
[
[
933,
192,
679
],
[
679,
38,
923
]
],
[
[
933,
54,
471
],
[
471,
208,
923
]
],
[
[
933,
71,
1097
],
[
1097,
225,
923
]
],
[
[
933,
71,
964
],
[
964,
71,
923
]
],
[
[
933,
225,
312
],
[
312,
71,
923
]
],
[
[
933,
225,
411
],
[
411,
225,
923
]
],
[
[
933,
211,
997
],
[
997,
71,
923
]
],
[
[
933,
212,
980
],
[
980,
71,
923
]
]
] |
[
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triflupromazine"
],
[
"Triflupromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temazepam"
],
[
"Temazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertraline"
],
[
"Sertraline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the severity of adverse effects when combined with {v}",
"Articaine"
]
],
[
[
"Dapiprazole",
"{u} may increase the antipsychotic activities of {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Articaine"
]
]
] |
Dapiprazole may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Articaine
Dapiprazole may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Articaine
Dapiprazole may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Articaine
Dapiprazole may increase the severity of adverse effects when combined with Ezogabine and Ezogabine may increase the severity of adverse effects when combined with Articaine
Dapiprazole may increase the severity of adverse effects when combined with Triflupromazine and Triflupromazine may increase the severity of adverse effects when combined with Articaine
Dapiprazole may increase the severity of adverse effects when combined with Temazepam and Temazepam may increase the severity of adverse effects when combined with Articaine
Dapiprazole may increase the severity of adverse effects when combined with Sertraline and Sertraline may increase the severity of adverse effects when combined with Articaine
Dapiprazole may increase the neurotoxic activities of Lithium cation and Lithium cation may increase the severity of adverse effects when combined with Articaine
Dapiprazole may increase the antipsychotic activities of Amisulpride and Amisulpride may increase the severity of adverse effects when combined with Articaine
|
DB01072
|
DB08882
| 564 | 693 |
Atazanavir
|
Linagliptin
|
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
|
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
|
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Atazanavir.
| 69 |
[
[
[
564,
92,
693
]
],
[
[
564,
223,
555
],
[
555,
1,
693
]
],
[
[
564,
6,
4590
],
[
4590,
160,
693
]
],
[
[
564,
21,
28509
],
[
28509,
175,
693
]
],
[
[
564,
180,
156
],
[
156,
26,
693
]
],
[
[
564,
92,
769
],
[
769,
31,
693
]
],
[
[
564,
249,
423
],
[
423,
31,
693
]
],
[
[
564,
223,
1018
],
[
1018,
31,
693
]
],
[
[
564,
223,
461
],
[
461,
69,
693
]
],
[
[
564,
71,
465
],
[
465,
225,
693
]
]
] |
[
[
[
"Atazanavir",
"{u} may decrease the therapeutic efficacy of {v}",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} may decrease the metabolism of {v}",
"Alogliptin"
],
[
"Alogliptin",
"{u} (Compound) resembles {v} (Compound)",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} may decrease the therapeutic efficacy of {v}",
"Gliquidone"
],
[
"Gliquidone",
"{u} may increase the hypoglycemic activities of {v}",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} may increase the serum concentration of {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may increase the hypoglycemic activities of {v}",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} may decrease the metabolism of {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may increase the hypoglycemic activities of {v}",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may decrease the metabolism of {v}",
"Linagliptin"
]
],
[
[
"Atazanavir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Linagliptin"
]
]
] |
Atazanavir may decrease the metabolism of Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Atazanavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Atazanavir (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Linagliptin (Compound)
Atazanavir can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Linagliptin
Atazanavir may decrease the therapeutic efficacy of Gliquidone and Gliquidone may increase the hypoglycemic activities of Linagliptin
Atazanavir may increase the serum concentration of Repaglinide and Repaglinide may increase the hypoglycemic activities of Linagliptin
Atazanavir may decrease the metabolism of Sunitinib and Sunitinib may increase the hypoglycemic activities of Linagliptin
Atazanavir may decrease the metabolism of Diltiazem and Diltiazem may decrease the metabolism of Linagliptin
Atazanavir may increase the severity of adverse effects when combined with Meperidine and Meperidine may increase the severity of adverse effects when combined with Linagliptin
|
DB00318
|
DB13872
| 579 | 910 |
Codeine
|
Lormetazepam
|
The relief of pain (analgesia) is a primary goal for enhancing the quality of life of patients and for increasing the ability of patients to engage in day to day activities. Codeine, an opioid analgesic, was originally approved in the US in 1950 and is a drug used to decrease pain by increasing the threshold for pain without impairing consciousness or altering other sensory functions. Opiates such as codeine are derived from the poppy plant, _Papaver somniferum_ (Papaveraceae). Codeine is utilized as a central analgesic, sedative, hypnotic, antinociceptive, and antiperistaltic agent, and is also recommended in certain diseases with incessant coughing.[LABEL,A175096]
|
Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia. It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.
|
The risk or severity of adverse effects can be increased when Codeine is combined with Lormetazepam.
| 48 |
[
[
[
579,
71,
910
]
],
[
[
579,
38,
1264
],
[
1264,
192,
910
]
],
[
[
579,
192,
287
],
[
287,
38,
910
]
],
[
[
579,
54,
1046
],
[
1046,
208,
910
]
],
[
[
579,
246,
288
],
[
288,
71,
910
]
],
[
[
579,
116,
163
],
[
163,
71,
910
]
],
[
[
579,
246,
828
],
[
828,
225,
910
]
],
[
[
579,
71,
961
],
[
961,
71,
910
]
],
[
[
579,
71,
949
],
[
949,
225,
910
]
],
[
[
579,
225,
540
],
[
540,
71,
910
]
]
] |
[
[
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} may decrease the therapeutic efficacy of {v}",
"Promazine"
],
[
"Promazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} may decrease the therapeutic efficacy of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
],
[
"Morphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
]
] |
Codeine may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Lormetazepam
Codeine may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Lormetazepam
Codeine may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Lormetazepam
Codeine may decrease the therapeutic efficacy of Promazine and Promazine may increase the severity of adverse effects when combined with Lormetazepam
Codeine (Compound) resembles Oxycodone (Compound) and Codeine may increase the severity of adverse effects when combined with Oxycodone and Oxycodone may increase the severity of adverse effects when combined with Lormetazepam
Codeine may decrease the therapeutic efficacy of Duloxetine and Duloxetine may increase the severity of adverse effects when combined with Lormetazepam
Codeine may increase the severity of adverse effects when combined with Fentanyl and Fentanyl may increase the severity of adverse effects when combined with Lormetazepam
Codeine may increase the severity of adverse effects when combined with Triprolidine and Triprolidine may increase the severity of adverse effects when combined with Lormetazepam
Codeine may increase the severity of adverse effects when combined with Morphine and Morphine may increase the severity of adverse effects when combined with Lormetazepam
|
DB13025
|
DB00906
| 936 | 201 |
Tiapride
|
Tiagabine
|
Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.
|
Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
|
The risk or severity of adverse effects can be increased when Tiapride is combined with Tiagabine.
| 48 |
[
[
[
936,
71,
201
]
],
[
[
936,
225,
156
],
[
156,
26,
201
]
],
[
[
936,
71,
142
],
[
142,
26,
201
]
],
[
[
936,
38,
1262
],
[
1262,
192,
201
]
],
[
[
936,
192,
287
],
[
287,
38,
201
]
],
[
[
936,
54,
1365
],
[
1365,
208,
201
]
],
[
[
936,
71,
41
],
[
41,
223,
201
]
],
[
[
936,
225,
648
],
[
648,
223,
201
]
],
[
[
936,
225,
1003
],
[
1003,
71,
201
]
],
[
[
936,
225,
394
],
[
394,
225,
201
]
]
] |
[
[
[
"Tiapride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tiagabine"
]
],
[
[
"Tiapride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tiagabine"
]
]
] |
Tiapride may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Tiagabine
Tiapride may increase the severity of adverse effects when combined with Phenytoin and Phenytoin can increase the metabolism of Tiagabine
Tiapride may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Tiagabine
Tiapride may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Tiagabine
Tiapride may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Tiagabine
Tiapride may increase the severity of adverse effects when combined with Clemastine and Clemastine may decrease the metabolism of Tiagabine
Tiapride may increase the severity of adverse effects when combined with Nefazodone and Nefazodone may decrease the metabolism of Tiagabine
Tiapride may increase the severity of adverse effects when combined with Lurasidone and Lurasidone may increase the severity of adverse effects when combined with Tiagabine
Tiapride may increase the severity of adverse effects when combined with Fluoxetine and Fluoxetine may increase the severity of adverse effects when combined with Tiagabine
|
DB01424
|
DB00215
| 374 | 556 |
Aminophenazone
|
Citalopram
|
Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests. The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942]
|
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
|
The metabolism of Citalopram can be decreased when combined with Aminophenazone.
| 46 |
[
[
[
374,
69,
556
]
],
[
[
374,
6,
12128
],
[
12128,
160,
556
]
],
[
[
374,
180,
173
],
[
173,
26,
556
]
],
[
[
374,
69,
284
],
[
284,
31,
556
]
],
[
[
374,
69,
878
],
[
878,
196,
556
]
],
[
[
374,
69,
547
],
[
547,
223,
556
]
],
[
[
374,
69,
497
],
[
497,
69,
556
]
],
[
[
374,
180,
156
],
[
156,
69,
556
]
],
[
[
374,
1,
552
],
[
552,
69,
556
]
],
[
[
374,
69,
527
],
[
527,
71,
556
]
]
] |
[
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may increase the hypoglycemic activities of {v}",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Cinacalcet"
],
[
"Cinacalcet",
"{u} may decrease the metabolism of {v}",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may decrease the metabolism of {v}",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may decrease the metabolism of {v}",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} (Compound) resembles {v} (Compound)",
"Methsuximide"
],
[
"Methsuximide",
"{u} may decrease the metabolism of {v}",
"Citalopram"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may increase the severity of adverse effects when combined with {v}",
"Citalopram"
]
]
] |
Aminophenazone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Citalopram (Compound)
Aminophenazone can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Citalopram
Aminophenazone may decrease the metabolism of Sulfadiazine and Sulfadiazine may increase the hypoglycemic activities of Citalopram
Aminophenazone may decrease the metabolism of Paroxetine and Paroxetine may increase the QTc prolonging activities of Citalopram
Aminophenazone may decrease the metabolism of Cinacalcet and Cinacalcet may decrease the metabolism of Citalopram
Aminophenazone may decrease the metabolism of Theophylline and Theophylline may decrease the metabolism of Citalopram
Aminophenazone can increase the metabolism of Carbamazepine and Carbamazepine may decrease the metabolism of Citalopram
Aminophenazone (Compound) resembles Methsuximide (Compound) and Methsuximide may decrease the metabolism of Citalopram
Aminophenazone may decrease the metabolism of Bupropion and Bupropion may increase the severity of adverse effects when combined with Citalopram
|
DB09242
|
DB00679
| 1,053 | 653 |
Moxonidine
|
Thioridazine
|
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.
|
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
|
The risk or severity of adverse effects can be increased when Moxonidine is combined with Thioridazine.
| 48 |
[
[
[
1053,
71,
653
]
],
[
[
1053,
225,
1304
],
[
1304,
196,
653
]
],
[
[
1053,
82,
689
],
[
689,
196,
653
]
],
[
[
1053,
246,
224
],
[
224,
196,
653
]
],
[
[
1053,
52,
968
],
[
968,
206,
653
]
],
[
[
1053,
71,
471
],
[
471,
208,
653
]
],
[
[
1053,
82,
1046
],
[
1046,
208,
653
]
],
[
[
1053,
47,
248
],
[
248,
69,
653
]
],
[
[
1053,
236,
678
],
[
678,
69,
653
]
],
[
[
1053,
246,
195
],
[
195,
69,
653
]
]
] |
[
[
[
"Moxonidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Apomorphine"
],
[
"Apomorphine",
"{u} may increase the QTc prolonging activities of {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may increase the hypotensive activities of {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may increase the QTc prolonging activities of {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may decrease the therapeutic efficacy of {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may increase the QTc prolonging activities of {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may increase the hypotensive activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may increase the hypotensive activities of {v}",
"Doxazosin"
],
[
"Doxazosin",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
]
],
[
[
"Moxonidine",
"{u} may decrease the therapeutic efficacy of {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
]
]
] |
Moxonidine may increase the severity of adverse effects when combined with Apomorphine and Apomorphine may increase the QTc prolonging activities of Thioridazine
Moxonidine may increase the hypotensive activities of Treprostinil and Treprostinil may increase the QTc prolonging activities of Thioridazine
Moxonidine may decrease the therapeutic efficacy of Amoxapine and Amoxapine may increase the QTc prolonging activities of Thioridazine
Moxonidine may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Thioridazine
Moxonidine may increase the severity of adverse effects when combined with Rotigotine and Rotigotine may increase the sedative activities of Thioridazine
Moxonidine may increase the hypotensive activities of Metyrosine and Metyrosine may increase the sedative activities of Thioridazine
Moxonidine may increase the atrioventricular blocking activities of Carvedilol and Carvedilol may decrease the metabolism of Thioridazine
Moxonidine may increase the hypotensive activities of Doxazosin and Doxazosin may decrease the metabolism of Thioridazine
Moxonidine may decrease the therapeutic efficacy of Cyclobenzaprine and Cyclobenzaprine may decrease the metabolism of Thioridazine
|
DB06216
|
DB01086
| 494 | 945 |
Asenapine
|
Benzocaine
|
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
|
Benzocaine is an ester local anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings. It is commonly used for local anesthesia in many over the counter products.[L32454,L32459,L32464] Benzocaine was first used for local anesthesia in dentistry.
|
The risk or severity of adverse effects can be increased when Asenapine is combined with Benzocaine.
| 48 |
[
[
[
494,
71,
945
]
],
[
[
494,
209,
1322
],
[
1322,
155,
945
]
],
[
[
494,
21,
28463
],
[
28463,
175,
945
]
],
[
[
494,
184,
674
],
[
674,
30,
945
]
],
[
[
494,
192,
679
],
[
679,
38,
945
]
],
[
[
494,
38,
405
],
[
405,
192,
945
]
],
[
[
494,
54,
1365
],
[
1365,
208,
945
]
],
[
[
494,
71,
480
],
[
480,
225,
945
]
],
[
[
494,
71,
63
],
[
63,
71,
945
]
],
[
[
494,
42,
280
],
[
280,
71,
945
]
]
] |
[
[
[
"Asenapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Procainamide"
],
[
"Procainamide",
"{u} (Compound) resembles {v} (Compound)",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etizolam"
],
[
"Etizolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benzocaine"
]
],
[
[
"Asenapine",
"{u} may increase the QTc prolonging activities of {v}",
"Propofol"
],
[
"Propofol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benzocaine"
]
]
] |
Asenapine may increase the severity of QTc prolonging effects when combined with Procainamide and Procainamide (Compound) resembles Benzocaine (Compound)
Asenapine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Benzocaine (Compound)
Asenapine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Benzocaine
Asenapine may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Benzocaine
Asenapine may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Benzocaine
Asenapine may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Benzocaine
Asenapine may increase the severity of adverse effects when combined with Etizolam and Etizolam may increase the severity of adverse effects when combined with Benzocaine
Asenapine may increase the severity of adverse effects when combined with Tranylcypromine and Tranylcypromine may increase the severity of adverse effects when combined with Benzocaine
Asenapine may increase the QTc prolonging activities of Propofol and Propofol may increase the severity of adverse effects when combined with Benzocaine
|
DB06725
|
DB01234
| 286 | 119 |
Lornoxicam
|
Dexamethasone
|
Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use in Japan.
|
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
|
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexamethasone.
| 48 |
[
[
[
286,
71,
119
]
],
[
[
286,
71,
135
],
[
135,
155,
119
]
],
[
[
286,
71,
129
],
[
129,
1,
119
]
],
[
[
286,
6,
7128
],
[
7128,
160,
119
]
],
[
[
286,
69,
795
],
[
795,
187,
119
]
],
[
[
286,
69,
657
],
[
657,
223,
119
]
],
[
[
286,
225,
628
],
[
628,
71,
119
]
],
[
[
286,
71,
148
],
[
148,
71,
119
]
],
[
[
286,
49,
877
],
[
877,
225,
119
]
],
[
[
286,
233,
798
],
[
798,
71,
119
]
]
] |
[
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clobetasol propionate"
],
[
"Clobetasol propionate",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluocortolone"
],
[
"Fluocortolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} may decrease the metabolism of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may decrease the metabolism of {v}",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Suprofen"
],
[
"Suprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceclofenac"
],
[
"Aceclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the neuroexcitatory activities of {v}",
"Fleroxacin"
],
[
"Fleroxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the nephrotoxic activities of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexamethasone"
]
]
] |
Lornoxicam may increase the severity of adverse effects when combined with Clobetasol propionate and Clobetasol propionate (Compound) resembles Dexamethasone (Compound)
Lornoxicam may increase the severity of adverse effects when combined with Fluocortolone and Fluocortolone (Compound) resembles Dexamethasone (Compound)
Lornoxicam (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dexamethasone (Compound)
Lornoxicam may decrease the metabolism of Ticagrelor and Ticagrelor may reduce the serum concentration of the active metabolites of Dexamethasone
Lornoxicam may decrease the metabolism of Voriconazole and Voriconazole may decrease the metabolism of Dexamethasone
Lornoxicam may increase the severity of adverse effects when combined with Suprofen and Suprofen may increase the severity of adverse effects when combined with Dexamethasone
Lornoxicam may increase the severity of adverse effects when combined with Aceclofenac and Aceclofenac may increase the severity of adverse effects when combined with Dexamethasone
Lornoxicam may increase the neuroexcitatory activities of Fleroxacin and Fleroxacin may increase the severity of adverse effects when combined with Dexamethasone
Lornoxicam may increase the nephrotoxic activities of Balsalazide and Balsalazide may increase the severity of adverse effects when combined with Dexamethasone
|
DB00599
|
DB00275
| 320 | 1,054 |
Thiopental
|
Olmesartan
|
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)
|
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS
|
Thiopental may increase the hypotensive activities of Olmesartan.
| 59 |
[
[
[
320,
82,
1054
]
],
[
[
320,
82,
1071
],
[
1071,
225,
1054
]
],
[
[
320,
82,
239
],
[
239,
71,
1054
]
],
[
[
320,
38,
702
],
[
702,
32,
1054
]
],
[
[
320,
71,
828
],
[
828,
206,
1054
]
],
[
[
320,
225,
280
],
[
280,
71,
1054
]
],
[
[
320,
71,
522
],
[
522,
71,
1054
]
],
[
[
320,
52,
1049
],
[
1049,
225,
1054
]
],
[
[
320,
225,
955
],
[
955,
225,
1054
]
],
[
[
320,
71,
724
],
[
724,
225,
1054
]
]
] |
[
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Telmisartan"
],
[
"Telmisartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the hypotensive activities of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propofol"
],
[
"Propofol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halothane"
],
[
"Halothane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Thiopental",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexmedetomidine"
],
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
]
] |
Thiopental may increase the hypotensive activities of Telmisartan and Telmisartan may increase the severity of adverse effects when combined with Olmesartan
Thiopental may increase the hypotensive activities of Valsartan and Valsartan may increase the severity of adverse effects when combined with Olmesartan
Thiopental may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Olmesartan
Thiopental may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Olmesartan
Thiopental may increase the severity of adverse effects when combined with Propofol and Propofol may increase the severity of adverse effects when combined with Olmesartan
Thiopental may increase the severity of adverse effects when combined with Halothane and Halothane may increase the severity of adverse effects when combined with Olmesartan
Thiopental may increase the orthostatic hypotensive activities of Bendroflumethiazide and Bendroflumethiazide may increase the severity of adverse effects when combined with Olmesartan
Thiopental may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may increase the severity of adverse effects when combined with Olmesartan
Thiopental may increase the severity of adverse effects when combined with Dexmedetomidine and Dexmedetomidine may increase the severity of adverse effects when combined with Olmesartan
|
DB00952
|
DB06288
| 1,310 | 980 |
Naratriptan
|
Amisulpride
|
Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
|
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea
|
The risk or severity of adverse effects can be increased when Naratriptan is combined with Amisulpride.
| 48 |
[
[
[
1310,
71,
980
]
],
[
[
1310,
71,
920
],
[
920,
212,
980
]
],
[
[
1310,
71,
18
],
[
18,
225,
980
]
],
[
[
1310,
21,
28437
],
[
28437,
175,
980
]
],
[
[
1310,
225,
543
],
[
543,
38,
980
]
],
[
[
1310,
71,
997
],
[
997,
57,
980
]
],
[
[
1310,
155,
558
],
[
558,
71,
980
]
],
[
[
1310,
270,
1308
],
[
1308,
71,
980
]
],
[
[
1310,
225,
221
],
[
221,
225,
980
]
],
[
[
1310,
71,
193
],
[
193,
71,
980
]
]
] |
[
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Remoxipride"
],
[
"Remoxipride",
"{u} may increase the antipsychotic activities of {v}",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Bradycardia"
],
[
"Bradycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} (Compound) resembles {v} (Compound)",
"Eletriptan"
],
[
"Eletriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Sumatriptan"
],
[
"Sumatriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
]
]
] |
Naratriptan may increase the severity of adverse effects when combined with Remoxipride and Remoxipride may increase the antipsychotic activities of Amisulpride
Naratriptan may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the severity of adverse effects when combined with Amisulpride
Naratriptan (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Amisulpride (Compound)
Naratriptan may increase the severity of adverse effects when combined with Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Amisulpride
Naratriptan may increase the severity of adverse effects when combined with Lithium cation and Lithium cation may increase the neurotoxic activities of Amisulpride
Naratriptan (Compound) resembles Eletriptan (Compound) and Eletriptan may increase the severity of adverse effects when combined with Amisulpride
Naratriptan (Compound) resembles Sumatriptan (Compound) and Naratriptan may increase the severity of adverse effects when combined with Sumatriptan and Sumatriptan may increase the severity of adverse effects when combined with Amisulpride
Naratriptan may increase the severity of adverse effects when combined with Nortriptyline and Nortriptyline may increase the severity of adverse effects when combined with Amisulpride
Naratriptan may increase the severity of adverse effects when combined with Levomilnacipran and Levomilnacipran may increase the severity of adverse effects when combined with Amisulpride
|
DB01110
|
DB00270
| 283 | 472 |
Miconazole
|
Isradipine
|
Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m
|
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
|
The risk or severity of adverse effects can be increased when Miconazole is combined with Isradipine.
| 48 |
[
[
[
283,
71,
472
]
],
[
[
283,
71,
503
],
[
503,
1,
472
]
],
[
[
283,
71,
329
],
[
329,
69,
472
]
],
[
[
283,
71,
512
],
[
512,
155,
472
]
],
[
[
283,
6,
4590
],
[
4590,
160,
472
]
],
[
[
283,
21,
28611
],
[
28611,
175,
472
]
],
[
[
283,
180,
156
],
[
156,
26,
472
]
],
[
[
283,
69,
615
],
[
615,
32,
472
]
],
[
[
283,
69,
1091
],
[
1091,
42,
472
]
],
[
[
283,
95,
1019
],
[
1019,
196,
472
]
]
] |
[
[
[
"Miconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nimodipine"
],
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrendipine"
],
[
"Nitrendipine",
"{u} may decrease the metabolism of {v}",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} may decrease the metabolism of {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
],
[
[
"Miconazole",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
]
] |
Miconazole may increase the severity of adverse effects when combined with Nimodipine and Nimodipine (Compound) resembles Isradipine (Compound)
Miconazole may increase the severity of adverse effects when combined with Nitrendipine and Nitrendipine may decrease the metabolism of Isradipine
Miconazole may increase the severity of adverse effects when combined with Nisoldipine and Nisoldipine (Compound) resembles Isradipine (Compound)
Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isradipine (Compound)
Miconazole (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Isradipine (Compound)
Miconazole can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Isradipine
Miconazole may decrease the metabolism of Sildenafil and Sildenafil may increase the antihypertensive activities of Isradipine
Miconazole may decrease the metabolism of Dronedarone and Dronedarone may increase the QTc prolonging activities of Isradipine
Miconazole may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Isradipine
|
DB09216
|
DB06786
| 449 | 122 |
Tolfenamic acid
|
Halcinonide
|
Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.
|
Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide.
|
The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Halcinonide.
| 48 |
[
[
[
449,
71,
122
]
],
[
[
449,
71,
94
],
[
94,
25,
122
]
],
[
[
449,
49,
879
],
[
879,
225,
122
]
],
[
[
449,
225,
11
],
[
11,
71,
122
]
],
[
[
449,
71,
742
],
[
742,
71,
122
]
],
[
[
449,
182,
687
],
[
687,
71,
122
]
],
[
[
449,
233,
768
],
[
768,
71,
122
]
],
[
[
449,
225,
1156
],
[
1156,
246,
122
]
],
[
[
449,
225,
479
],
[
479,
249,
122
]
],
[
[
449,
71,
124
],
[
124,
249,
122
]
]
] |
[
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} can decrease the bioavailability of {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the neuroexcitatory activities of {v}",
"Nalidixic acid"
],
[
"Nalidixic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carprofen"
],
[
"Carprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clonixin"
],
[
"Clonixin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the nephrotoxic activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benzoic acid"
],
[
"Benzoic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may increase the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the serum concentration of {v}",
"Halcinonide"
]
]
] |
Tolfenamic acid may increase the severity of adverse effects when combined with Magnesium oxide and Magnesium oxide can decrease the bioavailability of Halcinonide
Tolfenamic acid may increase the neuroexcitatory activities of Nalidixic acid and Nalidixic acid may increase the severity of adverse effects when combined with Halcinonide
Tolfenamic acid may increase the severity of adverse effects when combined with Carprofen and Carprofen may increase the severity of adverse effects when combined with Halcinonide
Tolfenamic acid may increase the severity of adverse effects when combined with Clonixin and Clonixin may increase the severity of adverse effects when combined with Halcinonide
Tolfenamic acid may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the severity of adverse effects when combined with Halcinonide
Tolfenamic acid may increase the nephrotoxic activities of Olsalazine and Olsalazine may increase the severity of adverse effects when combined with Halcinonide
Tolfenamic acid may increase the severity of adverse effects when combined with Benzoic acid and Benzoic acid may decrease the therapeutic efficacy of Halcinonide
Tolfenamic acid may increase the severity of adverse effects when combined with Posaconazole and Posaconazole may increase the serum concentration of Halcinonide
Tolfenamic acid may increase the severity of adverse effects when combined with Estrone and Estrone may increase the serum concentration of Halcinonide
|
DB06203
|
DB08804
| 555 | 806 |
Alogliptin
|
Nandrolone decanoate
|
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
|
Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis.[A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959 and in 1960, it was described as having a long duration of action and strong anabolic effect compared to nandrolone and other esters. Nandrolone decanoate was granted FDA approval on 5 October 1962.
|
Alogliptin may increase the hypoglycemic activities of Nandrolone decanoate.
| 8 |
[
[
[
555,
31,
806
]
],
[
[
555,
246,
606
],
[
606,
1,
806
]
],
[
[
555,
31,
811
],
[
811,
1,
806
]
],
[
[
555,
246,
1104
],
[
1104,
155,
806
]
],
[
[
555,
21,
28387
],
[
28387,
175,
806
]
],
[
[
555,
185,
423
],
[
423,
31,
806
]
],
[
[
555,
69,
640
],
[
640,
31,
806
]
],
[
[
555,
95,
1019
],
[
1019,
31,
806
]
],
[
[
555,
246,
82
],
[
82,
96,
806
]
],
[
[
555,
249,
198
],
[
198,
102,
806
]
]
] |
[
[
[
"Alogliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} may decrease the therapeutic efficacy of {v}",
"Levonorgestrel"
],
[
"Levonorgestrel",
"{u} (Compound) resembles {v} (Compound)",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Testosterone propionate"
],
[
"Testosterone propionate",
"{u} (Compound) resembles {v} (Compound)",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} may decrease the therapeutic efficacy of {v}",
"Norgestimate"
],
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may increase the hypoglycemic activities of {v}",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} may decrease the metabolism of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the hypoglycemic activities of {v}",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the hypoglycemic activities of {v}",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} may decrease the therapeutic efficacy of {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may increase the fluid retaining activities of {v}",
"Nandrolone decanoate"
]
],
[
[
"Alogliptin",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the hepatotoxic activities of {v}",
"Nandrolone decanoate"
]
]
] |
Alogliptin may decrease the therapeutic efficacy of Levonorgestrel and Levonorgestrel (Compound) resembles Nandrolone decanoate (Compound)
Alogliptin may increase the hypoglycemic activities of Testosterone propionate and Testosterone propionate (Compound) resembles Nandrolone decanoate (Compound)
Alogliptin may decrease the therapeutic efficacy of Norgestimate and Norgestimate (Compound) resembles Nandrolone decanoate (Compound)
Alogliptin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Nandrolone decanoate (Compound)
Alogliptin may increase the hypoglycemic activities of Repaglinide and Repaglinide may increase the hypoglycemic activities of Nandrolone decanoate
Alogliptin may decrease the metabolism of Quinine and Quinine may increase the hypoglycemic activities of Nandrolone decanoate
Alogliptin may increase the serum concentration of Mifepristone and Mifepristone may increase the hypoglycemic activities of Nandrolone decanoate
Alogliptin may decrease the therapeutic efficacy of Prednisolone and Prednisolone may increase the fluid retaining activities of Nandrolone decanoate
Alogliptin may increase the serum concentration of Cyclosporine and Cyclosporine may increase the hepatotoxic activities of Nandrolone decanoate
|
DB01201
|
DB00829
| 177 | 407 |
Rifapentine
|
Diazepam
|
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
|
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016. Combining diazepam, a proven effective therapy for acute repetitive seizures
|
The metabolism of Diazepam can be increased when combined with Rifapentine.
| 3 |
[
[
[
177,
26,
407
]
],
[
[
177,
26,
388
],
[
388,
1,
407
]
],
[
[
177,
26,
275
],
[
275,
225,
407
]
],
[
[
177,
26,
335
],
[
335,
155,
407
]
],
[
[
177,
6,
7128
],
[
7128,
160,
407
]
],
[
[
177,
26,
147
],
[
147,
26,
407
]
],
[
[
177,
26,
679
],
[
679,
38,
407
]
],
[
[
177,
97,
1083
],
[
1083,
38,
407
]
],
[
[
177,
97,
1257
],
[
1257,
192,
407
]
],
[
[
177,
26,
471
],
[
471,
208,
407
]
]
] |
[
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Estazolam"
],
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Clorazepic acid"
],
[
"Clorazepic acid",
"{u} (Compound) resembles {v} (Compound)",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} may decrease the serum concentration of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} may decrease the serum concentration of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Diazepam"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Diazepam"
]
]
] |
Rifapentine can increase the metabolism of Flurbiprofen and Flurbiprofen (Compound) resembles Diazepam (Compound)
Rifapentine can increase the metabolism of Estazolam and Estazolam may increase the severity of adverse effects when combined with Diazepam
Rifapentine can increase the metabolism of Clorazepic acid and Clorazepic acid (Compound) resembles Diazepam (Compound)
Rifapentine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Diazepam (Compound)
Rifapentine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Diazepam
Rifapentine can increase the metabolism of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Diazepam
Rifapentine may decrease the serum concentration of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Diazepam
Rifapentine may decrease the serum concentration of Perampanel and Perampanel may increase the central nervous system depressant activities of Diazepam
Rifapentine can increase the metabolism of Rotigotine and Rotigotine may increase the sedative activities of Diazepam
|
DB09162
|
DB01377
| 1,557 | 94 |
Ferric citrate
|
Magnesium oxide
| null |
Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.
|
Ferric citrate can cause a decrease in the absorption of Magnesium oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
| 66 |
[
[
[
1557,
89,
94
]
],
[
[
1557,
97,
877
],
[
877,
89,
94
]
],
[
[
1557,
251,
1561
],
[
1561,
89,
94
]
],
[
[
1557,
89,
848
],
[
848,
89,
94
]
],
[
[
1557,
89,
78
],
[
78,
246,
94
]
],
[
[
1557,
97,
1320
],
[
1320,
251,
94
]
],
[
[
1557,
243,
1564
],
[
1564,
251,
94
]
],
[
[
1557,
97,
877
],
[
877,
225,
80
],
[
80,
179,
94
]
],
[
[
1557,
251,
1561
],
[
1561,
97,
405
],
[
405,
71,
94
]
],
[
[
1557,
89,
848
],
[
848,
197,
1281
],
[
1281,
43,
94
]
]
] |
[
[
[
"Node-1557",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the serum concentration of {v}",
"Fleroxacin"
],
[
"Fleroxacin",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the serum concentration of {v}",
"Triethylenetetramine"
],
[
"Triethylenetetramine",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the absorption and serum concentration of {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
],
[
"Bismuth subcitrate potassium",
"{u} may decrease the therapeutic efficacy of {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the serum concentration of {v}",
"Ibandronate"
],
[
"Ibandronate",
"{u} may decrease the serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the absorption and serum concentration of {v}",
"Dipotassium phosphate"
],
[
"Dipotassium phosphate",
"{u} may decrease the serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the serum concentration of {v}",
"Fleroxacin"
],
[
"Fleroxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} can decrease the bioavailability of {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the serum concentration of {v}",
"Triethylenetetramine"
],
[
"Triethylenetetramine",
"{u} may decrease the serum concentration of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
]
],
[
[
"Node-1557",
"{u} may decrease the absorption and serum concentration of {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may increase the neuromuscular blocking activities of {v}",
"Doxacurium"
],
[
"Doxacurium",
"{u} may increase the neuromuscular blocking activities of {v}",
"Magnesium oxide"
]
]
] |
Node-1557 may decrease the absorption and serum concentration of Magnesium oxide
Node-1557 may decrease the serum concentration of Fleroxacin and Fleroxacin may decrease the absorption and serum concentration of Magnesium oxide
Node-1557 may decrease the serum concentration of Triethylenetetramine and Triethylenetetramine may decrease the absorption and serum concentration of Magnesium oxide
Node-1557 may decrease the absorption and serum concentration of Demeclocycline and Demeclocycline may decrease the absorption and serum concentration of Magnesium oxide
Node-1557 may decrease the absorption and serum concentration of Bismuth subcitrate potassium and Bismuth subcitrate potassium may decrease the therapeutic efficacy of Magnesium oxide
Node-1557 may decrease the serum concentration of Ibandronate and Ibandronate may decrease the serum concentration of Magnesium oxide
Node-1557 may decrease the absorption and serum concentration of Dipotassium phosphate and Dipotassium phosphate may decrease the serum concentration of Magnesium oxide
Node-1557 may decrease the serum concentration of Fleroxacin and Fleroxacin may increase the severity of adverse effects when combined with Prednisone and Prednisone can decrease the bioavailability of Magnesium oxide
Node-1557 may decrease the serum concentration of Triethylenetetramine and Triethylenetetramine may decrease the serum concentration of Magnesium sulfate and Magnesium sulfate may increase the severity of adverse effects when combined with Magnesium oxide
Node-1557 may decrease the absorption and serum concentration of Demeclocycline and Demeclocycline may increase the neuromuscular blocking activities of Doxacurium and Doxacurium may increase the neuromuscular blocking activities of Magnesium oxide
|
DB08881
|
DB06717
| 495 | 1,106 |
Vemurafenib
|
Fosaprepitant
|
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
|
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
|
The serum concentration of Fosaprepitant can be increased when it is combined with Vemurafenib.
| 72 |
[
[
[
495,
95,
1106
]
],
[
[
495,
21,
28667
],
[
28667,
175,
1106
]
],
[
[
495,
55,
878
],
[
878,
33,
1106
]
],
[
[
495,
249,
505
],
[
505,
95,
1106
]
],
[
[
495,
97,
182
],
[
182,
95,
1106
]
],
[
[
495,
251,
1110
],
[
1110,
95,
1106
]
],
[
[
495,
95,
648
],
[
648,
95,
1106
]
],
[
[
495,
97,
623
],
[
623,
251,
1106
]
],
[
[
495,
249,
574
],
[
574,
251,
1106
]
],
[
[
495,
249,
191
],
[
191,
119,
1106
]
]
] |
[
[
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation"
],
[
"Infestation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} may decrease the serum concentration of {v}",
"Ergocalciferol"
],
[
"Ergocalciferol",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} may decrease the serum concentration of {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} may decrease the serum concentration of {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may decrease the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Diethylstilbestrol"
],
[
"Diethylstilbestrol",
"{u} may decrease the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
]
] |
Vemurafenib (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Fosaprepitant (Compound)
Vemurafenib may increase the severity of QTc prolonging effects when combined with Paroxetine and Paroxetine may reduce the serum concentration of the active metabolites of Fosaprepitant
Vemurafenib may increase the serum concentration of Vinblastine and Vinblastine may increase the serum concentration of Fosaprepitant
Vemurafenib may decrease the serum concentration of Ergocalciferol and Ergocalciferol may increase the serum concentration of Fosaprepitant
Vemurafenib may decrease the serum concentration of Enzalutamide and Enzalutamide may increase the serum concentration of Fosaprepitant
Vemurafenib may increase the serum concentration of Nefazodone and Nefazodone may increase the serum concentration of Fosaprepitant
Vemurafenib may decrease the serum concentration of Medroxyprogesterone acetate and Medroxyprogesterone acetate may decrease the serum concentration of Fosaprepitant
Vemurafenib may increase the serum concentration of Diethylstilbestrol and Diethylstilbestrol may decrease the serum concentration of Fosaprepitant
Vemurafenib may increase the serum concentration of Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound) and Aprepitant may increase the serum concentration of Fosaprepitant
|
DB01037
|
DB00633
| 39 | 724 |
Selegiline
|
Dexmedetomidine
|
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
|
An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.
|
The risk or severity of adverse effects can be increased when Selegiline is combined with Dexmedetomidine.
| 48 |
[
[
[
39,
71,
724
]
],
[
[
39,
6,
12128
],
[
12128,
160,
724
]
],
[
[
39,
21,
29253
],
[
29253,
175,
724
]
],
[
[
39,
225,
1265
],
[
1265,
192,
724
]
],
[
[
39,
71,
679
],
[
679,
38,
724
]
],
[
[
39,
71,
702
],
[
702,
192,
724
]
],
[
[
39,
225,
587
],
[
587,
38,
724
]
],
[
[
39,
71,
1034
],
[
1034,
201,
724
]
],
[
[
39,
82,
1037
],
[
1037,
201,
724
]
],
[
[
39,
52,
828
],
[
828,
206,
724
]
]
] |
[
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} (Compound) causes {v} (Side Effect)",
"Respiratory depression"
],
[
"Respiratory depression",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Esmolol"
],
[
"Esmolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Dexmedetomidine"
]
],
[
[
"Selegiline",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Dexmedetomidine"
]
]
] |
Selegiline (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dexmedetomidine (Compound)
Selegiline (Compound) causes Respiratory depression (Side Effect) and Respiratory depression (Side Effect) is caused by Dexmedetomidine (Compound)
Selegiline may increase the severity of adverse effects when combined with Nabilone and Nabilone may increase the central nervous system depressant activities of Dexmedetomidine
Selegiline may increase the severity of adverse effects when combined with Thalidomide and Thalidomide may increase the central nervous system depressant activities of Dexmedetomidine
Selegiline may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the central nervous system depressant activities of Dexmedetomidine
Selegiline may increase the severity of adverse effects when combined with Ethanol and Ethanol may increase the central nervous system depressant activities of Dexmedetomidine
Selegiline may increase the severity of adverse effects when combined with Esmolol and Esmolol may increase the atrioventricular blocking activities of Dexmedetomidine
Selegiline may increase the hypotensive activities of Betaxolol and Betaxolol may increase the atrioventricular blocking activities of Dexmedetomidine
Selegiline may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Dexmedetomidine
|
DB06712
|
DB08933
| 435 | 1,114 |
Nilvadipine
|
Luliconazole
|
Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
|
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
|
The serum concentration of Luliconazole can be increased when it is combined with Nilvadipine.
| 72 |
[
[
[
435,
95,
1114
]
],
[
[
435,
6,
4590
],
[
4590,
160,
1114
]
],
[
[
435,
225,
1303
],
[
1303,
71,
1114
]
],
[
[
435,
69,
1113
],
[
1113,
95,
1114
]
],
[
[
435,
225,
198
],
[
198,
95,
1114
]
],
[
[
435,
236,
144
],
[
144,
95,
1114
]
],
[
[
435,
71,
280
],
[
280,
95,
1114
]
],
[
[
435,
180,
298
],
[
298,
95,
1114
]
],
[
[
435,
1,
329
],
[
329,
95,
1114
]
],
[
[
435,
186,
154
],
[
154,
95,
1114
]
]
] |
[
[
[
"Nilvadipine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} may decrease the metabolism of {v}",
"Boceprevir"
],
[
"Boceprevir",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} may increase the hypotensive activities of {v}",
"Dorzolamide"
],
[
"Dorzolamide",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propofol"
],
[
"Propofol",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} can increase the metabolism of {v}",
"Hexobarbital"
],
[
"Hexobarbital",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
],
[
"Nitrendipine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Nilvadipine",
"{u} may increase the antihypertensive activities of {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
]
] |
Nilvadipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Luliconazole (Compound)
Nilvadipine may increase the severity of adverse effects when combined with Methylergometrine and Methylergometrine may increase the severity of adverse effects when combined with Luliconazole
Nilvadipine may decrease the metabolism of Boceprevir and Boceprevir may increase the serum concentration of Luliconazole
Nilvadipine may increase the severity of adverse effects when combined with Cyclosporine and Cyclosporine may increase the serum concentration of Luliconazole
Nilvadipine may increase the hypotensive activities of Dorzolamide and Dorzolamide may increase the serum concentration of Luliconazole
Nilvadipine may increase the severity of adverse effects when combined with Propofol and Propofol may increase the serum concentration of Luliconazole
Nilvadipine can increase the metabolism of Hexobarbital and Hexobarbital may increase the serum concentration of Luliconazole
Nilvadipine (Compound) resembles Nitrendipine (Compound) and Nitrendipine may increase the serum concentration of Luliconazole
Nilvadipine may increase the antihypertensive activities of Vardenafil and Vardenafil may increase the serum concentration of Luliconazole
|
DB00800
|
DB00818
| 1,058 | 280 |
Fenoldopam
|
Propofol
|
A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
|
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.
|
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Propofol.
| 48 |
[
[
[
1058,
71,
280
]
],
[
[
1058,
21,
28714
],
[
28714,
175,
280
]
],
[
[
1058,
236,
164
],
[
164,
26,
280
]
],
[
[
1058,
71,
679
],
[
679,
38,
280
]
],
[
[
1058,
71,
1265
],
[
1265,
192,
280
]
],
[
[
1058,
236,
640
],
[
640,
42,
280
]
],
[
[
1058,
225,
1208
],
[
1208,
42,
280
]
],
[
[
1058,
71,
955
],
[
955,
42,
280
]
],
[
[
1058,
71,
471
],
[
471,
208,
280
]
],
[
[
1058,
225,
499
],
[
499,
223,
280
]
]
] |
[
[
[
"Fenoldopam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} may increase the hypotensive activities of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the QTc prolonging activities of {v}",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the QTc prolonging activities of {v}",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Propofol"
]
],
[
[
"Fenoldopam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may decrease the metabolism of {v}",
"Propofol"
]
]
] |
Fenoldopam (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Propofol (Compound)
Fenoldopam may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Propofol
Fenoldopam may increase the severity of adverse effects when combined with Thalidomide and Thalidomide may increase the central nervous system depressant activities of Propofol
Fenoldopam may increase the severity of adverse effects when combined with Nabilone and Nabilone may increase the central nervous system depressant activities of Propofol
Fenoldopam may increase the hypotensive activities of Quinine and Quinine may increase the QTc prolonging activities of Propofol
Fenoldopam may increase the severity of adverse effects when combined with Arsenic trioxide and Arsenic trioxide may increase the QTc prolonging activities of Propofol
Fenoldopam may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may increase the QTc prolonging activities of Propofol
Fenoldopam may increase the severity of adverse effects when combined with Rotigotine and Rotigotine may increase the sedative activities of Propofol
Fenoldopam may increase the severity of adverse effects when combined with Clomipramine and Clomipramine may decrease the metabolism of Propofol
|
DB00425
|
DB00898
| 287 | 587 |
Zolpidem
|
Ethanol
|
Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is available in both immediate acting and extended release forms [FDA label],. Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. This drug has the propensity to completely or partially
|
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
|
Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
| 15 |
[
[
[
287,
38,
587
]
],
[
[
287,
6,
10999
],
[
10999,
160,
587
]
],
[
[
287,
251,
147
],
[
147,
26,
587
]
],
[
[
287,
180,
173
],
[
173,
26,
587
]
],
[
[
287,
38,
1005
],
[
1005,
192,
587
]
],
[
[
287,
38,
142
],
[
142,
38,
587
]
],
[
[
287,
192,
1083
],
[
1083,
38,
587
]
],
[
[
287,
71,
193
],
[
193,
194,
587
]
],
[
[
287,
54,
1365
],
[
1365,
208,
587
]
],
[
[
287,
38,
1269
],
[
1269,
54,
587
]
]
] |
[
[
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Methocarbamol"
],
[
"Methocarbamol",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} can increase the absorption and serum concentration of {v}",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Ethanol"
]
],
[
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may increase the sedative activities of {v}",
"Ethanol"
]
]
] |
Zolpidem (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ethanol (Compound)
Zolpidem may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Ethanol
Zolpidem can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Ethanol
Zolpidem may increase the central nervous system depressant activities of Methocarbamol and Methocarbamol may increase the central nervous system depressant activities of Ethanol
Zolpidem may increase the central nervous system depressant activities of Phenytoin and Phenytoin may increase the central nervous system depressant activities of Ethanol
Zolpidem may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Ethanol
Zolpidem may increase the severity of adverse effects when combined with Levomilnacipran and Levomilnacipran can increase the absorption and serum concentration of Ethanol
Zolpidem may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Ethanol
Zolpidem may increase the central nervous system depressant activities of Stiripentol and Stiripentol may increase the sedative activities of Ethanol
|
DB01320
|
DB01595
| 150 | 442 |
Fosphenytoin
|
Nitrazepam
|
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
A benzodiazepine derivative used as an anticonvulsant and hypnotic.
|
The serum concentration of Nitrazepam can be increased when it is combined with Fosphenytoin.
| 72 |
[
[
[
150,
95,
442
]
],
[
[
150,
26,
388
],
[
388,
155,
442
]
],
[
[
150,
95,
1273
],
[
1273,
155,
442
]
],
[
[
150,
95,
1270
],
[
1270,
225,
442
]
],
[
[
150,
182,
342
],
[
342,
155,
442
]
],
[
[
150,
95,
312
],
[
312,
1,
442
]
],
[
[
150,
95,
407
],
[
407,
71,
442
]
],
[
[
150,
225,
948
],
[
948,
155,
442
]
],
[
[
150,
6,
4590
],
[
4590,
160,
442
]
],
[
[
150,
21,
28408
],
[
28408,
175,
442
]
]
] |
[
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Delorazepam"
],
[
"Delorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Fludiazepam"
],
[
"Fludiazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} (Compound) resembles {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Temazepam"
],
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Diazepam"
],
[
"Diazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethyl loflazepate"
],
[
"Ethyl loflazepate",
"{u} (Compound) resembles {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nitrazepam"
]
]
] |
Fosphenytoin can increase the metabolism of Flurbiprofen and Flurbiprofen (Compound) resembles Nitrazepam (Compound)
Fosphenytoin may increase the serum concentration of Delorazepam and Delorazepam (Compound) resembles Nitrazepam (Compound)
Fosphenytoin may increase the serum concentration of Fludiazepam and Fludiazepam may increase the severity of adverse effects when combined with Nitrazepam
Fosphenytoin may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol (Compound) resembles Nitrazepam (Compound)
Fosphenytoin may increase the serum concentration of Temazepam and Temazepam (Compound) resembles Nitrazepam (Compound)
Fosphenytoin may increase the serum concentration of Diazepam and Diazepam may increase the severity of adverse effects when combined with Nitrazepam
Fosphenytoin may increase the severity of adverse effects when combined with Ethyl loflazepate and Ethyl loflazepate (Compound) resembles Nitrazepam (Compound)
Fosphenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nitrazepam (Compound)
Fosphenytoin (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Nitrazepam (Compound)
|
DB00428
|
DB00712
| 901 | 388 |
Streptozocin
|
Flurbiprofen
|
An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.
|
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
|
Streptozocin may decrease the excretion rate of Flurbiprofen which could result in a higher serum level.
| 71 |
[
[
[
901,
94,
388
]
],
[
[
901,
94,
844
],
[
844,
155,
388
]
],
[
[
901,
94,
621
],
[
621,
225,
388
]
],
[
[
901,
94,
628
],
[
628,
1,
388
]
],
[
[
901,
18,
4570
],
[
4570,
172,
388
]
],
[
[
901,
21,
28440
],
[
28440,
175,
388
]
],
[
[
901,
94,
687
],
[
687,
28,
388
]
],
[
[
901,
225,
893
],
[
893,
205,
388
]
],
[
[
901,
71,
582
],
[
582,
223,
388
]
],
[
[
901,
95,
1421
],
[
1421,
225,
388
]
]
] |
[
[
[
"Streptozocin",
"{u} may decrease the excretion rate {v}",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} may decrease the excretion rate {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} (Compound) resembles {v} (Compound)",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} may decrease the excretion rate {v}",
"Naproxen"
],
[
"Naproxen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} may decrease the excretion rate {v}",
"Suprofen"
],
[
"Suprofen",
"{u} (Compound) resembles {v} (Compound)",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} (Compound) downregulates {v} (Gene)",
"CDC25B"
],
[
"CDC25B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} may decrease the excretion rate {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may decrease the metabolism of {v}",
"Flurbiprofen"
]
],
[
[
"Streptozocin",
"{u} may increase the serum concentration of {v}",
"Tenofovir disoproxil"
],
[
"Tenofovir disoproxil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flurbiprofen"
]
]
] |
Streptozocin may decrease the excretion rate Diflunisal and Diflunisal (Compound) resembles Flurbiprofen (Compound)
Streptozocin may decrease the excretion rate Naproxen and Naproxen may increase the severity of adverse effects when combined with Flurbiprofen
Streptozocin may decrease the excretion rate Suprofen and Suprofen (Compound) resembles Flurbiprofen (Compound)
Streptozocin (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Flurbiprofen (Compound)
Streptozocin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Flurbiprofen (Compound)
Streptozocin may decrease the excretion rate Nafamostat and Nafamostat may increase the anticoagulant activities of Flurbiprofen
Streptozocin may increase the severity of adverse effects when combined with Etacrynic acid and Etacrynic acid may decrease the diuretic activities of Flurbiprofen
Streptozocin may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may decrease the metabolism of Flurbiprofen
Streptozocin may increase the serum concentration of Tenofovir disoproxil and Tenofovir disoproxil may increase the severity of adverse effects when combined with Flurbiprofen
|
DB00477
|
DB09274
| 392 | 1,075 |
Chlorpromazine
|
Artesunate
|
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
|
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
|
The serum concentration of Artesunate can be increased when it is combined with Chlorpromazine.
| 72 |
[
[
[
392,
95,
1075
]
],
[
[
392,
69,
137
],
[
137,
33,
1075
]
],
[
[
392,
180,
173
],
[
173,
33,
1075
]
],
[
[
392,
42,
1097
],
[
1097,
33,
1075
]
],
[
[
392,
71,
385
],
[
385,
33,
1075
]
],
[
[
392,
223,
1116
],
[
1116,
33,
1075
]
],
[
[
392,
95,
539
],
[
539,
209,
1075
]
],
[
[
392,
95,
495
],
[
495,
55,
1075
]
],
[
[
392,
95,
314
],
[
314,
225,
1075
]
],
[
[
392,
155,
1379
],
[
1379,
95,
1075
]
]
] |
[
[
[
"Chlorpromazine",
"{u} may increase the serum concentration of {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} may decrease the metabolism of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} may increase the QTc prolonging activities of {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} may decrease the metabolism of {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} may increase the serum concentration of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} may increase the serum concentration of {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Artesunate"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Periciazine"
],
[
"Periciazine",
"{u} may increase the serum concentration of {v}",
"Artesunate"
]
]
] |
Chlorpromazine may decrease the metabolism of Amiodarone and Amiodarone may reduce the serum concentration of the active metabolites of Artesunate
Chlorpromazine can increase the metabolism of Nevirapine and Nevirapine may reduce the serum concentration of the active metabolites of Artesunate
Chlorpromazine may increase the QTc prolonging activities of Ezogabine and Ezogabine may reduce the serum concentration of the active metabolites of Artesunate
Chlorpromazine may increase the severity of adverse effects when combined with Amlodipine and Amlodipine may reduce the serum concentration of the active metabolites of Artesunate
Chlorpromazine may decrease the metabolism of Dexfenfluramine and Dexfenfluramine may reduce the serum concentration of the active metabolites of Artesunate
Chlorpromazine may increase the serum concentration of Artemether and Artemether may increase the severity of QTc prolonging effects when combined with Artesunate
Chlorpromazine may increase the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Artesunate
Chlorpromazine may increase the serum concentration of Dapsone and Dapsone may increase the severity of adverse effects when combined with Artesunate
Chlorpromazine (Compound) resembles Periciazine (Compound) and Periciazine may increase the serum concentration of Artesunate
|
DB01137
|
DB01189
| 884 | 914 |
Levofloxacin
|
Desflurane
|
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
|
Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.
|
Levofloxacin may increase the QTc-prolonging activities of Desflurane.
| 19 |
[
[
[
884,
42,
914
]
],
[
[
884,
42,
347
],
[
347,
71,
914
]
],
[
[
884,
21,
28614
],
[
28614,
175,
914
]
],
[
[
884,
42,
543
],
[
543,
38,
914
]
],
[
[
884,
196,
956
],
[
956,
42,
914
]
],
[
[
884,
42,
1187
],
[
1187,
42,
914
]
],
[
[
884,
185,
640
],
[
640,
42,
914
]
],
[
[
884,
275,
1210
],
[
1210,
42,
914
]
],
[
[
884,
42,
175
],
[
175,
225,
914
]
],
[
[
884,
185,
247
],
[
247,
71,
914
]
]
] |
[
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Isoflurane"
],
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} may increase the hypoglycemic activities of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the QTc prolonging activities of {v}",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the QTc prolonging activities of {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
]
],
[
[
"Levofloxacin",
"{u} may increase the hypoglycemic activities of {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
]
]
] |
Levofloxacin may increase the QTc prolonging activities of Isoflurane and Isoflurane may increase the severity of adverse effects when combined with Desflurane
Levofloxacin (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Desflurane (Compound)
Levofloxacin may increase the QTc prolonging activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Desflurane
Levofloxacin may increase the QTc prolonging activities of Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Desflurane
Levofloxacin may increase the QTc prolonging activities of Goserelin and Goserelin may increase the QTc prolonging activities of Desflurane
Levofloxacin may increase the hypoglycemic activities of Quinine and Quinine may increase the QTc prolonging activities of Desflurane
Levofloxacin (Compound) resembles Ofloxacin (Compound) and Levofloxacin may increase the QTc prolonging activities of Ofloxacin and Ofloxacin may increase the QTc prolonging activities of Desflurane
Levofloxacin may increase the QTc prolonging activities of Trazodone and Trazodone may increase the severity of adverse effects when combined with Desflurane
Levofloxacin may increase the hypoglycemic activities of Bromocriptine and Bromocriptine may increase the severity of adverse effects when combined with Desflurane
|
DB00353
|
DB00571
| 1,303 | 504 |
Methylergometrine
|
Propranolol
|
A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
|
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.
|
Methylergometrine may increase the vasoconstricting activities of Propranolol.
| 18 |
[
[
[
1303,
41,
504
]
],
[
[
1303,
71,
610
],
[
610,
155,
504
]
],
[
[
1303,
41,
576
],
[
576,
95,
504
]
],
[
[
1303,
41,
1037
],
[
1037,
71,
504
]
],
[
[
1303,
41,
1016
],
[
1016,
155,
504
]
],
[
[
1303,
10,
17951
],
[
17951,
159,
504
]
],
[
[
1303,
6,
4590
],
[
4590,
160,
504
]
],
[
[
1303,
7,
7956
],
[
7956,
161,
504
]
],
[
[
1303,
21,
28440
],
[
28440,
175,
504
]
],
[
[
1303,
71,
173
],
[
173,
26,
504
]
]
] |
[
[
[
"Methylergometrine",
"{u} may increase the vasoconstricting activities of {v}",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} may increase the vasoconstricting activities of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the serum concentration of {v}",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} may increase the vasoconstricting activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} may increase the vasoconstricting activities of {v}",
"Practolol"
],
[
"Practolol",
"{u} (Compound) resembles {v} (Compound)",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} (Compound) palliates {v} (Disease)",
"migraine"
],
[
"migraine",
"{u} (Disease) is treated by {v} (Compound)",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} (Compound) upregulates {v} (Gene)",
"EDEM1"
],
[
"EDEM1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Propranolol"
]
],
[
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Propranolol"
]
]
] |
Methylergometrine may increase the severity of adverse effects when combined with Atomoxetine and Atomoxetine (Compound) resembles Propranolol (Compound)
Methylergometrine may increase the vasoconstricting activities of Metoprolol and Metoprolol may increase the serum concentration of Propranolol
Methylergometrine may increase the vasoconstricting activities of Betaxolol and Betaxolol may increase the severity of adverse effects when combined with Propranolol
Methylergometrine may increase the vasoconstricting activities of Practolol and Practolol (Compound) resembles Propranolol (Compound)
Methylergometrine (Compound) palliates migraine (Disease) and migraine (Disease) is treated by Propranolol (Compound)
Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Propranolol (Compound)
Methylergometrine (Compound) upregulates EDEM1 (Gene) and EDEM1 (Gene) is upregulated by Propranolol (Compound)
Methylergometrine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Propranolol (Compound)
Methylergometrine may increase the severity of adverse effects when combined with Nevirapine and Nevirapine can increase the metabolism of Propranolol
|
DB00412
|
DB00805
| 514 | 31 |
Rosiglitazone
|
Minaprine
|
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be
|
Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.
|
Rosiglitazone may increase the hypoglycemic activities of Minaprine.
| 8 |
[
[
[
514,
31,
31
]
],
[
[
514,
6,
18777
],
[
18777,
160,
31
]
],
[
[
514,
223,
540
],
[
540,
184,
31
]
],
[
[
514,
223,
481
],
[
481,
31,
31
]
],
[
[
514,
185,
474
],
[
474,
31,
31
]
],
[
[
514,
69,
297
],
[
297,
31,
31
]
],
[
[
514,
95,
495
],
[
495,
55,
31
]
],
[
[
514,
69,
137
],
[
137,
223,
31
]
],
[
[
514,
223,
59
],
[
59,
223,
31
]
],
[
[
514,
31,
394
],
[
394,
223,
31
]
]
] |
[
[
[
"Rosiglitazone",
"{u} may increase the hypoglycemic activities of {v}",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} may decrease the metabolism of {v}",
"Morphine"
],
[
"Morphine",
"{u} can increase the therapeutic efficacy of {v}",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} may decrease the metabolism of {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} may increase the hypoglycemic activities of {v}",
"Gliclazide"
],
[
"Gliclazide",
"{u} may increase the hypoglycemic activities of {v}",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} may decrease the metabolism of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may decrease the metabolism of {v}",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} may decrease the metabolism of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Minaprine"
]
],
[
[
"Rosiglitazone",
"{u} may increase the hypoglycemic activities of {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may decrease the metabolism of {v}",
"Minaprine"
]
]
] |
Rosiglitazone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Minaprine (Compound)
Rosiglitazone may decrease the metabolism of Morphine and Morphine can increase the therapeutic efficacy of Minaprine
Rosiglitazone may decrease the metabolism of Sitagliptin and Sitagliptin may increase the hypoglycemic activities of Minaprine
Rosiglitazone may increase the hypoglycemic activities of Gliclazide and Gliclazide may increase the hypoglycemic activities of Minaprine
Rosiglitazone may decrease the metabolism of Tolbutamide and Tolbutamide may increase the hypoglycemic activities of Minaprine
Rosiglitazone may increase the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Minaprine
Rosiglitazone may decrease the metabolism of Amiodarone and Amiodarone may decrease the metabolism of Minaprine
Rosiglitazone may decrease the metabolism of Quinidine and Quinidine may decrease the metabolism of Minaprine
Rosiglitazone may increase the hypoglycemic activities of Fluoxetine and Fluoxetine may decrease the metabolism of Minaprine
|
DB00831
|
DB00215
| 940 | 556 |
Trifluoperazine
|
Citalopram
|
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
|
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
|
The metabolism of Citalopram can be decreased when combined with Trifluoperazine.
| 46 |
[
[
[
940,
69,
556
]
],
[
[
940,
6,
8339
],
[
8339,
160,
556
]
],
[
[
940,
7,
15689
],
[
15689,
161,
556
]
],
[
[
940,
21,
29369
],
[
29369,
175,
556
]
],
[
[
940,
69,
173
],
[
173,
26,
556
]
],
[
[
940,
71,
150
],
[
150,
26,
556
]
],
[
[
940,
116,
175
],
[
175,
196,
556
]
],
[
[
940,
71,
878
],
[
878,
196,
556
]
],
[
[
940,
155,
970
],
[
970,
196,
556
]
],
[
[
940,
225,
280
],
[
280,
196,
556
]
]
] |
[
[
[
"Trifluoperazine",
"{u} may decrease the metabolism of {v}",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) upregulates {v} (Gene)",
"PLS1"
],
[
"PLS1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) causes {v} (Side Effect)",
"Tetany"
],
[
"Tetany",
"{u} (Side Effect) is caused by {v} (Compound)",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may increase the QTc prolonging activities of {v}",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Thiothixene"
],
[
"Thiothixene",
"{u} may increase the QTc prolonging activities of {v}",
"Citalopram"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propofol"
],
[
"Propofol",
"{u} may increase the QTc prolonging activities of {v}",
"Citalopram"
]
]
] |
Trifluoperazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Citalopram (Compound)
Trifluoperazine (Compound) upregulates PLS1 (Gene) and PLS1 (Gene) is upregulated by Citalopram (Compound)
Trifluoperazine (Compound) causes Tetany (Side Effect) and Tetany (Side Effect) is caused by Citalopram (Compound)
Trifluoperazine may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Citalopram
Trifluoperazine may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin can increase the metabolism of Citalopram
Trifluoperazine (Compound) resembles Trazodone (Compound) and Trifluoperazine may increase the severity of adverse effects when combined with Trazodone and Trazodone may increase the QTc prolonging activities of Citalopram
Trifluoperazine may increase the severity of adverse effects when combined with Paroxetine and Paroxetine may increase the QTc prolonging activities of Citalopram
Trifluoperazine (Compound) resembles Thiothixene (Compound) and Thiothixene may increase the QTc prolonging activities of Citalopram
Trifluoperazine may increase the severity of adverse effects when combined with Propofol and Propofol may increase the QTc prolonging activities of Citalopram
|
DB01320
|
DB12483
| 150 | 160 |
Fosphenytoin
|
Copanlisib
|
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.
|
The metabolism of Copanlisib can be increased when combined with Fosphenytoin.
| 3 |
[
[
[
150,
26,
160
]
],
[
[
150,
26,
171
],
[
171,
26,
160
]
],
[
[
150,
251,
147
],
[
147,
26,
160
]
],
[
[
150,
97,
1086
],
[
1086,
223,
160
]
],
[
[
150,
95,
861
],
[
861,
223,
160
]
],
[
[
150,
26,
615
],
[
615,
223,
160
]
],
[
[
150,
225,
41
],
[
41,
223,
160
]
],
[
[
150,
33,
1077
],
[
1077,
223,
160
]
],
[
[
150,
99,
1088
],
[
1088,
223,
160
]
],
[
[
150,
97,
631
],
[
631,
249,
160
]
]
] |
[
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may decrease the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may decrease the metabolism of {v}",
"Copanlisib"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Simeprevir"
],
[
"Simeprevir",
"{u} may increase the serum concentration of {v}",
"Copanlisib"
]
]
] |
Fosphenytoin can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Copanlisib
Fosphenytoin may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Copanlisib
Fosphenytoin may decrease the serum concentration of Clotrimazole and Clotrimazole may decrease the metabolism of Copanlisib
Fosphenytoin may increase the serum concentration of Fluvoxamine and Fluvoxamine may decrease the metabolism of Copanlisib
Fosphenytoin can increase the metabolism of Sildenafil and Sildenafil may decrease the metabolism of Copanlisib
Fosphenytoin may increase the severity of adverse effects when combined with Clemastine and Clemastine may decrease the metabolism of Copanlisib
Fosphenytoin may reduce the serum concentration of the active metabolites of Isavuconazonium and Isavuconazonium may decrease the metabolism of Copanlisib
Fosphenytoin may increase the serum concentration of the active metabolites of Clarithromycin and Clarithromycin may decrease the metabolism of Copanlisib
Fosphenytoin may decrease the serum concentration of Simeprevir and Simeprevir may increase the serum concentration of Copanlisib
|
DB00230
|
DB01589
| 674 | 371 |
Pregabalin
|
Quazepam
|
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190,L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.
|
Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other receptors.
|
The therapeutic efficacy of Quazepam can be increased when used in combination with Pregabalin.
| 7 |
[
[
[
674,
30,
371
]
],
[
[
674,
30,
586
],
[
586,
71,
371
]
],
[
[
674,
30,
259
],
[
259,
95,
371
]
],
[
[
674,
92,
1273
],
[
1273,
1,
371
]
],
[
[
674,
92,
1270
],
[
1270,
225,
371
]
],
[
[
674,
30,
948
],
[
948,
1,
371
]
],
[
[
674,
30,
972
],
[
972,
225,
371
]
],
[
[
674,
10,
17078
],
[
17078,
164,
371
]
],
[
[
674,
21,
28384
],
[
28384,
175,
371
]
],
[
[
674,
92,
164
],
[
164,
26,
371
]
]
] |
[
[
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Triazolam"
],
[
"Triazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Flunitrazepam"
],
[
"Flunitrazepam",
"{u} may increase the serum concentration of {v}",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} may decrease the therapeutic efficacy of {v}",
"Delorazepam"
],
[
"Delorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} may decrease the therapeutic efficacy of {v}",
"Fludiazepam"
],
[
"Fludiazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Ethyl loflazepate"
],
[
"Ethyl loflazepate",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Halazepam"
],
[
"Halazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} (Compound) palliates {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is palliated by {v} (Compound)",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quazepam"
]
],
[
[
"Pregabalin",
"{u} may decrease the therapeutic efficacy of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Quazepam"
]
]
] |
Pregabalin can increase the therapeutic efficacy of Triazolam and Triazolam may increase the severity of adverse effects when combined with Quazepam
Pregabalin can increase the therapeutic efficacy of Flunitrazepam and Flunitrazepam may increase the serum concentration of Quazepam
Pregabalin may decrease the therapeutic efficacy of Delorazepam and Delorazepam (Compound) resembles Quazepam (Compound)
Pregabalin may decrease the therapeutic efficacy of Fludiazepam and Fludiazepam may increase the severity of adverse effects when combined with Quazepam
Pregabalin can increase the therapeutic efficacy of Ethyl loflazepate and Ethyl loflazepate (Compound) resembles Quazepam (Compound)
Pregabalin can increase the therapeutic efficacy of Halazepam and Halazepam may increase the severity of adverse effects when combined with Quazepam
Pregabalin (Compound) palliates multiple sclerosis (Disease) and multiple sclerosis (Disease) is palliated by Quazepam (Compound)
Pregabalin (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Quazepam (Compound)
Pregabalin may decrease the therapeutic efficacy of Phenobarbital and Phenobarbital can increase the metabolism of Quazepam
|
DB00619
|
DB00322
| 637 | 1,252 |
Imatinib
|
Floxuridine
|
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
|
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
|
The metabolism of Floxuridine can be decreased when combined with Imatinib.
| 46 |
[
[
[
637,
69,
1252
]
],
[
[
637,
21,
28389
],
[
28389,
175,
1252
]
],
[
[
637,
191,
243
],
[
243,
37,
1252
]
],
[
[
637,
210,
1388
],
[
1388,
56,
1252
]
],
[
[
637,
56,
340
],
[
340,
210,
1252
]
],
[
[
637,
69,
394
],
[
394,
69,
1252
]
],
[
[
637,
223,
428
],
[
428,
69,
1252
]
],
[
[
637,
95,
575
],
[
575,
69,
1252
]
],
[
[
637,
225,
292
],
[
292,
69,
1252
]
],
[
[
637,
182,
219
],
[
219,
69,
1252
]
]
] |
[
[
[
"Imatinib",
"{u} may decrease the metabolism of {v}",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} may increase the immunosuppressive activities of {v}",
"Roflumilast"
],
[
"Roflumilast",
"{u} may increase the immunosuppressive activities of {v}",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} may increase the immunosuppressive activities of {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may increase the immunosuppressive activities of {v}",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} may decrease the metabolism of {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may decrease the metabolism of {v}",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} may decrease the metabolism of {v}",
"Alosetron"
],
[
"Alosetron",
"{u} may decrease the metabolism of {v}",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} may increase the serum concentration of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may decrease the metabolism of {v}",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may decrease the metabolism of {v}",
"Floxuridine"
]
],
[
[
"Imatinib",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may decrease the metabolism of {v}",
"Floxuridine"
]
]
] |
Imatinib (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Floxuridine (Compound)
Imatinib may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Floxuridine
Imatinib may increase the immunosuppressive activities of Roflumilast and Roflumilast may increase the immunosuppressive activities of Floxuridine
Imatinib may increase the immunosuppressive activities of Fingolimod and Fingolimod may increase the immunosuppressive activities of Floxuridine
Imatinib may decrease the metabolism of Fluoxetine and Fluoxetine may decrease the metabolism of Floxuridine
Imatinib may decrease the metabolism of Alosetron and Alosetron may decrease the metabolism of Floxuridine
Imatinib may increase the serum concentration of Sulfisoxazole and Sulfisoxazole may decrease the metabolism of Floxuridine
Imatinib may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may decrease the metabolism of Floxuridine
Imatinib may increase the anticoagulant activities of Warfarin and Warfarin may decrease the metabolism of Floxuridine
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.